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Summary 
 
Throughout the process of neoplastic transformation cells progressively acquire functional capabilities 
that allow cancer cells to survive, proliferate and disseminate. These functions are acquired in different tumor 
types via distinct mechanisms during the course of multistep tumorigenesis. The most fundamental trait of 
cancer cells is their ability to sustain chronic proliferation (Malumbres and Barbacid, 2001; Hanahah and 
Weinberg, 2011). Selective cancer chemotherapy is based on the assumption that tumor cells proliferate 
rapidly and cytotoxic drugs gain specificity from their ability to preferentially kill rapidly proliferating cells 
(Chabner et al., 2006). Targeting the deregulated cell cycle of cancer cells seems to be a good therapeutic 
options.. The fragility of cancer cells when they undergo division serves as a critical point for intervention in 
chemotherapy (Chan et al., 2011). Mitosis is considered the most fragile period of the cell cycle, during which 
is highly susceptible to cell death when exposed to several insults. 
 
The great clinical success of microtubule poisons in clinics, such as taxanes and vinka-alkaloids, and 
the susceptibility of cells to mitotic arrest, has encouraged the development of agents that inhibit mitotic 
progression. However, microtubules are also necessary for multiple cellular processes in interphase and the 
use of this spindle poisons is associated with side-effects such as neurotoxicity, that can lead to irreversible 
neuropathies. The generation of anti-tumoral therapies that target proteins with specific functions in mitosis, 
although promising, has not achieved the desired efficiency in patients. In general, this new generation of 
mitosis targeted inhibitors show less anti-tumor activity than taxol, although the problem of neurotoxicity has 
been solved effectively. One of the reasons of the limited effect of these drugs may be the low mitotic rate in 
human tumors, much lower than in preclinical models (Malumbres and Doménech, 2013). Besides, the drug 
development programs have traditionally focused on developing inhibitors of Plk1 and Aurora A and B as anti-
tumor targets. Recently, several members of the family of kinesins are emerging as potential anti-tumor 
targets, however, there are a variety of kinases mitotic whose potential as a therapeutic target has not yet 
been explored, as is the case for: Nek, Mps1, Mast or Haspin.  
 
The arrest imposed by anti-mitotic drugs is often transient and the cells are able to exit from mitosis 
(i.e. DNA decondensates and the nucleus re-assemble in the absence of chromosomal segregation) in a 
process known as mitotic slippage (Brito and Rieder, 2006; Topham and Taylor, 2013). Mitotic slippage is 
considered one of the major mechanisms of resistance against anti-mitotic drugs, leading to the appearance 
of aneuploid cells that may continue proliferating, an undesirable outcome.  
 
 Eukaryotic cells have evolved mechanisms of control to detect errors that may occur during cell cycle 
and blocking progression until it is repaired. One of these mechanisms is mediated by the APC/C (Anaphase 
Promoting Complex or cyclosome), a multimeric complex with E3 ubiquitin ligase activity necessary for 
chromosome segregation, that target for degradation several cell cycle regulators. The APC/C recognizes its 
substrates through two adapter proteins; Cdh1 and Cdc20, being Cdc20  responsible for the function of 
APC/C during the initial stages of mitosis and for triggering the transition from metaphase to anaphase. When 
the chromosomes are perfectly aligned at the metaphase plate attached to microtubules of the bipolar 
spindle, the activation of APC/C by Cdc20 results in the elimination of two critical substrates; securin 
(separase inhibitor) and cyclin B (Cdk1 activator), which leads to mitotic exit (Manchado et al. 2010). In the 
absence of Cdc20, cells are unable to exit mitosis and remain arrested in metaphase for 6-36 hours till they 
inevitably die in mitosis (Manchado et al. 2010). Inhibition of the APC/C has recently been proposed as a 
therapeutic option for preventing mitotic slippage (Malumbres and Doménech, 2013;. Huang et al., 2009; 
Machado et al., 2011;. Rieder and Medema, 2009).  
 
How cells die in the absence of Cdc20 is an issue of great interest. The cellular alterations resulting 
from aberrant mitosis are collectively known as mitotic catastrophe (Vitale et al., 2011). Mitotic catastrophe 
(MC) can be defined as a type of cell death resulting from aberrant mitosis which takes place in the ongoing 
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mitosis or in the following interface (Galluzi et al, 2012;. Vitale et al., 2011). It is therefore different from 
apoptosis, necrosis or senescence and is driven by a poorly understood signaling cascade. MC can be 
considered a tumor-suppressor mechanism (Vitale et al., 2011) preventing chromosomal instability and the 
appearance of aneuploid cells. MC favors the disruption of tumor progression and its induction is a 
therapeutic endpoint. Despite the broad use of this concept, the exact molecular mechanism that determine 
cell death in response to these changes are still unknown. Furthermore, it is unclear whether these cell death 
pathways are functional during mitosis, or arise in the next cell cycle as a result of changes during mitosis. 
For instance, in a prolonged mitotic arrest specific caspases are activated, causing DNA damage and the 
induction of p53-dependent apoptosis in the following interface (Orth et al., 2012). Multiple evidences have 
established a link between the intrinsic or mitochondrial apoptotic pathway in response to mitotic aberrations 
(Huang et al, 2009;. Topham and Taylor, 2013), by contrast, the extrinsic pathway of apoptosis is not 
functional at this stage of the cell cycle (Matthess et al., 2010).  
This pathway is of great interest since, can be induced by treatment with several anti-tumoral agents, 
such as taxol. Despite its clinical relevance, little is known about the molecular pathways that mediate death 
in mitosis, mainly for the lack of a homogeneous model in which this process can be induced in an efficient 
and controlled manner. The generation of Cdc20 conditional knockout cells opens the possibility to analyze 
molecular pathways of death in mitosis in a controlled genetic model (Manchado et al., 2010). 
 
Material and Methods 
 
We made use of the mouse embryonic fibroblasts Cdc20(lox/lox), RERT (+,Cre) in which the 
conditional deletion of Cdc20 becomes effective after 4-OHT addition (Manchado et al., 2010). We have 
developed a strategy to follow individual cells for video microscopy expressing a histone reporter, H2B-GFP, 
after elimination of Cdc20 or chemical inhibition of mitosis. Mitotic onset is characterized by cell rounding, 
DNA condensation and the formation of the metaphase plate and cell death becomes evident by the addition 
to the culture media of To-Pro 3, a DNA dye which diffuses into the cell after membrane permeabilization that 
precedes death. This system allows the interrogation of the consequences of modulating several signaling 
pathways using siRNA or chemical inhibitors. Transfections of siRNA or plasmids were performed either with 
the Amaxa or Lipofectamine 2000 system following the manufacturer's instructions. For High-throughput 
studies the same experimental set up was followed (staining with To-Pro 3) but Opera microscope (Perkin 
Elmer) was used instead. For FRET the protocol described in Tsou et al., 2011  was followed and the 
fluorescence microscope (CCD) was used. For other life-cell studies SP5 confocal microscope was used-
WLL.  
Metabolic studies were performed in the Seahorse analyzer for measuring oxygen consumption and 
use extracellular acidification (Faubert et al, 2013;.. Wu et al, 2006). The analysis of extracellular metabolites 
was made by nuclear magnetic resonance (NMR) following the protocol described in Bradley et al., 2010. 
Determination of ATP levels was carried out as described in Saha et al., 2004. For the in vivo experiments 
MDA-MB-231 cells were injected subcutaneously in nude mice. When tumors reached an average volumen of 
150-200 mm3 received different treatments by intraperitoneal injection. All statistical analysis were performed 
with Prism 5 (GraphPad).  
 
In the search for specific mitotic killers, the massive screening was performed in the Opera 
microscope, whereas the single cell fate analysis was performes using Delta Vision microscope following the 
same protocols introduced earlier in this section.  
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Results  
 
1. Mitotic cell death pathways 
 
Using the Cdc20(lox/lox) RERT(+/Cre) or human cell lines arrested in mitosis by treatment with APC/C 
inhibitors, we have shown that depletion of pro-survival Bcl-2 family factors results in a dramatic reduction  
survival in mitosis. These results are consistent with recent data suggesting the importance of these factors in 
mitosis (Huang et al, 2009;. Inuzuka et al, 2011;. Topham and Taylor, 2013; Wertz et al., 2011). Intrinsic 
mitochondrial apoptotic pathway requires mitochondrial pore formation by Bak and Bax dimerization which 
precedes the release of cytochrome C and other pro-apoptotic factors and eventually caspase activation. The 
fact that Bax/Bak deficient cells die primarily by necrosis and autophagy during prolonged mitotic arrest 
suggest that other forms of cell death, in addition to apoptosis, may contribute to cell death in mitosis. 
Morphological characteristics of necrosis during mitosis were observed, however mitotic cell death seems to 
be independent of RIPK1 and RIPK3 activity and therefore programmed necrosis is not involved in MCD. 
Surprisingly, we identified autophagy as a pathway of great importance in controlling death during mitosis. 
Although traditionally, it is assumed that the processes of autophagy does not occur during this phase of the 
cell cycle (Eskelinen et al., 2002; Furuya et al, 2012;. Tasdemir et al., 2008), in this work we shown that 
autophagy remains during mitosis. It is a dynamic and progressive macro-autophagic process, which 
becomes massive at later mitotic arrest (24 hours). This autophagy can be enhanced by using inhibitors of 
mTOR and cooperates with apoptotic cell death in mitosis.  
 
Mitotic spindle assembly and chromosome segregation requires proper mitochondrial activity. It has 
recently been shown that Cdk1 is required to phosphorylate and activate various components of 
mitochondrial complex I, leading to an increase in mitochondrial respiration during G2/M (Wang et al., 2014). 
Therefore, inhibition of Cdk1 results in decreased mitochondrial activity (Wang et al., 2014) accompanied by 
reduced respiration and reduced ATP levels. During prolonged mitotic arrest observed a decrease in 
mitochondrial mass is observed, which becomes apparent after 3 hours in mitosis, initially it is due to the lack 
of organelles renewal during mitosis. This decrease in mitochondrial mass is further enhanced by the 
presence of mitophagy, an active process of autophagy which particularly target damaged mitocondria for 
elimination (Okamoto et al., 2014; Youle and Narendra, 2011). The balance between mitochondrial 
biogenesis and mitophagy determines the amount of healthy mitochondria present in the cell. The absence of 
biogenesis is probably due to the reduced transcription and translation, which perpetuates mitochondrial 
dysfunction, and is the cause of the decreased ATP levels during mitotic arrest. Mitochondrial integrity may 
therefore set the limit for cell survival for its key role in the regulation of metabolism and cell death. As a 
consequence of the loss of mitochondrial respiration, ATP production decreased (concomitantly increased 
AMP levels) leading to an energetic crisis which ultimately triggers AMPK activation, the bioenergetic sensor 
of the cell. In parallel to the decrease in oxidative phosphorylation, increase in glucose uptake is observed. 
AMPK boost glucose uptake and glycolysis through PFKFB3 activation. PFKFB3 (also known as PFK-2) is a 
key enzyme in the regulation of the glycolytic flux, modulating PFK-1 activity,  which catalyzes a primary 
checkpoint in glycolysis. PFK-1 catalyzes the conversion of fructose-6-phosphate (F6P) to fructose 1,6-
bisphosphate (F1, 6BP), an irreversible and limiting reaction in the pathway, frequently hyperactivated in 
cancer (Bando et al., 2010). AMPK phosphorylates and activates PFKFB3 at ser-461 resulting in an 
increased Vmx of the kinase activity and a decreased phosphatase activity, leading to increased production of 
Fru-6-P, the allosteric regulator of PFK-1, (Marsin et al., 2002; Novellasdemunt et al., 2012) and the 
concomitant increase in PFK-1 activity and glycolysis. PFKFB3 is often expressed in transformed cells and 
tumors (Almeida et al., 2010; Bando et al., 2005; Calvo et al., 2006; Chesney et al., 1999; Duran et al, 2008; 
Kesseler et al., 2008; Novellasdemunt et al., 2006; Riera et al., 2020; Yalcin et al., 2009) and it has been 
linked to Warburg effect (Marsin et al., 2002; Bando et al., 2005). While PFKFB3 is nuclear during interphase, 
AMPK is predominantly cytoplasmic (Tsou et al., 2011). Whereas in mitosis, upon nuclear envelope 
breakdown cytoplasmic compartments mix their content and this interaction is favoured. Genetic inhibition or 
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the use of chemical inhibitors of both  PFKFB3 and AMPK results in a reduced survival in mitosis. Similarly, 
the addition of glucose to the culture medium delays mitotic cell death. Therefore the induction of the 
glycolytic pathway during mitotic arrest is a mechanism that contributes to cell survival. 
 
2. Anti-mitotic compounds 
 
In the second part of this doctoral thesis we have focused on the search for compounds that reduce 
specifically cell viability of mitotic cells, that is, compounds that induce cell death in mitosis. To do this, we 
made use Cdc20 conditional knockout cells and we tested a library of 300 compounds in its ability to 
specifically kill cells in mitosis.  
This study has allowed us to identify Haspin kinase as a potential anti-mitotic target. Haspin is 
considered an atypical mitotic kinase responsible for phosphorylation of histone 3 in the threonine-3, which 
acts as an docking site for the chromosome passenger complex (CPC), consisting of survivin, Aurora B, 
Borealin and INCENP (Cuny et al., 2012). Haspin inhibition in Cdc20-null cells enhanced cell death in mitosis, 
while inhibition of Haspin in asynchronous cultures leads to a transient mitotic arrest often followed by cell 
death in mitosis, in agreement with previous data (Dai et al., 2005; Niedzialdhowska et al, 2012; Wang et al., 
2011). Haspin inhibitors results in a longer mitotic arrest than taxol treatment and it seems to be dependent 
on the activity of the mitotic checkpoint (SAC) given that treatment with reversine, an inhibitor of Mps1, the 
kinase activity of the SAC, rescued the normal duration of mitosis. However, it has been recently published 
that Haspin inhibition can abrogate SAC activity (De Antoni et al., Wang et al., 2010). 
 
Discussion 
 
1. Mitotic cell death pathways  
 
Here we have stablished that inhibition of survival pathways or  induction of cell death pathways in 
mitosis enhanced cell death during mitosis before mitotic slipagge occurs. This finding may have important 
implications in cancer therapy avoiding the accumulation of aneuploid cells and increasing the therapeutic 
efficacy of anti-mitotic drugs currently used in clinics. The combination of microtubule poisons and apoptosis 
inducers has been extensively studied (Inuzuka et al, 2011; Oltersdorf et al., 2005; Topham and Taylor., 
2013; Wertz et al., 2011) and are of particular interest in specific celular settings, for example in tumors 
overexpressing Bcl-2 (Oakes et al., 2011). Similarly, combinations of taxol and mTOR inhibitors or inhibitors 
of enzymes involved in metabolism have been extensively tested in xenograft models (Campone et al, 2009; 
Lieber et al., 2011; Meier et al., 2009). However, in this study we show for the first time the molecular basis 
underlying this synergistic effect. Together these data provide the molecular basis for new combination 
therapies directed against cell cycle and metabolism in cancer.  
 
2. Anti-mitotic compounds  
 
The molecular mechanism by which inhibition of Haspin results in cell death in mitosis is still unknown. 
As Haspin activity is responsible for the proper localization of the CPC, lack of Haspin activity could lead to 
misslocalization and deficient activation of Aurora B, therefore Aurora B inhibition might affect mitosis in the 
same way that inhibition of Haspin. However, genetic deletion of Aurora B in mouse embryonic fibroblasts, as 
well as the use of inhibitors of Aurora B leads to a shorter mitosis compared to control fibroblasts, as a results 
from premature inactivation of mitotic checkpoint point. Survivin, given its ability to prevent apoptosis by direct 
inhibition of caspases (Chan et al., 2012), seems to be a good candidate to explain the reduced survival after 
inhibition of Haspin in mitosis. Indeed, Survivin silencing shorten survival in mitosis, although this is 
something that needs to be further studied. Inhibition of Haspin in Survivin overexpressing tumors could be 
beneficial as anti-tumor therapy. 
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Resumen 
 
Introducción 
A lo largo del proceso de transformación neoplásica las células adquieren de manera progresiva una 
serie de alteraciones que les otorgan de la capacidad de sobrevivir, proliferar y diseminarse. Estas funciones 
son adquiridas por los distintos tipos tumorales mediante diferentes mecanismos y a varios tiempos durante 
el proceso secuencial de tumorigenesis. Un rasgo principal de las células tumorales es la capacidad de 
proliferación incontrolada (Malumbres and Barbacid, 2001; Hanahah and Weinberg, 2011). Por ello la 
quimioterapia actual se centra en atacar específicamente células con alta tasa proliferativa (Chabner et al., 
2006) y las estrategias que interfieren con el ciclo celular parecen ser una buena opción terapéutica. Entre 
otras estrategias, el bloqueo específico de la progresión mitótica parece un buen candidato para evitar el 
avance tumoral. La mitosis es la fase del ciclo celular de mayor fragilidad y de mayor sensibilidad a muerte 
en respuesta a daño, lo que la convierte en un punto crítico para la intervención terapéutica (Chan et al., 
2011).  
El gran éxito clínico alcanzado por los venenos de microtubulos, como taxanos y vinka-alkaloides, ha 
potenciado el desarrollo de agentes que inhiban la progresión mitótica. Sin embargo, el hecho de que el 
citoesqueleto de tubulina  desempeñe funciones fundamentales tanto en mitosis como en interfase, ha hecho 
replantear si el efecto observado por estos agentes se debe exclusivamente a su acción durante mitosis. De 
hecho, uno de los grandes problemas del uso de estas drogas es la gran neurotoxicidad asociada, lo que 
conlleva frecuentemente el cese del tratamiento. Se hace necesario el desarrollo de inhibidores de 
reguladores de mitosis; proteínas involucradas en la formación del huso y la progresión mitótica y que 
carezcan de estos efectos secundarios. De hecho, inhibidores selectivos de kinesinas y kinasas mitóticas 
están actualmente en diferentes fases de ensayos clínicos, aunque los resultados en pacientes no han 
alcanzado las expectativas. En general, esta nueva generación de inhibidores dirigidos a mitosis muestran 
menor eficacia anti-tumoral que el taxol, aunque el problema de la neurotoxicidad haya sido resuelto. Una de 
las razones por las que el efecto de estas drogas puede verse limitado es por la baja tasa mitótica en 
tumores humanos, mucho más reducida que en modelos preclínicos (Doménech and Malumbres, 2013). 
Además los programas de desarrollo de drogas se han centrado tradicionalmente en el desarrollo de 
inhbidores de Plk1 y Aurora A y B como dianas anti-tumorales. Recientemente varios miembros de la familia 
de las kinesinas están emergiendo como potenciales dianas anti-tumorales, sin embargo, hay una gran 
variedad de kinasas mitóticas cuyo potencial como diana terapéutica aún no ha sido explorado, como es el 
caso de: Nek, Mps1, Mast o Haspin. 
La parada en mitosis observada como consecuencia del tratamiento con drogas anti-mitóticas es 
frecuentemente transitoria y las células son capaces de salir de mitosis (es decir, son capaces de 
descondensar el ADN y ensamblar el nuevo núcleo en ausencia de segregación cromosomal), a pesar de la  
permanente actividad del punto de control mitótico en un proceso conocido como “escape mitótico” (Brito and 
Rieder, 2006; Topham and Taylor, 2013). El escape mitótico es considerado uno de los principales 
mecanismos de resistencia ante drogas anti-mitóticas. En estas condiciones es frecuente la aparición de 
células aneuploides que pueden continuar proliferando.  
 Las células eucariotas poseen mecanismos de control para detectar errores que puedan ocurrir 
durante el ciclo celular interrumpiendo la progresión y si es posible permitiendo su reparación. Uno de estos 
mecanismos está mediado por el APC/C (Anaphase Promoting Complex o ciclosoma), un complejo 
multimérico con actividad enzimática ubiquitina ligasa E3 necesario para la segregación cromosómica, que 
marca con ubiquitina diversos reguladores del ciclo celular para su posterior eliminación por el proteasoma. 
El APC/C reconoce sus sustratos gracias a dos proteínas adaptadoras; Cdh1 y Cdc20. Cdc20 es 
responsable de la función de APC/C durante las fases iniciales de mitosis y por desencadenar la transición 
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de metafase a anafase. Cuando los cromosomas están perfectamente alineados en la placa metafásica y 
anclados mediante los microtúbulos a ambos polos del huso, la activación de APC/C por Cdc20 resulta en la 
eliminación de dos sustratos críticos; securina (inhibidor de separasa) y ciclina B (activador de Cdk1), lo que 
conlleva salida de mitosis (Manchado et al. 2010). En ausencia de Cdc20, las células no son capaces de salir 
de mitosis y permanecen bloquedadas en metafase durante 6-36 horas e irremediablemente mueren 
(Manchado et al. 2010). La inhibición del APC/C ha sido recientemente propuesta como opción terapéutica 
para la prevención del escape mitótico (Doménech and Malumbres, 2013; Huang et al., 2009; Machado et 
al., 2011; Rieder and Medema, 2009).  
 
Cómo mueren las células que carecen de Cdc20 es una incógnita de gran interés. Se sabe que las 
células no pueden permanecer bloqueadas en mitosis durante mucho tiempo, ya que se lanza una cascada 
de muerte conocida como muerte celular en mitosis. En general, las alteraciones consecuencia de mitosis 
aberrantes se conocen como catástrofe mitótica (Vitale et al., 2011). La catástrofe mitótica (CM) puede ser 
definida como un tipo de muerte celular resultado de una mitosis aberrante que sucede en mitosis o en la 
interfase siguiente (Galluzi et al., 2012; Vitale et al., 2011). Es por tanto diferente de apoptosis, necrosis o 
senescencia y está conducida por una cascada de señalización apenas conocida. CM puede ser 
considerada un mecanismo oncosupresor (Vitale et al., 2011) ya que evita inestabilidad cromosómica y 
previene la aparición de células aneuploides. La interrupción de CM favorece la progresión tumoral y su 
inducción constituye un punto final terapéutico. A pesar del amplio uso que se hace de este concepto, no se 
conocen adecuadamente los mecanismos moleculares que determinan la muerte celular en respuesta a 
estas alteraciones. Además, no está claro si estas rutas de muerte celular son funcionales durante mitosis, o 
si por el contrario surgen como una consecuencia de alteraciones durante mitosis que se efectúan en el ciclo 
celular siguiente. Por ejemplo, un arresto mitótico prolongado activa parcialmente caspasas específicas, 
causando daño al ADN y la inducción de apoptosis dependiente de p53 en la interfase siguiente  (Orth et al., 
2012). Entre las rutas de muerte celular múltiples pruebas han establecido una conexión entre la vía 
intrínseca o mitocondrial de apoptosis en respuesta a aberraciones mitóticas (Huang et al., 2009; Topham 
and Taylor, 2013), por el contrario, la ruta extrínseca de apoptosis no es funcional en este estadio del ciclo 
celular (Matthess et al., 2010).  
Esta ruta es de gran importancia ya que, como se ha introducido anteriormente, se puede inducir por 
tratamiento con diversos compuestos químicos, como taxol, empleados en la terapia del cáncer. Pese a su 
gran relevancia clínica, no se conoce mucho sobre las rutas moleculares que median la muerte en mitosis, 
principalmente por falta de un modelo homogéneo en el que suceda este proceso de una manera eficiente y 
controlada. La generación de células con una deleción condicional en el gen Cdc20 inducible con 4-hidroxi-
tamoxifeno, abre la posibilidad de analizar las rutas moleculares de muerte en mitosis en un modelo genético 
controlado (Manchado et al., 2010).  
 
Materiales y Métodos 
Hemos usado los fibroblastos embrionarios de ratón Cdc20(lox/lox), RERT(+,Cre) en los que la 
deleción condicional del alelo Cdc20 se hace efectiva tras adición de 4-hidroxitamoxifen (4-OHT) por la 
presencia de la versión inducible de Cre (Manchado et al., 2010). Hemos desarrollado una estrategia por 
videomicroscopía, mediante la cual es posible seguir a cada célula de manera individual tras parada mitótica 
por eliminación de Cdc20 o inhibición química de mitosis. El comienzo de la mitosis se caracteriza por que la 
célula comienza a redondearse y el ADN a condensarse, hasta que se hace evidente la formación de una 
placa metafásica, para ello usamos células que expresen histona H2B-GFP, mientras que la muerte celular 
se hace evidente por la adición al medio de To-Pro3, un colorante de ADN que difunde al interior de la célula 
tras permeabilización de la membrana plasmática que antecede a la muerte. Este sistema permite 
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caracterizar las consecuencias de la alteración de varias rutas de señalización usando ARN inteferente 
(ARNi) o inhibidores químicos. Las transfecciones de ARNi o plásmidos fueron realizadas con el sistema 
Amaxa o con Lipofectamina 2000 siguiendo las instrucciones del fabricante. Para un análisis a mayor escala 
de estas rutas de muerte mitótica, se empleó el mismo desarrollo experimental (tinción con To-Pro 3), pero 
se utilizó un microscopio de análisis masivo: Opera (Perkin Elmer). Para los estudios de FRET se siguió el 
protocolo descrito en Tsou et al., 2011 un microscopio de fluorescencia (CCD) y para otros ensayos en 
células vivas se empleó el microscopio confocal SP5-WLL. 
Para los estudios metabólicos se empleó el analizador Seahorse, para medidas de consumo de 
oxígeno y acidificación extracelular (Faubert et al., 2013; Wu et al., 2006) y para el análisis de metabolitos 
extracelulares se emplearon técnicas de resonancia magnética nuclear (RMN) siguiendo el protocolo descrito 
en Bradley et al., 2010.  La determinación de niveles de ATP se llevó a cabo según lo descrito en Saha et al., 
2004. Para los experimentos in vivo se utilizaron ratones “desnudos” a los que se inyectó de manera 
subcutánea células de la línea MDA-MB-231 y cuando los tumores alcanzaron un volumen entre 150-200 
mm3 recibieron un tratamiento intraperitoneal con diferentes drogas.  Todos los análisis estadísticos fueron 
realizados con Prism 5 (GraphPad). 
Para la búsqueda masiva de compuestos que inducen muerte mitótica y su posterior análisis más 
detallado se emplearon los mismos protocolos descritos al inicio de este apartado. 
 
Resultados 
1. Rutas de muerte en mitosis 
 Haciendo uso de estas células Cdc20(lox/lox) RERT(+/Cre) y al mismo tiempo en células humanas 
bloqueadas en mitosis por inhibición del APC/C hemos mostrado que la eliminación de factores pro-
supervivencia de la familia Bcl-2 resulta en una reducción dramática de la supervivencia. Estos resultados 
están en concordancia con datos recientes que sugieren la relevancia de estos factores en mitosis (Huang et 
al., 2009; Inuzuka et al., 2011; Topham and Taylor, 2013; Wertz et al., 2011). La vía intrínseca mitocondrial 
de apoptosis requiere la formación del poro mitocondrial por dimerización de Bak y Bax que precede a la 
liberación de citocromo c y otros factores pro-apoptóticos y a la activación de caspasas. El hecho de que las 
células deficientes en Bax/Bak mueran principalmente por necrosis y autofagia durante bloqueo mitótico 
prolongado, sugiere que otras formas de muerte celular, además de apoptosis, pueden colaborar en la 
muerte celular en mitosis (MCM). De hecho, observamos características morfológicas de necrosis durante 
mitosis, aunque este tipo de muerte parece ser independiente de RIPK1 y RIPK3 y por tanto no se trata de 
un proceso necrótico programado o necroptosis. Sorprendentemente, hemos identificado a la autofagia como 
una ruta de gran importancia en el control de muerte durante mitosis. Aunque tradicionalmente se asume que 
los procesos de autofagia no suceden durante esta fase del ciclo celular (Eskelinen et al., 2002; Furuya et al., 
2012; Tasdemir et al., 2007; Tasdemir et al., 2008), en este trabajo hemos demostrado que la autofagia 
permanece durante mitosis. Se trata de una macro-autofagia dinámica y progresiva, que se induce de forma 
masiva a tiempos tardíos (24 horas) de arresto mitótico. Esta autofagia puede ser potenciada mediante el 
uso de inhibidores de mTOR y coopera con la apoptosis en muerte celular en mitosis.   
La formación del huso mitótico y segregación cromosómica requiere una correcta actividad 
mitocondrial. Se podría decir que la fosforilación oxidativa es la principal fuente de ATP en mitosis y que es 
esencial para la transición G2/M. De hecho, recientemente ha sido demostrado que Cdk1 es requerida para 
fosforilar y  activar varios componentes del complejo I mitocondrial, lo que lleva a un aumento de la 
respiración mitocondrial durante G2/M (Wang et al., 2014). Por el contrario, la inhibición de Cdk1 da lugar a 
una disminución en la actividad mitocondrial (Wang et al., 2014) acompañada de caída de la respiración y 
reducción en los niveles de ATP disponibles. Durante un bloqueo mitótico prolongado, hemos observado una 
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caída en la masa mitocondrial, que se hace evidente después de varias horas de arresto en mitosis y que 
inicialmente se debe a la falta de renovación de orgánulos durante mitosis. Esta caída en masa mitocondrial 
se ve potenciada por la presencia de mitofagia, un proceso activo de autofagia especialmente dirigido a la 
eliminación de mitocondrias dañadas y que suponen un daño potencial para la célula (Okamoto, 2014; Youle 
and Narendra, 2011). El balance entre biogenesis mitocondrial y mitofagia determina la cantidad de 
mitocondrias sanas presentes en la célula. La reducción en biogenesis se debe probablemente a la reducida 
transcripción y traducción en células mitóticas que perpetua la disfunción mitocondrial y es la causa de la 
reducción en los niveles de ATP durante arresto mitótico. La integridad mitocondrial puede tratarse del límite 
en cuanto a supervivencia celular ya que juega un papel fundamental en regulación de metabolismo y muerte 
celular.  
 
La pérdida de respiración mitocondrial conduce a una caída en la producción de ATP (y consecuente 
aumento en los niveles de AMP) lo que origina una crisis energética  desencadenante de  la activación de 
AMPK, el sensor bioenergético de la célula. Paralelamente a la reducción en fosforilación oxidativa hemos 
observado un aumento en el consumo de glucosa. Este aumento del consumo de glucosa y de glicólisis se 
debe a la regulación que ejerce AMPK sobre PFKFB3. PFKFB3 (también conocida como PFK-2) es una 
enzima clave en la regulación del flujo glicolítico, ya que modula la actividad PFK-1 que cataliza un punto 
primario de control de glicólisis. PFK-1 cataliza la conversión de fructosa-6-fosfato (F6P) a fructosa 1,6-
bifosfato (F1, 6BP), una reacción limitante e irreversible en la ruta que establece la velocidad del flujo 
glicolítico y aparece frecuente hiperactivada en cáncer (Bando et al., 2010). AMPK fosforila y activa PFKFB3 
en el residuo ser-461 que experimenta un incremento en la velocidad máxima de la reacción kinasa y 
disminución de la actividad fosfatasa, lo que da lugar a un incremento en la producción de Fru-6-P (Marsin et 
al., 2002; Novellasdemunt et al., 2012) que en consecuencia aumenta la actividad PFK-1 y la glicólisis. 
PFKFB3 se expresa en células transformadas y tumores (Almeida et al., 2010; Bando et al., 2005; Calvo et 
al., 2006; Chesney et al., 1999; Duran et al., 2008; Kesseler et al., 2008; Novellasdemunt et al., 2006; Riera 
et al., 2020; Yalcin et al., 2009) y se ha relacionado a esta proteína con el efecto Warburg (Marsin et al., 
2002; Bando H et al. 2005). PFKFB3 es nuclear durante interfase, mientras que la de AMPK es 
predominantemente citoplasmática (Tsou et al., 2011). En mitosis, esta interacción se ve favorecida, ya que 
la rotura de la envuelta nuclear resulta en la combinación de los compartimentos núcleo y citoplasma. La 
inhibición genética y el uso de inhibidores químicos de ambos AMPK y PFKFB3 da lugar a una reducción de 
la supervivencia en mitosis. Similarmente, la adición de glucosa al medio de cultivo de células mitóticas 
retrasa su muerte. Por tanto la inducción de la ruta glicolítica durante el bloqueo mitótico se trata de un 
mecanismo que contribuye a la supervivencia celular.  
 
2. Compuestos anti-mitóticos 
En la segunda parte de esta tesis doctoral nos hemos centrado en la búsqueda de compuestos que 
reduzcan, específicamente, la viabilidad en células mitóticas; es decir, compuestos que induzcan muerte 
celular en mitosis. Para ello, hemos usado de nuevo como modelo de estudio los fibroblastos embrionarios 
de ratón del modelo de eliminación condicional para Cdc20 y hemos testado una librería de 300 compuestos, 
en su habilidad para matar específicamente células en mitosis. 
 Este estudio nos ha permitido identificar la kinasa Haspin como una potencial diana anti-mitótica. 
Haspin se considera una kinasa atípica encargada de la fosforilación mitótica de la histona 3 en la treonina-3, 
que actúa como un sitio de anclaje para complejo pasajero cromosómico  (formado por survivina, Aurora B, 
borealina e INCENP) (Cuny et al., 2012). En células deficientes en Cdc20, la inhibición de Haspin potencia la 
muerte celular, mientras que la inhibición de Haspin en cultivos asíncronos conduce a una parada mitótica 
transitoria y muerte en mitosis, de acuerdo con datos previos (Dai J et al., 2005; Niedzialdhowska et al., 
2012; Wang et al., 2011). Los inhibidores de Haspin son capaces de producir una parada mitótica más 
prolongada que el taxol y al mismo tiempo son más. Esta parada en mitosis parece ser dependiente de la 
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actividad del punto de control mitótico, ya que tratamiento con reversina, un inhibidor de Mps1, la actividad 
kinasa del punto de control, es capaz de rescatar la duración normal de mitosis. Sin embargo, 
recienetemente ha sido publicado que,  la inhibición de Haspin puede inhibir la actividad del punto de control 
mitótico (De Antoni et al., Wang et al., 2010). 
 
Discusión 
 
1. Rutas de muerte celular en mitosis 
Estos datos son de gran relevancia en la terapia anti-tumoral ya que establecen que la inhibición de 
las rutas que mantienen supervivencia en mitosis o la inducción de rutas de muerte favorecen la muerte 
celular en mitosis antes de que tenga lugar el escape mitótico. Este hallazgo puede ayudar a prevenir la 
acumulación de células aneuploides y aumentar la eficacia terapéutica de estas drogas. La combinación 
entre venenos de microtúbulos e inductores de apoptosis ha sido extensamente estudiada (Inuzuka et al., 
2011; Oltersdorf et al., 2005; Topham and Taylor, 2013; Wertz et al., 2011) y son de particular interés en 
escenarios concretos, por ejemplo en tumores que sobreexpresan Bcl-2 (Oakes et al., 2011). Del mismo 
modo, las combinaciones de taxol e inhibidores de mTOR o inhibibores de enzimas involucradas en el 
metabolismo han sido ampliamente probados en modelos murinos de xenotransplantes (Campone et al., 
2009; Lieber et al., 2011; Meier et al., 2009). Sin embargo, en este estudio mostramos por primera vez las 
bases moleculares de este efecto sinergístico. En conjunto estos datos proporcionan las bases moleculares 
para nuevas terapias combinadas dirigidas contra el ciclo celular, rutas de muerte celular y metabolismo en 
cáncer.  
 
 2. Compuestos anti-mitóticos 
Parece lógico pensar que la inhibición de Haspin produzca el mismo resultado que la inhibición de 
Aurora B, ya que puede resultar en deslocalización del complejo pasajero cromosómico, y en consecuencia 
la deficiente activación de Aurora B. Sin embargo, la eliminación genética de Aurora B en fibroblastos 
embrionarios de ratón, así como el uso de inhibidores de Aurora B, resulta en una mitosis más corta que en 
fibroblastos control que es consecuencia de la inactivación prematura del punto de control mitótico, es decir, 
el resultado opuesto. Survivin, por su habilidad de prevenir apoptosis por inhibición directa de caspasas 
(Chan et al., 2012), parece ser un buen candidato para explicar la reducida supervivencia en mitosis tras 
inhibición de Haspin. De hecho, el silenciamiento de Survivin reduce la supervivencia en mitosis. Aunque es 
algo que necesita ser estudiado en profundidad, la inhibición de Haspin en tumores que sobreexpresan 
Survivin podría ser beneficioso como terapia anti-tumoral. 
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1. The mammalian cell cycle  
Cell division requires two major sequential steps: duplication of the genome, achieved during S-phase 
(or DNA synthesis phase), and chromosome segregation of newly replicated genomes into two daughter cells 
a process known as mitosis (M-phase; Figure 1). Two gap phases alternate: G2 in between S and the M-
phase and G1 in between M and the S-phase of the subsequent cell cycle. Upon unfavorable conditions, cells 
enter a resting state known as G0 or quiescence, a stage in which the majority of the cells in adult tissues are 
when they reach maturity. The three previous steps to M-phase are grouped and termed as interphase. 
Cell-cycle progression is based on highly ordered events forming a dependent sequence. If an early 
event is blocked, then usually none of the following events takes place, and a complex system of control at 
different levels allows the activation of each process at the right time in an ordered and irreversible way. 
Molecular basis of this mechanism of control relies in the activity of a family of cyclin-dependent protein 
kinases (Cdks) (Hartwell and Weinnert, 1989; Hunt, 1989; Hunt, 2001; Nurse, 1990; Nurse, 1994) that 
activates or inactivates target proteins to coordinate entry into the next phase of the cell cycle. Cdks are 
inactive in the absence of a partner cyclin, which form the regulatory subunits, and Cdks the catalytic subunits 
of an activated heterodimer. Different cyclin-Cdk combinations determine the downstream proteins targeted. 
Whereas Cdks levels remain constant throughout the cell cycle cyclins are synthesized and degraded at 
specific stages of the cell cycle. Proper progression through the cell cycle also depends on the timely 
phosphorylation-dephosphorylation, which may influence positively or negatively Cdks activity. Cdk2 
phosphorylation at Thr-160 activates, whereas Cdk1 phosphorylation at Thr-14 and Tyr-15 inhibits Cdk1 
activity (Gu et al., 1992; Lindqvist et al., 2009). The rise and fall of Cdks activity is also regulated by binding of 
Cdks inhibitor proteins, named CKI. CKI are grouped in two molecular families: INK4 whose four members 
(p16INK4a, p15INK4b, p18INK4c, p19INK4d) exclusively bind to and inhibit the D-type cyclin-dependent kinases 
(Cdk4 and Cdk6), and the CIP/KIP family, whose three members (p21CIP1/WAF1, p27KIP1, p57KIP2) are able to 
inhibit the activity of all Cdks (Sherr and Roberts, 1999). Expression of any of the CKIs results in growth 
arrest in the G1 phase and prevents entry into the DNA synthetic phase (Sherr and Roberts, 1999). The 
expression of cell cycle regulators is also controlled at the transcriptional level during early phases. Growth 
arrest is accomplished by repression of the E2F transcription factors by pRb binding, which are required for 
the transcriptional activation of genes necessary for DNA synthesis (Dyson, 1998). Mitogenic signals induce 
cyclins D expression that binds and activate Cdk4 and Cdk6 (Malumbres and Pellicer, 1998), which in turn 
phosphorylates pRb promoting its dissociation from E2F that is now able to induce the expression of essential 
proteins for cell cycle regulation.  
In addition, Cdks activity is regulated by proteolysis: ubiquitin ligases recognize cyclins at specific 
points of the cell cycle and target them for proteasome degradation. The major proteolytic activities are the 
SCF (Skp1/Cullin/F-box), which controls G1/S through G2/M transitions and the Anaphase-promoting 
complex (APC/C) (Acquaviva and Pines, 2006; Cardozo and Pagano, 2004; Harper et al., 2002; King et al., 
1996; Peters, 2006) that is responsible for targeting critical regulators for degradation during mitosis and G1 
until its activity is inhibited at the G1/S transition. The SCF complex participates in the ubiquitylation of cyclins 
D, E, A, and some Cdks inhibitors (CKIs) during G1 and S-phases, whereas the APC/C ubiquitylates cyclins 
A and B during mitosis.  
In summary, progression through the cell cycle is subject to several mechanisms of control at different 
levels in order to ensure a unidirectional sequence of events that follows each other. This complex system of 
control has the ability to delay progression into the subsequent phase when a defect has been detected 
providing of extra time for error correction and avoidance of damage accumulation. Hartwell and Weinert 
introduced this concept as ‘checkpoints’ in 1989. Checkpoint pathways are the mechanism by which an 
uncompleted cell cycle event sends an inhibitory signal to later events stopping progression. The eukaryotic 
cell cycle is guarded by at least by three checkpoints: at the G1/S boundary (G1 checkpoint), the G2/M 
boundary (G2 or DNA damage checkpoint), and the metaphase/anaphase boundary (mitotic or spindle 
assembly checkpoint; SAC).  
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Figure 1. The cell division cycle. Interphase consists on three phases: G1, S and G2 phases. During S-phase cell 
duplicate their genome that will be distributed giving rise to two complete daughter cells. G1 and G2 are the interval 
in between M-S and M-S respectively. These two gap phases are of relevant importance because provide time for 
growing and the accumulation of cellular components and organelles that afterward will distribute between the two 
daughter cells. When extracellular conditions are unfavorable cells can enter a resting state named G0. Most cells in 
adults are in a quiescent state that resembles G0 that in some cases can be bypassed upon mitogenic signals. Cell 
cycle progression is regulated by several checkpoints pointed out by arrows; G1 checkpoint, G2 checkpoint or DNA 
damage checkpoint and the mitotic checkpoint or SAC. (Adapted from Kong et al., 2010). Cdks are inactive in the 
absence of a partner cyclin and different cyclin-Cdk combinations determine the downstream proteins targeted. 
Whereas Cdks levels remain constant throughout the cell cycle cyclins are synthesized and degraded at specific 
stages of the cell cycle. The rise and fall of Cdks activity is also regulated by binding of Cdks inhibitor proteins: INK4 
whose four members (p16INK4a, p15INK4b, p18INK4c, p19INK4d) exclusively bind to and inhibit the D-type cyclin-
dependent kinases (Cdk4 and Cdk6), and the CIP/KIP family, whose three members (p21CIP1/WAF1, p27KIP1, p57KIP2) 
are able to inhibit the activity of all Cdks. The expression of cell cycle regulators is also controlled at the 
transcriptional level during early phases: repression of the E2F transcription factors by pRb binding, which are 
required for the transcriptional activation of genes necessary for DNA synthesis. In addition, Cdks activity is regulated 
by proteolysis: ubiquitin ligases recognize cyclins at specific points of the cell cycle and target them for proteasome 
degradation. APC/C ubiquitylates cyclins A and B during mitosis.  
 
2. Mitosis 
Mitosis is the last step of the mammalian cell cycle, by which the genetic material is equally distributed 
into two daughter cells. Cells undergo dramatic changes in structure at the transition from interphase to 
mitosis; despite being the shortest phase of the cell cycle it orchestrates major changes in multiple cellular 
components. This extraordinary conversion is required to successfully divide the entire cellular content to 
generate two viable daughter cells, each one containing an identical copy of the entire genome. The overall 
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changes need to be carefully controlled because a failure in cell division can lead to unequal segregation of 
chromosomes and genetic imbalance. Multiple kinases contribute to the transition into mitosis by 
phosphorylation of a large number of substrates (Dephoure et al., 2008) (Figure 1). The activity of these 
kinases induce cell rounding, chromosome condensation, nuclear envelope breakdown, organelle 
fragmentation, and spindle assembly, that is, turn the cell into a mitotic state consisting on 5 sequential 
phases: prophase, prometaphase, metaphase, anaphase and telophase (Figure 2). During prophase 
chromosomes start to condense, which is usually accompanied by the formation of microtubule asters around 
centrosomes and centromere separation. Microtubule dynamics results in the formation of the mitotic spindle, 
nuclear pores start to disassembly, followed by nuclear lamina depolimeryzation. NEBD (nuclear envelope 
breakdown) indicates the advent of prometaphase (Álvarez-Fernández and Malumbres, 2014; Guttinger et 
al., 2009). In this phase microtubules bind to kinetochores and metaphase is marked by the attachment and 
alignment of the chromosomes at the metaphase plate. Upon anaphase onset, sister chromatids separate 
towards the spindle poles, and during telophase chromosomes decondense giving rise to two identical 
daughter nuclei, in parallel cytokinesis begins, resulting in separation of cytoplasm and cell division.  
Nuclear and cytoplasmic compartments, which were separated during interphase, upon mitotic onset 
mix their content resulting in a dilution of nuclear and cytoplasmic activities, changes in stoichiometry of 
different enzymatic complexes or dissipation of the molecular gradients from nuclei to cytoplasm, which might 
affect the molecular environment of the cell, specifically its phosphorylation status that condition some 
enzymatic activities (Álvarez-Fernández and Malumbres, 2014). The Cdk1-cyclin B1 complex, through its 
cytoplasmic, nuclear and centrosomal localization, synchronize multiple of these different events during 
mitotic entry (Hunt 1989 and Nurse, 1990; Takizawa and Morgan, 2000). The microtubule spindle binds to 
condensed chromosomes, Golgi membranes clusters are divided into individual stacks (Lowe et al., 2000), 
nuclear envelope membranes are retracted into the ER (endoplasmic reticulum) and mitochondria are 
fragmented through the Cdk1-dependent phosphorylation of Drp1, the dynein responsible for mitochondrial 
fission (Taguchi et al., 2007). All these processes take place in an average time of an hour, in physiological 
conditions, and in the almost complete absence of protein synthesis. At this stage transcription is strongly 
suppressed and mitotic entry, as well as G0, results in a global down regulation by as much as 60 to 80% of 
cap-dependent mRNA translation (Stumpf et al., 20013). However, allowed by mTORC1 activity, some levels 
of mRNA translation of protein needed for maintain the mitotic state, such as cyclin B, are sustained during 
mitosis (Quin, et al., 2004; Siva, et al., 2008).  
The activation of the mitotic kinases is closely orchestrated through feedback and feed-forward loops 
in the mitotic entry network (Lindqvist et al., 2009). Cdk1-cyclin B1 complex is considered as the central 
component of the mitotic entry network that phosphorylates hundreds of proteins. Cdk1-dependent 
phosphorylation is an important determinant of the mitotic state, given that a large fraction of the mitotic 
phosphorylation occurs on Cdk1 consensus motifs and inhibition of Cdk1 activity forces cells to exit mitosis. In 
addition to Cdk1 activation, other kinases play an important role either in mitotic entry, progression through 
this phase or participating in additional levels of regulation of Cdk1 activity. Among this mitotic kinases are the 
Polo and Aurora family of kinases (Figure 1). Polo kinase family consists of five members being Plk1 (Polo-
like-kinase-1) the more extensively characterized. In the G2/M transition Plk1 promotes centrosome 
maturation (Lane and Nigg, 1996) and activates the transcription factor FoxM1, which enhances the 
transcription of some genes necessary for mitotic entry such as cyclin B, Plk1 and the phosphatase Cdc25 
(Fu et al., 2008). Plk1 also participates in the activation of Cdk1 through inhibition of Wee1 and Myt1, 
negative regulators of Cdk1 (Nakajima et al., 2003; Watanabe et al., 2004). It also phosphorylates the 
regulatory subunit of Cdk1-cyclin B complex (Toyoshima-Morimoto et al., 2001). And moreover is involved in 
cytokinesis (Lens et al., 2010). Among the Aurora family of kinases, Aurora A is also involved in centrosome 
maturation, mitotic spindle formation and Cdk1 activation through phosphorylation and Cdc25b activation 
(Barr and Gerley 2007; Dutertre et al., 2004; Lens et al., 2010; Malumbres, 2011). In late G2 Aurora B 
phosphorylates histone H3 at Ser-10, which is involved in chromosome condensation and is a hallmark of 
mitosis. Aurora B, in association with inner centromere protein (INCENP), Borealin and Survivin forms the 
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chromosomal passenger complex (CPC), which regulates proper kinetochore-microtubule attachment and 
cytokinesis (Carmena et al., 2012). Haspin phosphorylation of histone H3 at threonine 3 (H3T3ph) during 
mitosis promotes CPC components localization on mitotic chromatin, particularly at the centromere, which 
positions and activates Aurora B, leading to the downstream phosphorylation of a variety of substrates (De 
Antoni et al., 2012; Kelly et al., 2010; Wang et al., 2011) to ensure chromatin cohesion, metaphase alignment 
and normal progression through the cell cycle. Dephosphorylation of H3T3ph at the exit from M phase is 
required for proper chromosome decondensation and nuclear envelope formation (Kelly et al., 2010). Another 
family of kinases essential for mitosis is Nek kinases (NIMA-related kinases), which consist on 11 proteins, 
being Nek2 the most extensively characterized. Nek2 is involved in modulation and maintenance of 
centrosome. Some studies suggest that Nek2 activity regulates duplicated centrosomes separation upon 
mitotic onset by phosphorylation of centriolar proteins (Fry et al., 1998). The activity of all these mitotic 
kinases contributes to the phosphorylation of a wide spectrum of proteins involved in the necessary 
rearrangement that accompany mitosis 
 
Figure 2. Phases of mitosis. Mitosis consits on 5 sequential phases: prophase, prometaphase, metaphase, anaphase and 
telophase.  Chromosomes condensation and microtubule aster formation starts in prophase. Bipolar microtubule spindle is formed in 
prometaphase but is in metaphase when microtubules are perfectly attached to chromosome kinetochores at the metaphase plate. 
Upon anaphase onset sister chromatids separate followed by chromosome decondensation during telophase, giving rise to two 
genetically identical daughter cells. In addition to Cdk1, Polo and Aurora kinases family are also involved in mitotic entry and 
progression or participating in additional levels of regulation of Cdk1 activity.  In the G2/M transition Plk1 promotes centrosome 
maturation and is involved in cytokinesis. Aurora B in association with INCENP, Borealin and Survivin forms the CPC which 
regulates proper kinetochore-microtubule attachment and cytokinesis. And Aurora A is involved in mitotic spindle formation during 
prometaphase. 
 
3. The Anaphase-promoting complex/Cyclosome (APC/C) 
 
The APC/C was discovered by Avram Heshko and Marc Kirschner and is composed of roughly a 
dozen subunits, measures a massive 1.5 MDa being the most complex ubiquitin ligase discovered so far. It 
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was first characterized as the machinery needed for cyclins degradation upon exit from mitosis and the factor 
responsible for their cyclic expression pattern (Glotzer et al., 1991; Sudakin et al., 1995). This discovery was 
based on biochemical purification by the Hershko group who called it cyclosome, as well as identification by 
the Kirschner group of vertebrate homologues of yeast cell cycle mutants genes, previously isolated by Lee 
Hartwell and colleagues in the early 1970s, who termed it APC (anaphase-promoting complex). The term 
APC has been taken already for other proteins in the cell, so the current terminology is APC/C to properly 
acknowledge these early discoveries (Peters, 2006). The APC/C is an unusual complex multi-subunit E3 
ubiquitin ligase, that mediates the ubiquitylation of a broad array of mitotic regulatory proteins for its later 
degradation by the 26S proteasome (Peters, 2006; Thornton and Toczyski, 2006). The APC/C controls the 
cell cycle processes responsible for chromatid segregation at the metaphase to anaphase transition, the 
completion of mitosis, and the establishment and maintenance of G1. APC/C activity depends on the 
interaction with specific proteins known as co-activators. The best studied are the mitotic Cdc20/Fizzy and 
Cdh1/Hct1/Fizzy-related cofactors, which confer specificity for the substrate (Peters, 2006; Sullivan and 
Morgan, 2007).  
Throughout S- and G2-phases the APC/C remains inactive by binding of Emi1, which is degraded 
upon mitotic entry by another ubiquitin ligase: the SCF (Skp1/cullin/F-box)–β –TrCP (β -transducin repeat-
containing protein. Phosphorylation of many of the APC/C subunits upon mitotic onset by by Cdk-cyclin B and 
Plk1 (Golan et al., 2002) is a prerequisite for the binding of the substrate-specific cofactor Cdc20. On the 
contrary, the interaction APC/C-Cdh1 does not depends on the phosphorylation of APC/C subunits. Cdh1 
activates the APC/C at the final phases of mitosis and G1 (Peters, 2006), while earlier in mitosis Cdh1 is 
phosphorylated and inhibited. Cdk2 (cyclin-dependent kinase 2) and Cdk1 are the kinases responsible for 
Cdh1 phosphorylation during G2, S-phase and mitotic entry, impeding its interaction with APC/C until late 
stages of mitosis. When cyclin B is degraded and Cdk1 activity levels fall (Blanco et al., 2000; Zachariae et 
al., 1998) this phosphorylation is reversed by Cdc14 phosphatase (Wurzenberger and Gerlich, 2011). 
Dephosphorylated Cdh1 is now ready to replace Cdc20 as co-factor of APC/C, one of the first actions of the 
newly formed APC/C-Cdh1 is to degrade its predecessor Cdc20. Both co-factors participates in the 
recognition of those substrates that are going to be ubiquitylated by the APC/C through the WD40 domain at 
the C-terminal, which allows specific interactions with D-box, A-box or O-box domains (Araki et al., 2005; 
Fang et al, 1998; Littlepage et al., 2002; Pfleger and Kirschner, 2000). 
 
3.1 Relevance of APC/C-Cdc20 in mitotic exit 
Cdc20 was identified for the first time in 1973 by Lee Hartwell as a mutant strain of Saccharomyces 
cerevisae, which results in a permanent mitotic arrest (Hartwell et al., 1973).  Cdc20 is expressed during S-
phase, G2 and mitosis. However it can only bind to the APC/C when various subunits of this complex have 
been phosphorylated by mitotic kinases (Kramer et al., 2000). APC/C-Cdc20 activity is regulated by several 
mechanisms, being the most important the spindle assembly checkpoint (SAC; Figure 3). 
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Figure 3. The role of the APC/C during mitosis.  Once kinetochores are attached to microtubule spindle, the SAC is 
satisfied and the releasing from its inhibition the APC/C-Cdc20 complex. APC/C-Cdc20 targets cyclin B and securin for 
degradation by ubiquitylation.  Securin degradation leads to the activation of separase and the subsequent separation of 
the sister chromatids.  
 
For cells to segregate their genome, each chromosome must be attached in a bioriented manner to 
the mitotic spindle. The SAC monitors this attachment and in this way contributes to the fidelity of 
chromosome segregation and ensures that daughter cells inherit a complete copy of the genome, avoiding 
the generation of aneuploidy cells. The SAC negatively regulates the ability of Cdc20 to activate the APC/C, 
delaying anaphase onset until every chromosome is perfectly attached to microtubule spindle (Mussachio and 
Salmon, 2007). Unattached kinetochores in prometaphase activate the SAC by triggering a biochemical 
cascade that inhibits the APC/C, how exactly this signaling is performed is still controversial. The mitotic 
checkpoint complex (MCC) has emerged as the possible SAC effector (Varetti and Musscahio, 2008). The 
MCC contains three SAC proteins: Mad2, BubR1/Mad3 and Bub3, as well as Cdc20 (Musacchio and Salmon, 
2007). This multiprotein complex binds the APC/C as a pseudosubstrate inhibitor (Burton and Solomon, 
2007) impeding its catalytic activity and delaying the onset of the anaphase.  
Several independent studies converge in proposing a model in which MCC complex formation is 
triggered by specific interactions between Mad1 and Mad2 at the level of the kinetochores that are not bound 
to the spindle. When bound to Mad1, Mad2 suffers a conformational change, adopting a conformation known 
as close-Mad2 (C-Mad2) (De Antoni et al., 2005; Kulukian et al., 2009; Simonetta et al., 2009). This 
conformational change of Mad2 is needed to promote the formation of a complex with Cdc20 and BubR1 
(Mussachio and Salmon, 2007). According to this model, the APC/C is kept inactive because Cdc20 has been 
hijacked by the MCC and also because the MCC binds APC/C through Cdc20. However the majority of the 
cellular Cdc20 pool is not forming a complex with Mad2 and it has been also shown that Cdc20 undergoes 
continuous ubiquitin-dependent degradation, and it is continuously resynthesized during mitotic arrest, in a 
manner that involves polyubiquitylation by the APC/C (Ge et al., 2009; Nilsson et al., 2008). In this model 
Mad2 catalyzes the interaction between Cdc20 and BubR1, which presents Cdc20 to the APC/C. It is 
believed that this SAC-mediated degradation of Cdc20 keeps Cdc20 levels bellow a threshold, which would 
suppress its function as an APC/C co-activator. 
When all kinetochores become attached to spindle microtubules and under tension, the SAC activity is 
rapidly switched off, MCC dissociates from the APC/C, Cdc20 is relieved from SAC proteins and serves as an 
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APC/C coactivator promoting mitotic exit (Howell et al., 2000; Rieder et al., 1995). As well as with the effector 
mechanism of the SAC, little is known about how SAC is satisfied and how its inhibitory signal is 
extinguished. Several studies suggest that, polyubiquitylation of Cdc20 by APC/C is the major mechanism for 
SAC inactivation.  Mutliubiquitylation of Cdc20 allows its rapid dissociation from the complex Mad2-BubR1-
Bub3 and binding to the APC/C. Whereas de-ubiquitytilating enzymes acts on Cdc20, while the SAC is still 
active, stabilizing the complex Cdc20-Mad2-BubR1-Bub3 (Reddy et al., 2007; Stegmeier et al., 2007). 
Moreover, checkpoint antagonists, such as p31comet, are involved in SAC silencing. This mechanism is 
based on p31comet competition for binding to C-Mad2, the Mad2 conformation that binds to Cdc20. 
Kinetochores negatively regulate the ability of p31comet to bind to C-Mad2, but reactivation of p31comet at 
metaphase, when kinetochores are bound to microtubule spindle, would trigger SAC inactivation (Vink et al., 
2006; Xia et al., 2004). However there are no obvious orthologues for p31comet in lower eukaryotes. 
APC/C-Cdc20 mediates the anaphase onset leading to mitotic exit by polyubiquitylating two key 
substrates, securin and cyclin B (Lim et al., 1998; Shirayama et al., 1999), thereby promoting its destruction 
by the 26S proteasome (Basserman et al., 2013; Peters, 2006; Skaar and Pagano, 2009;). Securin is a 
stoichiometric inhibitor of the protease separase/Esp1 whereas Cdk1-cyclin B directly binds and inhibits 
securin (Stemmann et al., 2011). Upon securin and cyclin B degradation, separase can cleave centromeric 
cohesins that keeps sister chromatids together. Concomitantly, proteolysis of cyclin B inactivates Cdk1. It was 
indeed demonstrated in budding yeast that Cdc20 is not essential in cells that lack both securin and Clb2, 
emphasizing the importance of degradation of these two substrates for metaphase and mitotic exit 
(Shrirayama et al 1999, Thornton and Toczyski 2003).  
Cdk1 activity is the driving force for mitotic progression; its inactivation is therefore the major molecular 
event that triggers mitotic exit favoring the reversion of all the changes imposed by the entry into mitosis 
(Sigrist et al., 1995). Many of the mitotic phosphorylations need to be removed and phosphatases now play 
its role. In budding yeast, Cdc14 phosphatase promotes mitotic exit by dephosphorylating Cdk1 targets 
(Queralt and Uhlmann, 2008), in contrast mammalian homologs (Cdc14a, b and c) do not seem to be 
required for mitotic exit (Mocciaro and Shiebel, 2010). However PP1 and PP2A-B55δ, which are inactive 
during mitosis, are reported to be important for mitotic exit (Mochida and Hunt, 2007; Mochida et al., 2009; 
Wu et al., 2009) in Xenopus egg extracts. Cdk1 inhibition leads to PP1 activation by auto-dephosphorylation 
and inactivation of its inhibitor I1 (Wu et al., 2009). In addition, a recent screen has identified PP2A-B55α as a 
regulator of mitotic exit in human cells, involved in DNA decondensation, reorganization of the nuclear 
envelope among other events (Schmitz et al., 2010). In an independent study premature exit of mitosis has 
been reported as a consequence of PP2A activation induced by Mastl knockdown in human cells (Burguess 
et al., 2010). Multiple phosphatases seem to regulate mitotic exit in mammals, but how phosphatases 
become actives is not well known.  A feasible mechanism is that phosphatases undergo auto-
dephosphorylation upon Cdk1 inactivation (Wu et al., 2009) and other possibility to regain activity might be 
that different phosphatases regulate selected steps of pospho-epitopes, generating a multilevel regulation, in 
a dephosphorylation cascade (Medema and Linqvist, 2011). Once the Cdk1 activity ceased and 
phosphatases become active, the removal of the Cdh1 phosphorylated residues, results in the formation of a 
new APC/C-Cdh1 complex. This complex catalyzes the degradation of Aurora A and Plk1 kinases which 
favors mitotic exit and G1 progression. 
In addition, APC/C-Cdc20 complex promotes the degradation of additional substrates such as cyclin 
A, Nek2A and p21 Cip1 at the mitotic onset, independently of the SAC activity (Amador et al 2001; Di Fiore 
and Pines; Geley et al 2001; Wolthuis et al 2008).  Cdh1 is not able to compensate for the lack of Cdc20, this 
is not due to differences in substrate specificity because Cdh1 is also able to target securin and cyclin B for 
degradation, rather, this reflects the fact that Cdc20 absence arrests cells with high Cdk1 activity, and this 
activity is known to inhibit Cdh1 function, because it cannot be de-phosphorylated and therefore binds APC/C.  
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Small residual amounts of Cdc20 are sufficient to exit mitosis (Baumgarten et al., 2009; Wolthuis et al., 
2008). Mitotic exit is likely to be efficient with as little as 5% of cellular Cdc20 (Wolthuis et al., 2008), giving an 
explanation for previous reports indicating that Cdc20 knockdown by RNAi does not result in cyclin B 
stabilization or mitotic arrest (Clarke et al., 2009).  A Cdc20 conditional knockout (KO) mouse model was 
generated recently in our lab (Manchado et al., 2010). Genetic ablation of Cdc20 results in metaphase arrest 
in vivo. Since Cdc20 is essential for anaphase onset, conditional genetic elimination of Cdc20 results in 
complete metaphase arrest in embryonic or somatic cells in vivo. In the absence of Cdc20 cells are not able 
to progress to anaphase and remain arrested in mitosis in the presence of condensed DNA. In this Cdc20 KO 
cells are arrested in mitosis with high Cdk1 activity, in the absence of cyclin A and B degradation. These cells 
can only be forced to exit mitosis if Mastl is depleted and Cdks activity is suppressed simultaneously by the 
addition of roscovitine (a Cdks inhibitor). Inhibition of PP2A or combined knockdown of B55α and B55δ in 
these cells, delays Cdks-substrates dephosphorylation indicating that act cooperatively to revert mitotic 
phosphorylations (Manchado et al., 2010).  
 
4. Metabolism and the cell cycle 
The regulation of metabolism and growth must be tightly coupled in order to guarantee the efficient 
use of energy and anabolic substrates throughout the cell cycle. The notion that the cell cycle is 
fundamentally linked to something, whose intracellular abundant or activity oscillates in temporal coordination 
with cell-cycle progression, come from the 50´s. Early evidences shows that a preparation phase, that 
requires efficient respiration and carbohydrate utilization in aerobic conditions, is needed prior mitosis 
(Swann, 1957), however, once mitosis is initiated it could proceed in the absence of new ATP production and 
anaphase and cytokinesis could be completed in the presence of any energy production inhibitors. In the 
same way, Bullough postulated, in the “energy reservoir hypothesis”, that an active production of energy is 
vital only during the period that immediately precedes the prophase termed as “antephase” (Bullough, 1952), 
however, by the time mitosis becomes recognizable, it is highly independent of external conditions. Thus, it 
seems that the critical importance of the active production of energy in the antephase may be related either to 
a demand for energy at this time, or to the necessity for energy storage in the maintenance of the cell during 
division (Bullough, 1952). In line with these observations, Gelfant in 1969 observed that glycolytic waves 
precede mitosis and claimed that the inhibition of the energy pathways during mitosis does not affect the 
undergoing mitosis but prevents the following mitotic entry. In agreement with this need of glucose 
accumulation it has been recently reported that glycogen is required for microtubule assembly in meiotic 
extract (Aaron et al., 2013). Mitosis is a phase in which several high-energy consuming processes are active, 
such as chromosome condensation, microtubule network organization, mitotic spindle formation (Álvarez-
Fernández and Malumbres 2014; Janssen and Medema 2011; Medema and Lindqvist 2011) and a prolonged 
mitosis could therefore result in energy deprivation. Specific depletion of ATP pools with DNP, azide or AMP-
PNO, results in a rapid prolonged mitotic arrest in mammalians cells (Burgess et al., 2014; Lee et al., 1989; 
Spurck et al., 1987). ATP is needed for microtubule disassembly and therefore depletion of ATP stabilizes 
microtubules. Moreover, the depletion of ATP also depletes Mad2 and BubR1 from kinetochores, with both 
proteins accumulating at spindle poles, however this does not appear to affect their ability to bind Cdc20 and 
inhibits the APC/C (Howell et al., 2000; Hoffman et al., 2000; Howell et al., 2001).  G1/S and G2/M 
checkpoints are also energy-sensitive and require pronounced bioenergy supply for de novo synthesis of 
biomasses needed for cell-cycle phase transitions (Sweet and Singh, 1995; Sweet and Singh, 1999).  
Accumulating molecular evidences suggest that mitochondrial respiration is linked with cell-cycle 
regulation: cyclinD1 coordinates mitochondrial biogenesis in G1 progression (Sakamaki et al., 2006), cyclin E 
controls the formation of high energy-charged mitochondria in the G1/S transition (Mitra et al., 2009) and 
Cdk1-cyclin B1 is involved in the integration of mitochondrial fission with the onset of G2/M transition (Taguchi 
et al., 2007). Moreover, mitochondrial metabolism cooperates with the process of cell division, a functionally 
efficient mitochondrial complex I in OXPHOS is required not only for overall mitochondrial respiration 
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(Roessler et al., 2010), but also for successful cell-cycle progression (Osusu-Ansah et al., 2008). Cdk1-cyclin 
B1 regulates mitochondria metabolism to coordinate G2/M progression: a fraction of Cdk1-cyclin B1, located 
in the matrix of mitochondria, is responsible for the phosphorylation of some components of mitochondrial 
complex I. This phosphorylation is responsible for the upregulation of its enzymatic activity and boost ATP 
generation (Wang et al., 2014a).  
 
4.1 APC/C-Cdh1 and metabolism 
 
APC/C-Cdh1 regulates the glycolysis-promoting enzyme PFKFB3 (6-phosphofructo-2-kinase/fructose-
2, 6-biphosphatase isoform 3) and GLS1 (glutaminase 1), a critical enzyme in glutaminolysis. Decreased 
activity of APC/C-Cdh1 in mid-to-late G1 releases both proteins for being ubiquitylated and targeted for 
degradation, which explains the simultaneous increase in the utilization of glucose and glutamine for cell 
proliferation. This occurs at a time consisting with the nutrient-sensitive G1 restriction point, described as the 
stage in G1 beyond which cells no longer require the presence of mitogenic signals for progression along the 
cell cycle. PFKFB3 is also a substrate for the ubiquitin ligase SCF at the onset of S-phase. For these reasons, 
the activity of PFKFB3 is short lasting, coinciding with a peak in glycolysis in mid-to-late G1, whereas the 
activity of GLS1 remains high throughout S-phase. Both glucose and glutamine are required for progression 
through the restriction point, whereas only glutamine is necessary for progression through S-phase into cell 
division (Colombo et al., 2010), suggesting that glycolysis and glutaminolysis plays different roles at different 
stages of the cell cycle.  
 
Figure 4. Levels of PFKFB3 are controlled by 
APC/C-Cdh1 and SCF-b-TrCP. Glycolysis peaks 
in late G2 due to the non-degradation of PFKFB3 
by this two complexes, whereas glutaminolysis 
takes place late G2 till G27M transition coincident 
with the inactivation of APC/C-Cdh1. The R 
represents the restriction point beyond what a cell 
has committed to cycle. (Adapted from Moncada 
et al., 2012).  
 
PFKFB3 (also known as PFK-2) is a key regulator of glycolytic flux by modulating PFK-1 activity, 
which catalyzes a primary control point of glycolysis: the conversion of fructose-6-phosphate (F6P) to fructose 
1,6-biphosphate (F1, 6BP), a rate-limiting and irreversible early reaction in the pathway constituting the 
pacemaker of glycolysis. PFK-1 is an allosteric enzyme subjected to extensive regulation by various 
metabolites in the glucose metabolism pathway. Cells can increase or decrease the rate of glycolysis by 
controlling PFK-1 through allosteric activation or inhibition. A total of six ligand binding sites are found in PFK-
1: the substrate-binding sites for ATP and F6P, activator-binding sites: for AMP and fructose-2, 6-biphosphate 
(F2, 6BP), and inhibitors binding sites for ATP and citrate. Binding of citrate enhances the inhibitory effect of 
ATP, which is inhibitor and substrate. When the tricarboxylic acid cycle (TCA cycle) is highly active, ATP and 
citrate accumulate, indicating an adequate supply of energy, which in turn inhibits glycolysis. However 
increasing evidences suggest that cancer cells may have acquired ability to evade this feedback regulation 
(Mor, et al., 2011). F2, 6BP is generated from F6P through phosphorylation by phosphofructokinase-2 (PFK-
2). Increased glucose uptake and hexokinase activity (first enzyme of glycolysis) leads to elevated levels of 
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F6P, yielding more F2, 6BP, which represents an allosteric feedforward mechanism that enhances glycolysis 
when glucose is abundant. The steady-state concentration of F2,6BP depends on the enzymatic activity of 
PFK-2, which is a bifunctional enzyme that catalyzes either the phosphorylation of F6P to F2, 6BP (kinase 
activity) or the dephosphorylation of F2,6BP to F6P (phosphatase activity). The enzyme exists in multiple 
isoforms, sharing 85% of sequence homology, encoded by four genes termed from PFKFB1 to PFKFB4. 
Among them PFKFB1, PFKFB2 and PFKFB4 localize to the cytoplasm, where glycolysis takes place, 
whereas PFKFB3 localizes in the nuclei. Nuclear PFKFB3 did not stimulate the glycolytic flux, but its 
cytoplasmic mutant was able to enhance glycolytic rate (Yalcin et al., 2009) suggesting the possibility for 
cellular compartmentalization of F2, 6BP. Depending on the stimuli there may exist a concentration gradient 
between nucleus and cytoplasm, so that a relative increase of F2, 6BP in the cytoplasm might activate 
glycolysis, whereas in the nucleus might signal cells to a more efficient use of glucose to proliferate (Yalcin et 
al., 2009). The relative functions of PFKFB3 and PFKFB4 are of particular interest because they are activated 
in human cancers and increased by mitogens and low oxygen. 
 
5. Cell cycle, metabolism and cancer 
 
5.1 Altered cell cycle and metabolism, two hallmarks of cancer 
Cell cycle deregulation is a common feature of human cancers (Malumbres and Barbacid, 2001). 
Tumor cells accumulate mutations that results in unscheduled proliferation, genomic instability and 
chromosomal instability. Normal cells evolve progressively to a neoplastic state, by successive acquisition of 
several capabilities. Hanahan and Weinberg gather the different alterations that accompany cell 
transformation and define six hallmarks of cancer as acquired functional capabilities that allow cancer cells to 
survive, proliferate and disseminate. These functions are acquired in different tumor types via distinct 
mechanisms and at various times during the course of multistep tumorigenesis. The most fundamental trait of 
cancer cells is their ability to sustain chronic proliferation. Normal tissues carefully control the production and 
release of growth-promoting signals in order to ensure a homeostasis of cell number and maintenance of 
tissue architecture, whereas cancer cells can acquire the capability to sustain proliferative signaling and 
evading the anti-proliferative signals in many ways (Witsch et al., 2010). Growth factor independence may 
also derive from the constitutive activation of components of signaling pathways operating downstream of the 
receptors bypassing the need to stimulate these pathways by its ligand. Somatic mutations may activate 
these downstream pathways resulting in constitutive signaling. Activating K-RAS mutations are frequently 
found in human cancers, they are common in: pancreatic cancer, colorectal cancer, lung adenocarcinoma, 
gall bladder cancer, bile duct cancer, and thyroid cancer.  Similarly, mutations in the catalytic subunit of 
phosphoinositide 3-kinase (PI3K) which hyperactivate the signalling cascade including its key Akt/PKB signal 
transducer, are being detected in an array of tumour types (Yuang and Cantley, 2008). Acquisition of the 
multiple hallmarks depends in a large part on a succession of alterations in the genomes of neoplastic cells. 
The development of genomic instability in cancer cells enables tumorigenesis, by generating random 
mutations, including chromosomal rearrangements that further contribute to tumor development. 
Cancer is a disease arising from genetic and epigenetic alterations in oncogenes and tumor 
suppressors genes, many of which are also able to reprogram metabolism. Thus, the metabolic changes 
occurring in cancer might be considered a secondary effect to the transformation process, however, as 
altered metabolism is a universal property of cancer cells, Hanahan and Weinberg have recently included the 
capability to reprogram cellular metabolism as a hallmark of cancer (Hanahan and Weinber, 2011). 
Compared to normal cells, cancer cells strongly upregulate glucose uptake and glycolysis to give rise to 
increased yield of intermediate glycolytic metabolites and the end product pyruvate in order to fulfill the 
requirements for neoplasic proliferation. Moreover, glycolysis is uncoupled from the mitochondrial tricarboxylic 
acid cycle (TCA) and oxidative phosphorylation (OXPHOS) in cancer cells. Consequently, the majority of 
glycolysis-derived pyruvate is diverted to lactate fermentation, converted to lactate in the cytoplasm by lactate 
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dehydrogenase (LDH) and secreted, rather from being oxidized through mitochondrial metabolism. This 
metabolic phenotype is known as the Warburg effect and occurs even in the presence of sufficient oxygen to 
support mitochondrial respiration. This metabolic phenomenon was first described by Otto Warburg in 1956 
and is also referred as to aerobic glycolysis. Although human cancers display a diverse range of metabolic 
profiles, the Warburg metabolic phenotype is a widespread cancer-associated trait. Indeed, enhanced 
glucose uptake by cancer cells has become the basis for positron emission tomography (PET) with 18-
fluorodeoxyglucose (FDG), which preferentially accumulates in tumor cells as a result of their rapid uptake of 
glucose. Several oncogenes and associated proteins such as HIF-1, RAS, C-MYC, Oct, SRC and p53 can 
influence energy substrate utilization by affecting cellular targets, leading to metabolic changes that favor 
cancer cell survival independently of the control of cell proliferation. These oncogenes stimulate the 
enhancement of aerobic glycolysis and at least some of them can directly target the OXPHOS machinery, i.e. 
RAS E1A affects early steps of tumorigenesis, increase in oxygen consumption and superoxide production, 
(Jose et al., 2011). To which extent normal and neoplastic cells share metabolic pathways remains unknown 
and is of particular interest since the existence of relevant differences in the metabolic pathways of cancer 
and normal cells would suggest the possibility of developing therapeutic approaches that selectively interfere 
with cancer metabolism without side-effects related to the mechanism of action. 
 
5.2 Mitotic targeted therapies: 
Deregulated cell cycle is a common feature of cancer cells and multiple strategies have been 
proposed in the last few years to impair tumor cell proliferation, current efforts can be broadly divided into 
three different groups. Initial strategies were designed to inhibit the machinery that drives the entry into the 
cell cycle imposed by oncogenic signals (G1 phase) and DNA synthesis (S phase) (Malumbres, 2001). 
Mechanistically, inhibition of cell cycle entry (i.e., by inhibiting interphase Cdks) is likely to induce cell cycle 
arrest or quiescence but not apoptosis, generating viable quiescent cells. The use of small-molecule inhibitors 
for interphase Cdks may result in certain levels of apoptosis, although the lack of specificity of these 
compounds prevents any detailed molecular conclusion. Interfering with the G1/S machinery or abrogation of 
the DNA damage checkpoint generally prevents DNA replication (Bucher et al., 2008; Toledo et al., 2011), 
thus rendering diploid interphase cells that cannot proliferate but are viable. For instance, inhibition of Cdk4 
prevents the development of lung tumors induced by K-Ras oncogene by triggering senescence, a permanent 
arrest in G0/G1. The two first approaches are clearly based on the specific signals originated from the 
oncogenic stress in tumour cells. This has been far more difficult to achieve in targeted therapies directed 
against mitosis given the conservation in the essential mechanism that regulates chromosome segregation in 
normal or tumour cells. 
The fragility of cancer cells when they undergo division serves as a critical point for intervention in 
chemotherapy (Chan et al., 2011). Mitosis is considered the most fragile period of the cell cycle, during which 
is highly susceptible to cell death when exposed to various insults. The chromosomes are in highly 
condensed state and not protected by the nuclear envelope, in fact it has been shown that mitotic cells have 
enhanced sensitivity for example to radiation treatment (Stobbe et al., 2002). The great success of spindle 
poisons in clinics and the susceptibility of cells to mitotic arrest have led in the last years to a search for 
improved therapeutic strategies based on specific mitotic targets (Figure 4). The discovery of centrosome and 
mitotic regulators that function during S phase, or M phase provided further additional targets, such as mitotic 
kinases or the mitotic spindle machinery, required for chromosome segregation. Thus, targeting mitosis offers 
several possibilities to kill cancer cells that we will discuss right after. 
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Figure 5. Strategies for targeting mitosis in cancer therapy. Inducing an aberrant mitosis by targeting microtubules, 
inhibition of mitotic kinases or kinesins induces a SAC dependent mitotic arrest that eventually leads to cell death in mitosis, 
if not cell will slip out mitosis without segregating their genome, therefore giving rise to viable aneuploid cells that may die in 
the subsequent interphase or remain viable. Other possible approach is the abrogation of the SAC activity, leading to a 
similar outcome. However the more efficient therapeutic approach, it has been recently proposed is the inhibition of mitotic 
exit forcing cell to die in mitosis (Domenéch & Malumbres, 2013). 
 
 
a) Targeting mitotic entry: Cdk1 is the major kinase activity that drives entry into mitosis. Inhibition of 
Cdk1 prevents mitotic entry leading to G2 arrest. Strong inhibition of Cdk1 is likely to be toxic for normal cells 
limiting its therapeutic use, however it can be useful in specific cellular settings and synthetic lethal 
interactions exist with GSK3B (Mayes et al., 2011), in Myc-overexpressing tumors (Goga et al., 2007) and 
partial inhibition of Cdk1 sensitize BRCA-proficient cancer cells to inhibit PARP (Johnson et al., 2011). 
 
b) Targeting spindle dynamics: classical antimitotic therapies have made use of the spindle poisons 
that bind tubulin subunits and either stabilize, for example taxanes (paclitaxel, Nab-paclitaxel and docetaxel) 
now widely used to treat breast and ovarian tumors, non-small-cell lung cancer and Kaposi’s sarcoma, or de-
stabilizing, for example; vinka-alkaloids (vinorelbine, vinblastine, vincristine) used in a broad range of 
hematological malignancies. All this compounds prevents microtubule dynamics, a process required for the 
generation of a functional bipolar spindle and for chromosome segregation during mitosis. This situation is 
monitored by the SAC which delays mitosis until errors in microtubule–kinetochore attachment are resolved 
(Musacchio et al., 2007; Kops et al., 2005) by inhibiting APC/C-Cdc20, thus inhibiting mitotic exit (see above 
section 2.1). The SAC-dependent delay in mitosis increases the susceptibility of cells to undergo cell death. 
Alternatively, cells can escape from the mitotic arrest by slowly degrading cyclin B, a process known as 
mitotic slippage even in the presence of an active SAC. Mitotic slippage is thought to be one of the major 
mechanisms of resistance against antimitotic drugs. Microtubules are also necessary for multiple cellular 
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processes in interphase and the use of this spindle poison is associated with side-effects such as 
neurotoxicity, that can lead to irreversible neuropathies due to the effect of this drugs in microtubules, the 
basic components of neurons. Patients treated with these drugs develop severe myelosuppression derived 
from proliferation impairment of cycling bone marrow cells. Besides the fact that mitosis is not a key target of 
microtubule agents in patient tumors (Komlodi and Pasztor, 2011) it is expected that dividing cells are more 
vulnerable to these microtubule-disturbing agents due to the increased rate or microtubule turnover during 
mitosis. In addition, patients treated with microtubule poisons often acquire resistance to these drugs. Thus, 
although inhibiting microtubule function has demonstrated a significant antitumor activity, the side effects of 
these drugs limit their use and have prompted to identify alternative antimitotic drugs. 
 
c) Mitotic targets: Most current efforts have mostly focused on the inhibition of Plk1 and Aurora (A 
and B) kinases. These proteins are overexpressed in multiple tumors and are essential components of cell 
division since their inactivation results in lack of chromosome segregation, polyploidy and, eventually, cell 
death. Multiple small-molecule inhibitors have been developed in the last years and some of them have been 
tested in clinical trials. Mitotic targets also include kinesins, a class of motor proteins with ATPase activity that 
move along microtubule filaments and are required for proper microtubule function. Several members of the 
kinesin superfamily, such as Eg5 and CENP-E are now emerging as putative anticancer targets. The main 
side effect observed was reversible hematological toxicity and some limited, but encouraging antitumor 
activity was observed promoting Phase II studies in monotherapy (Table 1) and combination (Table 8) in solid 
and hematopoietic tumors. However, the evidence for clinical efficacy was reduced with very limited objective 
responses and these compounds were mostly ineffective in patients. 
 
Target Inhibitor Tumour types Description 
Plk1 BI2536 
Phase I/II in solid tumours and 
relapsed hematopoietic 
malignancies 
Partial antitumor activity. Reversible 
neutropenia. 
 BI6727 Phase I advanced solid tumours 
Some partial responses and stable disease. 
Most trial ongoing 
 GSK461364 
Phase I in advanced solid 
tumors and Non-Hodgkin’s 
lymphoma 
Prolonged stable disease in 15% of the 
patients. 
 ON 01910. Na 
Phase I/II Hematopoietic and 
advanced solid cancer 
Propose AKT2 phosphorylation and cyclin D1 
expression as biomarkers. Mostly ongoing / no 
results published 
Aurora  Solid tumour cell lines 
Growth inhibition and apoptosis in vivo and in 
vitro. 
 
AZD1152 
(AurkB-specific) 
Phase I/II study AML and Phase 
I trials patients with advanced 
solid malignancies. 
Overall hematologic response rate 27%. One 
out of the four entered complete remission for 
AML. But No objective tumour responses 
observed, but stable disease in 23% of the 
patients. 
 
MLN8237 
(AurkA-specific) 
Phase I Advanced solid tumours 
and phase I/ II AML. Phase I 
refractory ovarian, fallopian tube 
or primary peritoneal carcinoma 
Good tolerability and favourable 
pharmacokinetics, produces neutropenia and 
stomatitis. Modest response as a single agent, 
durable disease. 
 
MLN8054 
(AurkA-specific) Phase I advanced solid tumor 
Dose-escalating study. Recommended dose 
for phase II clinical trials was not established 
 
VX-680 (MK-
0457, pan Aurk 
inhibitor) 
Phase I/II Advanced 
hematopoietic and solid tumors Ongoing / no results published 
 
AMG 900 (pan-
Aurora inhibitor) 
Phase I acute leukaemia and 
solid tumor Ongoing / no results published 
Mps1 NMS-P715 Cultured cells 
Aneuploidy and cell death in a variety of 
tumour cell lines. Inhibits tumour growth. 
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Target Inhibitor Tumour types Description 
 MPI-0479605 Colon carcinoma cell lines 
Aberrant mitosis and growth arrest. Cells 
undergo mitotic catastrophe and/or apoptosis 
 Reversine Colon carcinoma cell lines Low doses selectively kill p53-null cells 
Cenp-E GSK923295 Phase I in refractory cancer 
Limited side effects. One patient with a 
durable partial response. 
Eg5 AZD4877 
Phase I solid tumor, phase II 
advanced bladder cancer 
Acceptable safety profile. But little evidence of 
clinical efficacy 
 SB-715992 
Phase I metastatic cancer and 
tumors resistant to taxanes 
and/or platinum 
The most common toxicities were nausea, 
diarrhea, fatigue and neutropenia. Some 
partial responses. Mostly ongoing / 
unpublished data 
 SB-743921 Phase I lymphoma, solid tumors Partial responses. 
 ARRY-520 
Phase I solid advanced cancer, 
advanced myeloid leukaemia Relative lack of clinical activity in solid tumours 
 ARQ621 
Phase I metastatic solid, 
hematologic Ongoing / no results published 
 LY2523355 
Phase I Solid and hematopoietic 
tumors Ongoing / no results published 
 MK0731 Phase I Solid tumours 
Lengthening of stable disease in patients with 
taxane resistant tumors 
 
Table 1. Mitotic drugs: recent preclinical and clinical Studies as monotherapy.  
Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; pH3, phospho-histone H3. 
 
 
d) Targeting the mitotic checkpoint: SAC abrogation results in defective or abnormal chromosome 
segregation, generating polyploid or aneuploid cells that may lead to chromosomal instability (CIN), therefore 
promoting tumorigenesis. Abrogation of the mitotic checkpoint specifically generates lethal aberrations in 
chromosomal unstable tumour cells. As most tumors are aneuploid or display certain levels of CIN, SAC 
abrogation may induce further levels of instability and may  be therefore used as a therapeutic strategy as it is 
shown by genetic elimination of Mad2 or BubR1 results in chromosome missegregation that triggers cell 
death (Baker et al., 2004; Dai et al., 2004a; Dobles et al., 2000; Michel et al., 2001). One of the SAC 
druggable components is the kinase Mps1 which is required for SAC activity and its inhibition results in 
defective chromosome segregation, mitotic catastrophe and frequent cell death in a variety of tumor cell lines, 
with certain preference for p53 mutant cells (Castedo et al., 2004). Mps1 inhibitors have been only evaluated 
in preclinical assays (Table 1). In a general overview, the first generation of clinical trials for mitotic targeted 
therapies has not reached the expectations raised from preclinical models, at least for solid tumors and a 
crucial question that emerge from these studies is to what extent targeting the cell cycle merely results in 
proliferative arrest or induces tumor cell death, and which are the major resistance mechanisms. In addition, 
the potential as cancer targets of many other kinases such as the Nek family, Mps1, Mastl or haspin remains 
to be explored.  
e) Targeting mitotic exit. Cells that escape from mitotic cell death and undergo mitotic slippage, can 
either die at the following cell cycle, arrest in a tetraploid state or undergo several rounds of division, 
depending on the status of genes such as p53 (Lanni et al., 1998; Rieder et al., 2009). Remarkably, several 
independent studies have observed no correlation between cell death and mitotic duration, suggesting that 
cell fate after treatment with antimitotic drugs is not exclusively dictated by mitotic length, although inhibition 
of apoptosis increases mitotic slippage which may indicate that both processes are somehow linked. 
Gascoigne and Taylor proposed a model based on two competing networks, one that involves mitotic cell 
death pathways and other that regulates cyclin B1 degradation and therefore mitotic exit. These two networks 
have specific thresholds that compete during mitotic arrest. If cyclin B1 levels fall under a certain threshold 
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before caspase activation has reached its cell death threshold, then cells will exit from mitosis. On the other 
hand, if cyclin B1 levels fall slowly, then cell death threshold will be achieved first and cells will die in mitosis 
(Figure 6). This model, however, does not provide an answer to the question on how a delayed mitosis could 
result in caspase activation.  
 
 
Figure 6.  The model of the two competing networks. Cell fate during prolonged mitotic arrest depends on cell death 
pathways activation and cyclin B1 degradation with specific thresholds that compete during mitotic arrest. The network that first 
reaches its threshold of activation will dictate cell fate. If cyclin B1 is degraded before caspases are active cell will slip out 
mitosis, whereas if cyclin b levels fall slower that caspase are active, cell will die in mitosis. And cell fate does not correlate with 
the duration of the mitotic arrest (adapted from Gascoigne and Taylor 2009). 
 
 
Multiple networks dictate cell fate during or after mitotic arrest, but preventing mitotic exit invariably 
results in cell death. Therefore, it is predictable that completely blocking mitotic exit might be a powerful 
strategy to induce mitotic cell death and may have stronger effects than targeting the spindle or mitotic entry. 
Preventing mitotic exit has been recently proposed as a complementary alternative since cells cannot survive 
for long time in mitosis and they eventually die if components of the mitotic exit pathway, such as the E3 
ubiquitin ligase APC/C, are inhibited (Huang et al., 2009a; Zeng et al., 2009). Inhibition of the APC/C, with a 
small-molecule inhibitor named pro-TAME, efficiently arrests tumor cells in mitosis and triggers cell death 
(Zeng et al., 2010; Zeng and King, 2012). Our group has recently demonstrated that, impairing cyclin B1 
degradation in vivo by genetic elimination of Cdc20 is highly efficient in killing cells in mitosis and preventing 
tumor growth in vivo (Figure 7). Moreover, preventing mitotic exit is much more efficient in killing tumor cells 
than targeting the spindle assembly with classical spindle poisons or new drugs inhibiting Eg5 or Plk1 
(Manchado et al., 2010). Importantly, mitotic exit inhibition also affects pRb-null, p53-null or SAC-deficient 
cells suggesting widespread uses. Altogether, these results suggest that drugs that target Cdc20 or other 
components involved in cyclin B1 degradation, such as core components of the APC/C or the proteasome, 
could be quite effective in killing tumor cells. Indeed, a genome-wide RNAi screen has recently identified 
synthetic lethal interaction between K-RAS oncogenic signaling and the inhibition of core subunits of the 
APC/C, such as APC1 and APC472 (Luo et al., 2009). While partial inhibition of APC/C-Cdc20 may synergize 
with microtubule poisons, combination with Cdk1 inhibitors should be avoided. Strong inhibition of APC/C-
Cdc20, however, is likely to be highly efficient in inducing apoptotic cell death and this last property should be 
used in therapeutic scenarios in which proliferation of normal cells is abrogated, such as after food starvation 
or in combination with G1-arresting agents, to selectively protect these normal cells against efficient mitotic 
chemotherapies. Thus, efforts to obtain fundamental insights into why some cells that arrest in mitosis die 
without exiting mitosis will be extremely important in enhancing our understanding sensitivity to anti-mitotic 
chemotherapy. 
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Figure 7. Cdc20 ablation is more efficient in tumor regression in vivo than current antimitotic drugs. Tumor volume diminished 
significantly upon in vivo ablation of Cdc20 when compared with drugs targeting mitosis (Manchado et al., 2010). 
 
 
 
6. Mitotic catastrophe and mitotic cell death: a molecular definition 
Induction of aberrant mitosis in tumor cells leads to mitotic arrest, the consequence of which can be, 
but not always, cell death. As a whole, the cellular alterations resulting from aberrant mitosis are known as 
mitotic catastrophe (Vitale et al., 2011). Mitotic catastrophe (MC) can be defined as a type of cell death 
resulting from aberrant mitosis, either in mitosis or in the subsequent interphase (Galluzi et al., 2012; Vitale et 
al., 2011), that precedes and is different from apoptosis, necrosis or senescence and is driven by a poorly 
understood signaling cascade. MC should be considered as an oncosupressive mechanism (Vitale et al., 
2011) avoiding chromosomal instability (CIN) by preventing aneuploidization. The disruption of MC leads to 
cancer progression and its induction constitutes a therapeutic endpoint. Given the lack of an accurate and 
consistent definition of MC, as long as cell death processes are activated within the duration of mitosis 
leading up to cell death thereafter, they are regarded as MCD (Figure 8). From now on, we will refer as mitotic 
cell death (MCD) as the special type of MC that leads to cell death during mitosis and therefore in the 
absence of mitotic slippage, which results the more interesting outcome from a therapeutic point of view. 
 
 
 
Figure 8. Definition and types of mitotic catastrophe. Normal cells progress through interphase and mitosis to complete a normal 
cell cycle.  By contrast cells bearing mitotic perturbations that are detected during mitosis are always accompanied at some degree 
by mitotic arrest.  Cells arrested in mitosis can have different fates: die without exit mitosis (b) mitotic cell death. (c) Undergo cell 
death in the subsequent cell cycle (as often occurs alter radio induced cell death). (d) Or exit mitosis and undergo senescence. 
(Adapted from Vitale et al., 2011). 
 
 
MC was first described in Schizosaccharomices pombe, as a temperature–sensitive lethal phenotype, 
linked to gross abnormalities of chromosome segregation observed in some mutants strains (Ayscough et al., 
1992; Molz et al., 1989). Although there is no broadly accepted definition of the term, it was first attempted to 
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be defined morphologically, referred to as a type of cell death resulting from abnormal mitosis which usually 
ends in the formation of large cells with multiple micronuclei and decondensed chromatin (Roninson et al., 
2001). However, reports describing mitotic catastrophe frequently show cells with some phenotypic 
characteristic of apoptosis, such as hypercondensed chromatin aggregates (Ianzini and Mackey, 1997; 
Roninson et al., 2001; Swanson et al., 1995). It has been argued that mitotic catastrophe would be 
fundamentally different from apoptosis because, in some scenarios, manipulations that prevent apoptosis, i.e. 
overexpression of Bcl-2 in etoposide-treated HeLa cells or MDR1 overexpression in irradiated tumor cells, 
can actually enhance the frequency of catastrophic mitosis (Lock and Stribins-kiene, 1996; Ruth and 
Roninson, 2000). Moreover, the fact that caspase inhibitors such as Z-VAD.fmk can fail to prevent the 
appearance of dying giant multinucleated cells induced, for instance by treatment with spindle poisons, has 
been used to conclude that mitotic catastrophe would be unrelated to apoptosis (Nabha et al., 2002, Niikura 
et al., 2007), assuming that apoptosis must be mediated by caspases. However, it is now well established 
that apoptosis may occur in a caspase-independent manner (Joza et al., 2001; Susin et al., 1999), meaning 
that failure to prevent cell death by caspase inhibitors cannot be used as an argument to define this type of 
cell death as non apoptotic. The co-existence of caspase-dependent and caspase-independent mechanisms 
in mitotic cell death can be explained by the Bcl-xL activity, which controls a switch between cell death modes 
during mitotic arrest. In mammary cells treated with paclitaxel or depleted in Cdc20, in the presence of Bcl-xL, 
die in mitosis through caspase and Bak /Bax–independent mechanisms, however, after depletion of Bcl-xL, 
which is required to maintain mitochondrial integrity, converts cell response to antimitotic drugs to efficient 
caspase and Bax-dependent apoptosis (Bah et al., 2014).  
At least two subtypes of mitotic catastrophe can be distinguished: one that kill cells during or close to 
metaphase in a p53 independent manner, and a second ona that can occur after failed mitosis in a partially 
p53-dependent manner (Figure 9). A mitotic delay of only 2 hours can result in p53 activation and therefore, a 
prolonged mitosis can activate stress responses in mitotic cells (Uetake and Slunde, 2010). In fact, the loss of 
p53 can sensitize cells to microtubule poisons (Hawkins et al., 1996). Thus cells could have evolved an 
intrinsic pro-apoptotic pathway responsible for clearance of cells that spend too much time in mitosis.  
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Figure 9. Mitotic cell death after mitotic catastrophe. a) Mitotic catastrophe (MC) as a death in mitosis consequence 
of an aberrant mitosis. b) It can be considered an especial form of apoptosis in which upon and stimuli, often triggered 
by DNA damage; caspase 2 becomes active and have a pre-mitochondrial role. c) Avoidance of mitotic catastrophe 
leads to aneuploid cell able to cycle. d) Caspase-independent cell death that shares morphological features of 
apoptosis and necrosis. (adapted from Vakfahmetoglu et al., 2008). 
 
 
From a molecular point of view, mitotic catastrophe may differ from classical apoptosis in the activation 
of a particular mitochondrial permeabilization pathway. During mitotic arrest caspase-2 (usually linked to DNA 
damage) stimulates mitochondrial membrane permeabilization facilitating the release of several caspase 
activators that finally lead to the caspase-3 activation, the major effector caspase (Kroemer et al., 2007). The 
BH3-only protein Bid has been proposed to be the main activity by which the caspase-2 induces 
mitochondrial permeability (Bonzon et al., 2006), its cleavage form, t-Bid (C-terminal truncated) translocate to 
mitochondria promoting further caspase activation (caspase-9 and the effector caspase-3, caspase-6 and 
caspase-7). Moreover, as cells enter mitosis, Bid is phosphorylated on ser-66 and this phosphorylated form of 
Bid primes cells to undergo mitochondrial apoptosis if mitotic exit is delayed (Wang et al., 2014).  
Cdk1-cyclinB1 has a central role in controlling both mitotic duration and the apoptotic machinery.  On 
one hand Cdk1 activity protects mitotic cells against apoptosis by phosphorylation of caspase-9 (Allan et al., 
2007; Castedo et al., 2002) and controls Fas-mediated apoptosis by regulating caspase-8 activity (Matthess 
et al., 2010), hampering their ability to trigger the intrinsic or extrinsic apoptotic pathway respectively (Figure 
10 upper pannel). Cdk1-cyclin B also suppresses apoptosis upstream of mitochondrial cytochrome c release 
by phosphorylating caspase-2 and preventing caspase activation (Andersen et al., 2009). 
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Figure 10.  The dual role of 
Cdk1 in MCD   On one hand 
Cdk1 sustained activation 
during prolonged mitotic arrest 
leads to phosphorylation of 
caspases 2, 8 and 9 protecting 
from caspase-dependent cell 
death, while on the other hand 
phosphorylates the pro-survival 
factors Bcl-1, Bcl-Xl and Mcl-1 
and it also affects the turnover 
of Mcl-1. Hyperphosphorylation 
of Mcl-1 makes it more prone 
to phosphorylation by other 
kinases such as CKII, JNK and 
p38 and impedes 
dephosphorylation catalyzed 
by PP2A. This 
hyperphosphorylation makes it 
more susceptible to be 
ubiquitylated by the SCF 
complex and degraded by the 
proteasome (adapted from 
Manchado et al 2011). 
 
Sensitivity to anti-tubulin chemotherapeutics is regulated by Mcl-1 and FBW7 (Wertz et al., 2011). 
Phosphorylation of Mcl-1 by Cdk1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest 
(Harley et al., 2010). During a normal mitosis, transient activation of Cdk1 fails to reach the phosphorylation 
threshold that override the antiapoptotic activity of Mcl-1, Bcl-2 and Bcl-xL. If Cdk1 is active for too long the 
threshold is reached causing inactivation of the antiapoptotic function and eventually apoptosis. Recently has 
been shown that Cdk1 affects the turnover of Mcl-1 (Figure 10 bottom pannel). Phosphorylation of Mcl-1 
makes it sensitive to the polyubuquitylation by the SCF complex. Once Mcl-1 is phosphorylated additionally 
by JNK, p38 and CKII kinases, it is recruited to the SCF by the tumor suppressor Fbw7 and degraded by the 
proteasome.  During a normal mitosis phosphorylation is counteracted by PP2A and other phosphatases 
(Wertz et al., 2011). APC-Cdc20 is also involved in the degradation of Mcl-1 when is phosphorylates by Cdk1 
in cells arrested in mitosis (Harley et al., 2010). But Cdk1 also controls the activity of other pro-survival factor 
such as Bim (Fhearraigh et al., 2011) which hyperphosphorylation during prolonged mitotic arrest is an 
important cell death signal. Cdk1-cyclin B1 phosphorylation acts as a functional link coupling mitotic arrest 
and apoptosis, however how Cdk1 sets the balance between cell death and survival it is not known yet. In 
addition to Cdk1 other mitotic regulators, such as Polo-like kinases, may also participate in balancing the 
activity of the pro-survival factors in mitotic arrest. Contrarily to Cdk1, Plk-1 seems to have a pro-death role by 
phosphorylating and weakening Bcl-xl pro-survival activity (Tamura et al., 2009). Moreover, sequential 
phosphorylation of caspase-8 by Cdk1 and Plk1 triggers apoptotic cell death during mitosis (Matthess et al., 
2013).  
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While Cdk1 is clearly involved in modulating survival in mitosis, the role of the mitotic checkpoint in 
survival in response to mitotic inhibitors is controversial. Sustained activation of the SAC, for instance by 
overexpression of the Mad checkpoint proteins, leads to mitotic arrest frequently followed by apoptosis and 
caspases has been shown to cleave some SAC components, a phenomenon that may be linked to mitotic 
slippage (Castedo et al., 2004). However, studies in which the SAC is satisfied, in Cdc20 null cells, suggest 
that the SAC per se do not have a pro-apoptotic role (Castedo et al., 2004). Recent studies demonstrate that 
even in the absence of checkpoint activation, mitotic arrest induced by Cdc20 Knockdown (KD) or 
overexpression of the non-degradable form of cyclin B, leads to FLIP down regulation and sensitivity of tumor 
cell lines to TRAIL (Sánchez-Perez et al., 2014). Consequently a pro-apoptotic signal independent of the SAC 
might be accumulated to trigger cell death during mitotic arrest (Jackson et al., 2007). Survivin is the only 
functional link between mitotic machinery and apoptosis, and it has been shown to inhibit activation of 
caspases (Dohi et al., 2004; Li et al., 1998; Shin et al., 2001; Tamm et al., 1998). At the beginning of mitosis, 
survivin associates with mitotic spindle microtubules forming a complex with INCENP, borealin and Aurora B 
(O´connor et al., 2002; Wall et al., 2003) forming the chromosome passenger complex CPC. Either 
knockdown of survivin or INCENP has a similar phenotype, disrupted microtubule formation, polyploidy and 
massive apoptosis (Cutts et al., 1999; Uren et al., 2000). Recent studies provide evidence that survivin is 
required for a sustained mitotic arrest in response to the lack of tension at the kinetochore (Carvalho et al 
2003; Lens et al 2003). Indeed, survivin depletion by siRNA leads to a prometaphase delay without effect on 
chromosome alignment. The APC/C complex itself may have a role in the modulation of cell death, since 
APC/C-Cdh1 indirectly inhibits apoptosis by degradation of MOAP-1, a Bax activator (Huang et al., 2012). 
And more importantly APC/C-Cdc20 has been implicated in inhibition of apoptosis by targeting the pro-
apoptotic factor Bim for degradation (Wan et al., 2014).  
Together this findings shown that a prolonged mitosis can result in both inhibition of the anti-apoptotic 
machinery and activation of a pro-apoptotic pathway, which provides a plausible mechanism to explain cells 
sensitivity to a delayed mitosis. Therefore preventing mitotic slippage or modulating the cell death pathways 
that trigger cell death in mitosis should enhance the efficacy of antimitotic drugs. This molecular pathway may 
have relevant implications for designing future therapeutic strategies aimed at inhibiting APC/C and for 
preventing adaptation to the apoptotic cell death imposed by defective mitotic exit. As previously suggested, 
APC/C–Cdc20 inhibitors could be useful in combination with other mitotic poisons by slowing cyclin B1 
degradation and thus providing enough time to reach the apoptotic threshold of tumor cells.  
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Blocking mitotic progression has been proposed as an attractive therapeutic strategy to impair 
proliferation of tumor cells. Mitotic arrest induced by anti-mitotic drugs such as taxanes and vinka-alkaloids s 
may lead to cell death; however, how cells survive during prolonged mitotic arrest and which are the 
pathways that determine survival in these conditions is not well understood. The molecular links between 
mitosis and apoptosis have been extensively studied, however there are also multiple evidences that death in 
mitosis might be apoptosis-independent.  By using a genetic model of defective mitotic exit in mammalian 
cells, Cdc20 knockout mouse model, we aim to accomplish the following objectives 
 
1. Understand the molecular mechanisms that govern cell survival in mitosis. 
 
2. Evaluate the therapeutic benefit of interfering with the pathways responsible for survival during            
prolonged mitotic arrest. 
 
3. Identify compounds that specifically induce cell death in mitosis. 
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1. Cell culture and synchronization 
 
1.1 Cell culture and synchronization 
The Cdc20 conditional allele and its deletion by 4-OHT-inducible forms of Cre (RERT) were reported 
previously (Manchado et al., 2010). Atg5 and Bax/Bak mutant MEFs were described previously (Buytaert et 
al., 2006; Salazar et al., 2009; Tsukamoto et al., 2008). MEFs and human cell lines were growth in 
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) complemented with10% fetal bovine serum (FBS) and 
gentamycin at 37ºC and 5% CO2. For synchronization in G2, Cdc20(lox/lox); RERT (+/Cre) MEFs and MDA-
MB-231 cells were treated with RO-3306 (Calbiochem; 5µM) for 18 hours and released in DMEM with or 
without 4-OHT (Sigma; 1µM), or DMEM with or without Taxol (Sigma; 700 nM) and proTAME (Boston 
Biochem., Inc.; 10µM). For mitotic synchronization of Cdc20-proficient mouse or human cultures, cells were 
treated for 12 hours with 200 nM nocodazole (Sigma) and released in fresh media containing 10 µM MG132. 
For synchronization in S-phase, HeLa cells were treated with thymidine (Sigma; 604 µg/mL) for 24h and 
released in fresh DMEM. Cells were treated with small molecule inhibitors as indicated in Table 2. One µM 
TO-PRO®-3 Iodide (642⁄661; Invitrogen T3605) was added to cultures to monitor cell death. 
This is shown in Figure 11, when asynchronic cell cultures were synchronized in G2 by the addition of 
RO-3306, a Cdk1 inhibitor either in the presence or the absence of 4-OHT. After RO-3306 wash out cells are 
able to enter mitosis, but whereas in Cdc20(∆/∆) mitotic exit is completely prevented due to the lack of 
APC/C-Cdc20-dependent cyclin B1 degradation, Cdc20(lox/lox) cells are able to exit mitosis and progress 
normally through the cell-cycle. Cdc20(∆/∆) are not able to resolve anaphase and remain stuck in metaphase 
until cell death. Mitotic figures accumulate over time, about 40% of cells are in mitosis 0.5 h after the G2 
release, reaching 80% at 8 hours after RO-3306 wash-out (Figure 11c). As previously reported (Manchado et 
al., 2010), no Cdc20(∆/∆) cell was able to exit from the mitotic arrest suggesting that this APC/C cofactor is 
essential for mitotic slippage.  
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Figure 11. Synchronization of cells in mitosis. a) Schematic representation of the protocol followed for synchronization 
in Cdc20(∆/∆) and Cdc20(lox/lox). Asynchronous cells were synchronized in G2 by the addition of the Cdk1 inhibitor RO-
3306, in the absence of 4-OHT (blue) presence of 4-OHT (red), added 12 hours prior RO-3306- RO-3306 is washed-out 
after 18 hours of treatment. b) Excision of Cdc20 upon 4-OHT treatment. c) Synchronized mitotic entry in Cdc20-null cells 
after release from RO-3306. Cdc20(lox/lox) cells were treated with 4-OHT to eliminate Cdc20 12 hours prior the addition 
of RO-3306, a Cdk1 inhibitor, to arrest cells in G2. This compound was washed-out 18 hours after allowing mitotic entry; 
in the absence of Cdc20 cells remain arrested in mitosis. Mitotic figures accumulate over time reaching  80% of mitotic 
figures 8 hours after RO-3306 release. d) Synchronized mitotic entry in Cdc20(lox/lox) cells after release from RO-3306. 
Cdc20(lox/lox) cells were treated with RO-3306, in the absence of 4-OHT, to arrest cells in G2. This compound was 
washed-out 18 hours after allowing mitotic entry in the presence of Cdc20 cells are able to exit mitosis and progress 
normally throughout the cell cycle. 
 
 
1.2 Transfection/Nucleofection 
Human cells lines and MEFs were transfected in subconfluency with Lipofectamine 2000 (Invitrogen) 
for plasmids transfection (LC3-GFP) and Amaxa system for siRNA against specific transcripts (Dharmacon 
smart pool), respectively, in accordance with the macturer´s recommendations. For Haspin knock down the 
following siRNA were used. 
hHaspin GGCAUCUGAUGCUGAAAAG 
mHaspin GGUCAUCUCUCUUUAGCCU 
 
1.3 Treatments 
The following drugs were used in cultured cells at the indicated concentrations:  
Inhibitor Target Concentration Source 
2-DG Hexokinase 5-20mM Sigma 
3MA Vps34 (PI3KCIII) 5mM Sigma 
3PO PFKFB3 1-100µM Millipore 
ABT-264 Bcl-2 family + Mcl-1 100nM ActiveBiochem 
ABT-737 Bcl-2 family 100nM Selleckbio 
AICAR AMPK activator 1mM Sigma 
AKTIV Akt 2µM Calbiochem 
Antimycin A mitochondrial electron transport 1µM Sigma 
BEZ235 mTORC1 and PI3K 20nM SelleckBio 
C75 Fatty acid synthase 10µgr/mL Sigma 
Cyclosporin A Cyclophilin 5µM Sigma 
Compound C AMPK 10µM Calbiochem 
Material and Methods 
 
 46
Inhibitor Target Concentration Source 
E64d Cathepsin and capain 1µgr/mL Sigma 
FCCP H+ ionophore 1µM Sigma 
LY294002 PI3K 20µM Calbiochem 
Metformin AMPK activator 1mM Sigma 
MG132 Proteasome inhibitor 10µM Sigma 
Monastrol Eg5 100µM Sigma 
Necrostatine-1 RIPK1 20µM Enzo 
Nocodazol Microtubules 200nM Sigma 
Okadaic Acid PP1/PP2A 1µM Sigma 
Oligomycin A F0 part of the H+-ATP-synthase 2-10µM Sigma 
Oxamate LDHA 1mM Sigma 
PD98059 MEK1 and MEK2 20µM Calbiochem 
Pepstatin A Cathepsin and calpain 5µgr/mL Sigma 
proTAME APC/cyclosome 10µM Boston Biochem 
PP242 mTORC1 10nM Sigma 
Rapamycin mTORC1 500nM Sigma 
RO-3306 Cdk1 1-10µM Sigma 
Roscovitine Cdk1 100µM Sigma 
Rotenone mitochondrial electron transport 1µM Sigma 
SB-203580 p38MAPK 20µM Enzo 
Taxol Microtubules 20-700nM Sigma 
Temsirolimus mTORC1 100nM Sigma 
Z-VAD-fmk Pan caspase inhibitor 20µM Calbiochem 
 
Table 2. Inhibitors used in this work. 
 
 
1.4 Viral infections 
Human cell lines at 60-70% confluency were infected with lentiviruses containing H2B-GFP. For IF 
Cdc20 (lox/lox), RERT (+, KI) MEFs at 60-70% confluency were infected either with retroviruses containing 
Lamina-CFP or lentiviruses containing Cherry-LC3GFP.  For increasing the infection efficiency, two 
consecutive rounds of infection were performed. In order to generate stable cell lines cells were sorted in 
Influx sorted or FACs Aria. 
 
1.5 Flow cytometry 
Asynchronous cells were trypsinized for 5 min at 37ºC and resuspended in complete medium. In order 
to recover mitotic cells, mitotic shake-off was performed. Cell cycle profile assay were performed by adding 
0.2µg/ml DAPI (Sigma) to the samples prior to run them on the LSR Fortessa (BD, San Jose). 10,000 single 
events were acquired. All data were analyzed using FlowJo v9.6.4 (Treestar, Oregon). For cell viability 
assays 1 µM TO-PRO®-3 Iodide (642⁄661; Invitrogen T3605) was added. To quantify mitochondrial mass, 
cells were resuspended in complete medium with 10 nM Mitotracker Deep Red FM (MTDR, M22426, 
Invitrogen) and 1 /mL propidium iodide (P4864, Sigma) and then incubated for 15 min at 37ºC. Using an 
FC500 flow cytometer (Beckman Coulter), 10,000 cells were acquired in the FL3 and FL4 channels. Mean 
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fluorescence in the FL4 channel in the viable cell (PI-negative) population was plotted and normalized against 
that of untreated cells. 
 
1.6 ROS measure 
To monitor ROS, cells were grown on µCLEAR bottom 96-well plates (Greiner Bio-One), treated with 
specific drugs and incubated for 30 min at 37ºC as indicated in OxiSelect TM Intracellular ROS assay kit, Cell 
Biolabs and 5 µg/ml Hoechst 33342 (Invitrogen H3570). Images were automatically acquired from each well 
by an Opera High-Content Screening System (Perkin Elmer) as indicated above. 
 
 
2. Immunofluorescence and biochemical analysis 
2.1 Western blotting  
Asynchronous cells were trypsinized for 5 min at 37ºC and resuspended in complete medium. In order 
to recover mitotic cells, mitotic shake-off was performed. Harvested cells were lysed in RIPA or a buffer 
containing 50 mM Tris HCl, pH 7.5, 1 mM phenylmethylsulfonyl fluoride, 50 mM NaF, 5 mM sodium 
pyrophosphate, 1 mM sodium orthovanadate, 0.1% Triton X-100, 1 µg/ml leupeptin, 1mM EDTA, 1 mM 
EGTA and 10 mM sodium-glicerophosphate. (Salazar et al., 2009) and 30 µg of total protein was separated 
by SDS-PAGE in Criterion Bis-Tris geles (BioRad), transferred to nitrocellulose membranes (BioRad) by wet 
transference. Membranes were blocked with 5% milk in 0,005% TBS-Tween 20 and probed with antibodies 
against as indicated in Table 3. The secondary antibodies were HPR-conjugated (DAKO) and western blot  
(WB) was developed using the ECL system (PerkinElmer). Analysis of WB levels were performed in Image J. 
 
Antigen Source Ig Source Use 
α-tubulin Mouse Sigma WB 
ACC Rabbit Cell Signalling WB 
AMPK Rabbit Cell Signalling WB 
Akt Rabbit Cell Signalling WB 
Bcl-2 Rabbit Cell Signalling WB 
Bcl-X Mouse BD Pharmigen WB 
Bim Rabbit Abcam WB 
Caspase 2 Rabbit Abcam WB 
Caspase 3 Rabbit Cell Signalling WB 
Cdc20 Rabbit Santa Cruz WB 
Cdc27 Mouse Abcam WB 
ERK Rabbit Cell Signalling WB 
LC3b Rabbit Sigma WB 
Mcl-1 Rabbit Rockland WB 
p62 Mouse Sigma WB 
PARP Rabbit Cell Signalling WB 
PFKFB3 Rabbit Cell Signalling WB 
Phospho-ACC Rabbit Cell Signalling WB 
Phospho-AMPK(Thr172) Rabbit Cell Signalling WB 
Phospho Akt (ser473) Rabbit Cell Signalling WB 
Phospho-Erk (Thr202/Tyr204) Rabbit Cell Signalling WB 
Phospho-(Ser) CDK substrates Rabbit Cell Signalling WB 
Phospho-Histone 3 (ser10) Rabbit Millipore WB 
Phospho-S6-ribosomal protein (ser235/236) Rabbit Cell Signalling WB 
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Antigen Source Ig Source Use 
Survivin Rabbit Novus Biological WB 
Vinculin Mouse Sigma WB 
 
Table 3. WB; western blot 
 
 
2.2 Inmunofluorescence  
For immunofluorescence, cells were fixed in 4% buffered paraformaldehyde for 10 min at RT, 
permeabilized in 0.15% Triton-X 100 for 5-10 min at RT and stained with 4,6 diaminophenylindole (DAPI; 
Prolong Gold antifade, Invitrogen) to visualize nuclei. Images were captured using a laser scanning confocal 
microscope TCS-SP5 (AOBS) Leica or a Leica DMI 6000B microscope. For Lamina-CFP, a Cdc20 (lox/lox), 
RERT (+, KI) stable cell lines were generated. For mitophagy quantification, before fixation cells were 
incubated with Mitotracker Deep Red FM (MTDR, M22426, Invitrogen) for 30 min at 37 ºC. 
 
2.3 Immunohistochemistry 
For immunohistochemistry dissected tumors were fixed in 10%-buffered formalin (Sigma) and 
embedded in paraffin wax. Sections of 3-5 µm thickness were stained with active caspase 3 (C3A) antibody 
and analyzed. Table 3 the slides were digitalized by MIRAX digital slide scanner (Zeiss). 
 
2.4 Real-time reverse-transcription PCR (qRT-PCR) 
For quantitative RT-PCR studies total RNA was isolated by using the Qiagen RNeasy kit according to 
the manufacturer’s instructions. cDNA was synthesized with a Superscript III reverse transcriptase 
(Invitrogen) and PCR amplification was performed using  SYBR Green PCR Master mix (Applied Biosystems) 
with specific primers (Table 4). mRNA levels were normalized to β-actin mRNA levels in murine cells and to 
GAPDH for human cell lines.  
 
Gene  Sequence 
AMPKα1 Forward AGTCAAAGCCGACCCAATGA 
 Reverse GGATTCTTCCTTCGTACACGC 
AMPKα2 Forward ATGGCTGAAGTGTACCGAGC 
 Reverse AGCTCCGACTGTCTACCAGG 
Bak Forward CATCTTGGGTCAGGTGGGTC 
 Reverse TGGAACTCTGTGTCGTAGCG 
Bax Forward TCTCCGGCGAATTGGAGATG 
 Reverse CGTGTCCACGTCAGCAATCA 
Beclin1(BECN1) Forward TTGAAACTCGCCAGGATGGT 
 Reverse ATCAGATGCCTCCCCGATCA 
Drp1 Forward TCAGAAATGCTACTGGCCCC 
 Reverse TCACGGGCAACCTTTTACGA 
hHaspin Forward TGAAACGAGAGCCATGACCG 
 Reverse CCATATGTGCGGAAAAGCCG 
mHaspin Forward ACACGCAGGCTCTTGACTC 
 Reverse GTACGTTCGAAAGAGCCGGG 
Raptor Forward CTGCTCGTGGCAAGTTTGTT 
Material and Methods 
 
 49
Gene  Sequence 
 Reverse CTGCTTACTGGGGTGCAGTT 
RIPK1 Forward ACATCAATGCAAAGCCCACG 
 Reverse TGCAGATCACGAACTGCTCA 
RIPK3 Forward GTACGTTCGAAAGAGCCGGG 
 Reverse ATCTTGTCACCAGAGCCTGC 
Survivin Forward ATCTGGCAGCTGTACCTCAAG 
 Reverse TTCTATGCTCCTCTTCGCTCT 
ULK1 Forward CCTGACTTCCTACAGCGGAG 
 Reverse CTAGCCAACAGGGTCAGCAA 
Vps34 (PI3KCIII) Forward AGACTTCAGGCCTTGCTTGG 
 Reverse CTTGACGCAAGTCGTCTCCA 
 
Table 4. qRT-PCR primers used in this work. 
 
 
3. Microscopy 
3.1 Videomicroscopy 
For videomicroscopy human and murine cell lines expressing stable H2B-GFP were plated on eight-
well glass-bottom dishes (Ibidi) and imaged with a DeltaVision RT imaging system (Applied Precision, LLC; 
IX70/71; Olympus) equipped with a Pl APO 20X/ 1.42 NA objective lens, maintained at 37 °C in a humidified 
CO2 chamber. 1 µM TO-PRO®-3 Iodide (642⁄661; Invitrogen T3605) was added before start recording. 
Images were acquired every 10 or 15 min, and processed and analyzed using ImageJ software.  
 
3.2 High-throughput microscopy (HTM) 
For HTM cells were grown on µCLEAR bottom 96-well plates (Greiner Bio-One). After specific 
treatments, 1 µM TO-PRO®-3 Iodide (642⁄661; Invitrogen T3605) and 5 µg/ml Hoechst 33342 (Invitrogen 
H3570) were added. After 30 min of incubation at 37ºC, images were automatically acquired from each well 
by an Opera High-Content Screening System (Perkin Elmer). A 20x magnification lens was used and pictures 
were taken at non-saturating conditions. Images were segmented using the Hoechst 33342 staining to 
generate masks matching cell nuclei from which the mean TO-PRO®-3 signal were calculated. For the 
screening of 200 compounds Cdc20(lox/lox) MEFs expressing H2B-GFP cells were grown on µCLEAR 
bottom 96-well plates (Greiner Bio-One). After specific treatments at the indicated times and 1 µM TO-PRO®-
3 Iodide (642⁄661; Invitrogen T3605) addition, images were automatically acquired from each well by an 
Opera High-Content Screening System (Perkin Elmer). A 10x magnification lens was used and pictures were 
taken at non-saturating conditions. Images were segmented using the GFP staining to generate masks 
matching cell nuclei from which the mean TO-PRO®-3 signal were calculated. Based on the distribution of 
TO-PRO3 intensity in untreated cells, a threshold for cell viability was established. Data were filtrated using 
SPSS. 
 
3.3 FRET  
For FRET analysis (Tsou et al., 2011), cells were plated on eight-well flow chambers (Ibidi) and 
Imaged with a Leica AF6000W  equipped with a  fast external filter wheels, Hamamatsu CCD Camera,  HCX 
PL APO 40X/ oil 1.25  NA objective lens and AFC hardware autofocus system, maintained at 37 °C in a 
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humidified CO2 chamber. Images were acquired every 1 or 10 min. Images were processed and analyzed 
using ImageJ software.  
 
3.4 Life-cell confocal microscopy 
Images were captured using a laser scanning confocal microscope TCS-SP5 (AOBS) Leica or a Leica 
DMI 6000B microscope, HCX PL APO 63X/oil 1.25x objective lens, maintained at 37 °C in a humidified CO2 
chamber. 
 
3.5 Transmission electron microscopy (TEM) 
Cells were fixed for 4 hours at 4°C in 4% paraformaldehyde (w/v) and 2.5% glutaraldehyde (v/v) in 0.4 
M HEPES buffer pH 7.4, washed and fixed again in aqueous 1% (w/v) osmium tetroxide, and embedded in 
Epon. Electron microscopy was performed with a JEOL 1230 transmission electron microscope, at 80 kV, on 
ultra-thin sections of 60 nm. 
 
 
4. Metabolic assays  
4.1 Seahorse metabolic profiling 
Oxigen consumption rate (OCR) and the extracellular acidification rate (ECAR) of cells were measured 
with an XF96 Extracellular Flux Analyzer (Seahorse Bioscience). In brief, cells were plated at 1.5-2 ×104 
cells/well in buffered DMEM containing 25 mM glucose and 2 mM glutamine. Cells were incubated in a CO2-
free incubator at 37°C for 1 h to allow for temperature and pH equilibration prior to loading into the XF96 
apparatus. Assays consisted of sequential mix (2 min), pause (2 min), mix (0.33 min) and measurement (4 
min) cycles, allowing for determination of OCR/ECAR every 8.33 min. Mitotic cells were obtained after shake 
off and plated in BD Cell-TaK coated plates (Faubert et al., 2013; Wu et al., 2006). 
 
4.2 Nuclear magnetic resonance (NMR) 
For NMR analysis of cell media metabolites (Bradley et al, 2010), 0.5 x106 MEFs were plated (in 
triplicate) in DMEM containing 5 mM U13C-labeled glucose and 10% dialyzed FBS and were synchronized as 
described above. 500 µL of cell media supernatant were sampled for every time point (at 0 h, when cells are 
washed and fresh 13C-label medium is added, and 4, 8, and 24 h, or 3, 6, 18 and 36 h afterwards), and 
centrifuged at 10,000 xg for 10 min using 10Kd Spin Columns (BioVision) to eliminate high molecular mass 
components (mainly albumin from serum). NMR samples were prepared mixing 400 uL of medium filtrate with 
200 uL of NMR buffer (PBS 3X in 70% deuterated water, 0.3 mM TMSP, and 0,09% sodium azide) and 
transferred to 5 mm NMR tubes for measurement. High-resolution NMR spectra were registered on a Bruker 
Avance spectrometer operating at 16.4 T (proton Larmor frecuency of 700 MHz) at 293 K using a room 
temperature TXI probe with pulsed field gradient capabilities, and equipped with a BACS120 sample changer. 
1D proton NMR spectra (1dH) of cell growth media were recorded using a NOESY pulse sequence 
(noesygppr1d in Bruker nomenclature) employing pulse field gradients during the mixing time of 10 ms and 
low power (50 db) presaturation of the residual water signal during the 2 s recovery delay between 
consecutive scans. 256 scans were accumulated using a spectral width of 20 ppm and acquisition time of 1.6 
s, resulting in typical acquisitions times of 17 min per sample. Analogous parameters were used to record 
13C-filtered 1D proton NMR spectra (1dHC), which allows selective observation of 13C-bound protons (from 
13C-glucose and metabolic transformation products thereof). 1dHC spectra were recorded using the first 
increment of a 2D sensitivity-enhanced 1H-13C heteronuclear single quantum coherence experiment (2dHC, 
hsqcetgpsisp2 in Bruker nomenclature) (Schleucher et al., 1994; Willker et al., 1993) without 13C decoupling 
during the 1.6 s acquisition time. All 1dH and 1dHC free induction decays (FIDs) were processed with 
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exponential multiplication (0.5 Hz line-broadening) before Fourier transformation and baseline corrected 
afterwards using Topspin2.1 (Bruker). 1H chemical shifts were referenced to internal TMSP (0.00 ppm). 
Concentrations of metabolites in 1dH spectra were obtained by comparing metabolite signal integrals to that 
of the added standard (TMSP), considering the number of equivalent protons in each chemical group of each 
metabolite. Integration regions of variable size were manually defined using the AMIX3.8 software (Bruker) in 
order to cover all detected signals (but water) and adjusted (to accommodate small variations in signal 
positions presumably due to differences of pH and ionic strength between samples) for each set of spectra. In 
1dH experiments signal-specific correction factors were applied for incomplete recovery of magnetization 
during the incomplete relaxation delay, and the number of equivalent protons in each resonance (as well as 
the 9 protons in TMSP) was taken into account to calculate absolute metabolite concentrations from the 
corresponding signal/s, which resulted in a 5-fold saving in NMR acquisition time over the alternative method 
which requires recording fully relaxed spectra. These correction factors were determined from the ratio of 
each signal integrals in two spectra acquired on a representative sample: that in a regular 1dH experiment 
recorded with 2 s recovery delay, and the corresponding one in the fully relaxed spectrum, recorded with 10 s 
recovery delay. The total integral of the different well-resolved signals of glucose (the only 13C-labeled 
nutrient) and that of the methyl signal of lactate in 1dHC spectra was used to quantify the relative decrease of 
U-13C6-glucose and the relative increase of 13C3-lactate in the media. These were converted into approximate 
molar concentrations using the known initial concentration of 13C6-glucose in the medium and the maximum 
final lactate, as measured from the two 13C-satellites of the methyl resonance of lactate in 1dH spectra. 
Unlabeled glucose uptake and lactate production was also measured using the central (non-satellite) signals 
of the H4 protons of (unlabeled) glucose at 3.41 ppm (that overlap for α and β glucose) and the doublet of 
the lactate methyl signal at 1.33. In order to normalize for the (possibly) variable amount of cells in each plate 
the total metabolite signal of each 1dH NMR spectrum (calculated as the sum of all integration regions, 
excluding the TMSP and contaminants signals) of each polar extract sample was taken into account, and 
1dH-derived integrals and 2dHC-derived intensities of samples with a reduced amount of metabolite signal 
were divided by the corresponding reduction factor to match the most concentrated sample in each set.  
 
4.3 HPLC ATP  
Concentration of ATP was determined spectrophotometrically as described previously (Saha et al., 
2004). 
 
5. In vivo studies 
Mice were injected subcutaneously in the right and the left flank with 3 x106 MDA-MB-231 cells in 0.1 
ml of PBS + 0.5% BSA. 20 days after cell injection, tumors had grown to an average volume of 150-200 mm3. 
Mice were then divided into different experimental groups of 5 animals each, which received the following 
treatments as intraperitoneal injections: saline (control); 5 mg/kg Taxol; 5 mg/kg 3PO; 25 mg/kg 3PO; 50 
mg/kg 3PO; 5 mg/kg Taxol + 5 mg/kg 3PO; 5 mg/kg Taxol + 25 mg/kg 3PO; 5 mg/kg Taxol + 50 mg/kg 3PO. 
The injection was repeated every two days and treatment was continued for 12 days. Tumor volumes were 
monitored using calliper measurements and were calculated by the formula: (4p/3) * (w/2)2 * (l/2). 
 
6. Statistics 
Statistical analysis was carried out using Prism 5 (GraphPad). All statistical tests were performed 
using two-sided, unpaired Student’s t tests, or the Fisher’s exact test. Data with p<0.05 were considered 
statistically significant (*, p<0.05; **, p<0.01; ***, p<0.001). 
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1. Molecular pathways that modulate cell viability in mitosis 
Inhibition of mitotic progression leads to prolonged mitotic arrest which may results in cell death in 
mitosis, or more frequently, mitotic exit in the absence of proper chromosome segregation and an active SAC 
(mitotic slippage). While many of the aneuploid cells may die because of massive chromosome imbalance, 
survivors may continue proliferating, which is clearly an undesirable outcome. Thus, efforts to obtain 
fundamental insights into the regulation of mitotic cell death will be extremely important in enhancing our 
understanding of drug sensitivity in cancer cells.  MCD can be exploited as a strategy to increase the efficacy 
of chemotherapeutic agents such as microtubule poisons. Cdc20-null cells are the ideal scenario to 
characterize the molecular requirements for cell death in mitosis. 
 
2.1 Mitotic cell death is modulated by the intrinsic apoptotic pathway 
 
As previously introduced, we have developed a new strategy to follow individual cell fate by 
videomicroscopy after mitotic arrest caused by genetic depletion of Cdc20 or chemical inhibition of mitosis in 
human cells. We use H-Ras-transformed Cdc20-conditional knockout cells expressing a histone H2B-GFP 
reporter as well as an inducible form of the Cre recombinase. Addition of tamoxifen results in the activation of 
Cre, the excision of Cdc20 exons and metaphase arrest.  We also use some human cell lines expressing the 
histone H2B-GFP reporter in which we mimic the metaphase arrest exerted by Cdc20 ablation by using 
proteasome inhibitor or an APC/C inhibitor. Cell death becomes evident in these cells by the use of a soluble 
dye, To-Pro3, which diffuses into the cells after the permeabilization of the membranes that accompanies cell 
death. Mitotic onset is characterized by cell rounding accompanied by DNA condensation. This system allows 
the interrogation of the consequences of modulating several signalling pathways by using RNA interference 
or specific chemical inhibitors. By measuring survival in mitosis (SiM), which is the time from mitotic entry till 
cell death in mitosis (To-pro3 staining). 
Cdc20(∆/∆) cells display a variable SiM of 20 ± 14 h until they finally died in mitosis (Figure 12b,c) in 
the complete absence of mitotic exit, previously reported (Manchado et al., 2010). Initially we evaluated the 
relevance of the apoptotic pathway in mitotic cell death. The two pathways of apoptotic cell death converge in 
the activation of caspases, but can be distinguished by the requirement of Bcl-2 family proteins and by which 
caspases are crucial for their execution. The intrinsic or mitochondrial pathway, regulated by Bcl-2 family 
proteins, generally leads to the activation of caspase-9, whereas the extrinsic or death-receptor pathway is 
triggered by ligation of the death receptor which can recruit and activate caspase-8, an event that leads to the 
subsequent activation of downstream effectors caspases-3, 6 or 7 (Youle et al., 2008). Bcl-2 family proteins 
play pivotal roles in controlling programmed cell death and have been classically grouped into three classes: 
the pro-survival members; Bcl-2, Bcl-xL, Bfl-1/A1, Bcl-w, Mcl-1, Boo, NR-13, BHRF1, LMW5-HL, ORF16, KS-
Bcl-2, E1B-19K, and Ced-9, and the pro-apoptotic members which includes: Bax, Bak, and Bok (Adams and 
Cory, 1998). A third divergent class is the BH3-only proteins (Bad, Bid, Bik, Bim, BMF, Noxa and Puma), 
which selectively interact with anti-apoptotic Bcl-2 family members (Huang and Strasser, 2000). The pro-
apoptotic family members Bak and Bax are crucial for permeabilization of the outer mitochondrial membrane 
by oligomerization and formation of a pore and the subsequent release of apoptogenic molecules such as 
cytochrome c and DIABLO, which ultimately leads to caspase activation (Youle et al., 2008). The anti-
apoptotic members Bcl-2 and Bcl-xL bind and prevent Bak and Bax homo or heterodimerization (Willis et al., 
2007a-b) repressing Bak and Bax proteins. It is still controversial how BH3-only proteins can activate Bak and 
Bax proteins, one model states that it occurs through direct binding and inhibition of Bcl- 2 family members, 
but an opposing model argue that Bid, Bim and Puma directly activates Bak and Bax (Youle et al., 2008, 
Zong et al., 2008). 
To test the relevance of apoptosis in MCD, we transfected these cells with small interfering siRNAs 
(Figure 12d,e) against several apoptotic regulators following the protocol depicted in Figure 12a. Knockdow of 
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Mcl-1, a pro-survival regulator of the Bcl2 family involved in the response to taxol (Inuzuka et al., 2011; Wertz 
et al., 2011) resulted in early MCD (SiM 9.5 ± 6.5 h). Similar studies suggested the involvement of Bcl-x in 
preventing MCD in fibroblasts whereas the differences induced by knockdown of Bcl-2 did not reach statistical 
significance despite an efficient downregulation of protein levels (Figure 12c,e). Contrarily, knockdown of both 
caspase-2 and caspase-3 significantly delayed MCD (SiM 25.5 ± 17.2 h; Figure 12b,c). The involvement of 
the apoptotic machinery was also validated using the pan-caspase inhibitor ZVAD or two different inhibitors of 
the Bcl-2 family (Figure 12d). SiM was improved with ZVAD treated cells and significantly decreased after 
application of Bcl-2 family inhibitors (Figure 20d) being more dramatic in the case of ABT-263, perhaps as a 
consequence of the more potent effect of this compound against Mcl-1 (Rooswinkel et al., 2012; Tse et al., 
2008). Downregulation or inactivation of caspases or Bax /Bak, proteins delayed but did not prevent MCD, 
resulting in SiM 34 ± 28 h, as all cells died in these assays in the absence of Cdc20 (Figure 20c,d). Similar 
data were obtained when human cancer cells (HeLa or MDA-MB-231) were subjected to a similar protocol for 
synchronization (Figure 21c) and treated with either caspase or Bcl-2 family inhibitors, suggesting that 
apoptosis is involved but not essential for MCD. 
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Figure 12. MCD is modulated by the intrinsic apoptotic pathway. a) Schematic representation of the protocol for time-lapse 
microscopy in Cdc20-deficient cells. Cells are subjected to two consecutive rounds of transfection, at 72 and 24 hours before start 
recording, respectively. 4-OHT was added 18 hours before the video. In contrast, for chemical inhibition, inhibitors were injected 
after the beginning of the video to cells that has been treated with 4-OHT for 24 hour. Only mitotic cells were considered for the 
analysis in order to avoid a possible detrimental effect of the indicated treatments on mitotic entry. b) Representative micrographs 
of Cdc20-deficient cells after the indicated periods of arrest in mitosis in the presence of siRNAs against Mcl-1 or caspase-2 and 3. 
c) Plots representing the duration of mitosis (from mitotic entry till cell death in mitosis) in Cdc20-null cells treated with the 
indicated interfering RNAs or in the presence of the caspase inhibitor ZVAD. d) Plots representing the duration of mitosis (from 
metaphase till cell death in mitosis) in Cdc20-null cells treated with the indicated Bcl-2 family inhibitors. e) Inmunodetection of the 
indicated proteins after treatment with the indicated siRNAs. f) Efficiency of siRNA Knockdown by qPCR analysis of mRNA levels 
(48 h after siRNA nucleofection). Data were normalized by β-actin  mRNA levels. g) Plots representing the duration of mitosis 
(from metaphase in the presence of MG132 to cell death) in either in HeLa or MDA-MB-231 cell lines after addition of the 
indicated drugs.  In c and g dots represent individual cells and a red line indicates the mean. n.s., not significant. **, p<0.01; ***, 
p<0.001 (Student’s t-test).   
 
To further understand whether this was a consequence of partial inactivation of apoptosis, we made 
use of Bax /Bak double knockout MEFs in which the intrinsic apoptotic pathway is completely inhibited  
(Lindsten et al., 2000; Wei et al., 2001). To mimic the metaphase arrest caused by Cdc20 ablation, cells were 
released from a nodazole-induced prometaphase arrest in the presence of the proteasome inhibitor MG132, 
thus preventing cyclin B degradation and mitotic exit (Figure 13a). This protocol resulted in a SiM of 13.0 ± 
9.5 h in wild-type cells, which was significantly expanded to 39.0 ± 28.9 h in average in the absence of Bak 
and Bax (Figure 13b). Yet, all cells died in mitosis in these conditions.  
 
 
Figure 13. Apoptosis participates in MCD but 
is not essential. a) Schematic representation of 
the protocol for time-lapse microscopy in Cdc20-
deficient cells. Human and murine cell lines 
were synchronized in prometaphase with 
nocodazol, after 12 hours of treatment cells are 
released in MG132, avoiding cyclin B 
proteasomal degradation. b) Plots representing 
the duration of mitosis (from metaphase in the 
presence of MG132 to cell death) either in Bak 
/Bax wild type or double-knock out cells. In b 
dots represent individual cells and a red line 
indicates the mean. n.s., not significant. **, 
p<0.01; ***, p<0.001 (Student’s t-test). 
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2.2 Sustained activation of Cdk1 has a pro-death role in MCD 
Cdk1 sustained activation during prolonged mitotic arrest, is known to balance pro-apoptotic and pro-
survival signals. We next tested in Cdc20-null MEFs the role of Cdk1 activity. Upon Cdks inhibition, by the 
addition of roscovitine, in Cdc20(∆/∆) SiM was extended 5 hours in average  (Figure14), whereas inhibition 
of PP1 and PP2A, the phosphatases that counteracts Cdk1 activity, by the addition of 1µM okadaic acid 
(OA), does not affects SiM. This result suggested that Cdk1 activity contributes to survival in mitosis in 
Cdc20-null cells. 
 
Figure 14. Cdk1 sustained activity 
in prolonged mitotic arrest 
contributes to cell death. Plots 
representing the duration of mitosis 
(from metaphase to cell death) in 
Cdc20-null cells after roscovitine, 
okadaic acid or ZVAD addition. 
Roscovitine addition significantly 
delays SiM, but caspases inhibition is 
more efficient in extending SiM. Boxes 
represent individual cells and a black 
line indicates the mean. n.s., not 
significant. **, p<0.01; ***, p<0.001 
(Student’s t-test). There were only 
considered for this assay those cells 
that were already in mitosis before the 
additon of the compounds, avoiding 
interferences in mitotic entry. 
 
2.3 Necroptosis is not a major pathway for cell death in mitosis 
We next investigated other pathways known to regulate cell death. Necrosis, often viewed as an 
accidental and unregulated cellular event, can also be executed in a regulated manner known as necroptosis 
(Hitomi et al., 2008). The term necroptosis is used to designate one particular type of programmed necrosis 
that depends on the serine/threonine kinase activity of RIPK1 (receptor-interacting protein kinases) and 
RIPK3, which can be viewed as a form of cell death with a necrotic appearance. TNF or TRAIL triggered the 
formation of a RIPK1/RIPK3 complex, the initial step of the ripoptosome formation, which eventually leads to 
the downstream activation of caspase-8 (Golstein and Kroemer, 2007). As displayed in Figure 15, down-
regulation of both RIPK1 and RIPK3 by using siRNAs, or inhibition of RIPK1 with necrostatin-1, did not alter 
SiM in Cdc20-null cells (Figure 15). This result suggests that necroptosis or programmed necrosis is not a 
major pathway for death in mitosis.  
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Figure 15. Necroptosis is not involved in mitotic cell death a) Plots representing the duration of mitosis (from mitotic entry till 
cell death) in Cdc20-null cells treated with the indicated interfering RNAs or in the presence of the caspase inhibitor ZVAD. b) 
Efficiency of siRNA Knockdown by qPCR analysis of mRNA levels (48 h after siRNA nucleofection). Data were normalized by β-
actin mRNA levels. c) Plots representing the effect of necrostatin in duration of mitosis (from metaphase till cell death) in Cdc20-
null cells. In a and c dots represent individual cells and a red line indicates the mean. n.s., not significant. **, p<0.01; ***, p<0.001 
(Student’s t-test).  
 
 
2.4 A role for autophagy during mitotic arrest 
Autophagy is a highly conserved process in which cytoplasmic content and organelles are surrounded 
by double-membrane vesicles called autophagosomes (De Duve et al., 1963), which are delivered to 
lysosomes, for digestion, forming autophasolysosome (Rubinsztein et al., 2007). Autophagy can be both, a 
selective process or a non-selective pathway for degradation of bulk cytoplasmic content (Fimia et al., 2013). 
It is a cellular response to a variety of internal and external stress stimuli like nutrient deficiency, hypoxia, ER 
stress, oxidative stress and activated oncogenes. It is critical during starvation in order to provide essential 
nutrients during stress and also serves as a quality control to remove damaged and dysfunctional organelles, 
misfolded proteins, etc. Typically is a protective pro-survival response, however, if hyperactivated, it will 
ultimately kill the cell (Rosenfeldt and Ryan, 2011) considered an independent form of programmed cell 
death, called type II cell death (Galluzi et al., 2012). Three types of autophagy are defined, depending on the 
route of delivery to the lysosome: microautophagy, charepone-mediated autophagy and macroautophagy. In 
this work we will focus on macroautophagy, hereafter simply termed autophagy.  
Autophagy has been proposed to be inhibited in mitosis (Eskelinen et al., 2002, Furuya T et al., 2010; 
Gwinn et al., 2010; Ramírez-Valle et al., 2010), however, it has also been shown that autophagy can persist 
during mitosis (Liu et al., 2009), so we tested the changes in this process during entry into mitosis and 
prolonged mitotic arrest. One of the hallmarks of autophagy is the conversion of the soluble form of the 
microtubule-associated protein 1 light-chain 3 (LC3b-I), to the lipidated and membrane-associated form 
(LC3b-II), which acquires a cytoplasmic dotted pattern. To gain insight into the possible role of autophagy in 
MCD, the autophagic flux was scored using a fluorescent-tagged LC3 sensor in which the pH sensitivity 
differences exhibited by GFP (green fluorescent protein) and RFP (red fluorescent protein) can monitor 
progression from the autophagosome to autophagolysosome (Kimura et al., 2007, Mizushima et al., 2010). 
Whereas autophagosomes emit both mRFP/GFP signals, autolysosomes emit only an acid-stable mRFP 
signal because the pH-sensitive GFP signal is quenched in acidic lysosomes. Cdc20-null cells were first 
synchronized in G2 using the Cdk1 inhibitor RO-3306 and mitotic entry and progression were monitored after 
release from this compound (Figure 16a and Figure 16a,b). The levels of puncta LC3 signals were modest 
during normal mitosis in asynchronous cultures in the absence of 4-OHT or in the initial arrest in Cdc20-null 
cells (Figure 16b). However, both the green and red signals accumulated with time upon prolonged mitotic 
arrest, indicating that autophagy is a dynamic process and that autophagic flux is not impaired in mitosis. 
Accumulation of puncta LC3b-II was significantly prevented in the presence of the Class III PI3K inhibitor 3-
methyladenine (3MA), and increased upon treatment with the mTOR inhibitor PP242. Together this data 
indicates the presence of a dynamic authophagy flux in mitotic cells. 
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Figure 16. Dynamic autophagy in prolonged mitosis. a) Protocol for Cdc20-null cells synchronization, 4-OHT is added to an 
asynchronic culture 12 hours before the RO-3306 addition. Treatment with this Cdk1 inhibitor for 18 hours will synchronize cell 
at the edge of G2-M phase. RO-3306 wash out allows cell to progress to mitosis in the absence of Cdc20. b) Life confocal 
microscopy pictures of Cdc20-null cells transiently expressing the CherryLC3GFP system in the presence of an mTOR inhibitor 
and a 3MA. Colocalization of Cherry and GFP is present in autophagosomes, whereas in a more advanced stage of autophagy 
GFP is loss after acidification by the fusion of autophagosomes with lysosomes. Quantification of the autophagic flux, the criteria 
for considering a cell positive for autophagy is the presence of at least 5 puncta. Data are represented as the mean ± SEM 
(n=30 cells per condition). 
 
 
The presence of double-membrane vesicles with the morphological features of autophagosomes was 
also verified by electron microscopy in Cdc20(∆/∆) (Figure 17). Following the same protocol for 
synchronization, pictures were taken after 6, 24 and 36 hours of mitotic arrest, and in asynchronous cultures. 
In addition, co-incubation during mitotic arrest with the lysosomal protease inhibitors E64D (a calpain and 
cathepsin B inhibitor) and pepstatin A (PA, an inhibitor of aspartic proteases), which blocks the last step of 
autophagic degradation, enhanced the accumulation of autophagic vesicles present per cell. 
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Figure 17. Presence of autophagosomes in cells arrested in mitotic. Electron microscopy pictures from Cdc20-null after 6, 
24 and 36 hours of mitotic arrest and asynchronous cultures, in the presence and absence of E64D/PA. Shows an accumulation 
of autophagosomes in time, which is potentiated by the addition of E64D/PA. Scale bars 2µM. 
 
 
The presence of LC3bII is markedly increased after 24 or 36 h of mitotic arrest in parallel to the 
cleavage of caspase-3, both in mouse and human cells indicating the concomitant presence of autophagy 
and apoptosis in these cultures (Figure 18a-b). 
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Figure 18. LC3bII increases throughout the time of 
mitotic arrest concomitantly to caspase-3  activation. 
a) Inmunodetection of the indicated proteins in Cdc20-null 
cells. The phosphorylated form of Akt at Ser473 rapidly 
decreases upon mitotic onset whereas ERK 
phosphorylation (Thr-202/Tyr204) fluctuates during mitotic 
arrest. LC3bII accumulates in time concomitantly with 
caspase 3 activation in Cdc20-null MEFs. b) 
Inmunodetection of the indicated proteins in MDA-MB-231 
breast cancer cell line. Cdc20-null cells and human cell 
lines were synchronized at the G2/M boundary by 
inhibition of Cdk1, upon RO-3306 addition, 18 hours after 
cells were released from RO-3306. For human cells the 
release from Cdk1 inhibition is performed in the presence 
of taxol and proTAME (an APC/C inhibitor), mimicking the 
arrest imposed by Cdc20 ablation. 
 
For a deeper characterization of autophagic flux in mitosis, we performed a LC3 turnover assay in 
Cdc20 null and MDA-MB-231 cells. The increased LC3bII levels after blockage of the last step of autophagic 
degradation by E64D/PA treatment confirms the presence of a dynamic autophagy flux during mitosis. The 
ratio (LC3bII vehicle/LC3bII in the presence of E64D/PA) represents the amount of LC3b that it is being 
loaded onto the autophagosomes at any given time (Klionsky et al., 2012). This ratio was normalized to one 
hour after release from G2, which is the average duration of a physiological mitosis, and represented in 
Figure 19. There is a tendency to LC3bII accumulation over time of mitotic arrest in both murine and human 
cells, however, levels of LC3bII are slightly lower at 1 hour of arrest compared to the levels of asynchronous 
cultures, this suggest the presence of basal autophagy in interphase which is reduced upon mitotic entry, but 
potentiated in a prolonged mitotic arrest (Figure 19). 
 
Figure 19. LC3 turnover assays show active autophagic flux in MEFs and human cell lines. a) Inmunodetection of the 
indicated proteins in Cdc20-null cells and quantification of LC3b levels in the presence and absence of E64D/PA double 
treatment, in asynchronic culture and Cdc20-null cells over time relative to one hour after RO-3306 release. b) 
Inmunodetection of the indicated proteins in MDA-MB-231 cells arrested in mitosis after RO-3306 release in the presence of 
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taxol and pro-TAME. Quantification of LC3b levels in the presence and absence of cathepsin and calpains inhibitors in 
asynchronic culture MDA-MB-231 cells arrested in mitosis relative to one hour after RO-3306 release. LC3bI and II levels are 
shown in high (upper panel) and low exposure (bottom LC3 panel).  
 
 
To discard the possibility of a cell-cycle dependent regulation of autophagy HeLa cells were 
synchronized in S-phase by incubation with thymidine for 24 hours and protein levels of some regulators of 
autophagy were monitored throughout the cell cycle. Cell cycle phases were identified by flow cytometry 
profiles of DNA content (Figure 20).  The peak of mitosis is reached at 8-10h after S-phase release, 
corresponding to the higher levels of Cdks substrates phosphorylation. Atg5, Atg7 and LC3b protein levels 
remain constant throughout the cell cycle, suggesting that autophagy is induced upon prolonged mitotic 
arrest, but not in a normal mitosis. In addition, LC3bII is more abundant in Cdc20(∆/∆) (cells arrested in 
mitosis) than in Cdc20(lox/lox) MEFs after RO-3306 release (Figure 20c).  
 
Figure 20. Autophagy is not induced in a normal-lasting mitosis. a) Schematic representation of the protocol for HeLa cells 
synchronization in S-phase. HeLa cells were treated with thymidine for 24 hours and released into fresh medium, protein levels 
were inmunodetected. b) DNA content y DAPI staining analyzed by flow cytometry. Initially the population is arrests before 
duplicate DNA content and after wash out of thymidine cell progress through the cell cycle reaching the peak of mitosis between 
8-10h, exit mitosis and re-enter a new cell cycle. c) Inmunodetection of LC3 protein levels at different time points after release 
from RO-3306 in the presence (mitotic population) or absence of 4-OHT (cells that underwent normal cell cycle). 
 
 
The majority of pro-autophagic events converge on the serine/threonine protein kinase mTOR 
(mammalian target of rapamycin). Another nutrient-sensitive signaling pathway is the class III 
phosphatidylinositol 3-kinase (PI3KC3 also named Vps34). While mTORC1 is usually repressing the 
autophagic machinery, Vps34 promotes the activation of autophagy proteins (Atgs) involved in the initial 
phase of the autophagosome formation. In several scenarios, triggering autophagy relies on the inhibition of 
mTORC1, an event that promotes the activation of downstream autophagy proteins such as Ulk1 or Vps34 in 
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complex with Beclin-1 (Rosenfeldt and Ryan, 2011). We next tested whether the presence of autophagy was 
able to modulate MCD by scoring the SiM upon downregulation of several autophagy regulators (Figure 21). 
Raptor, the catalytic subunit of mTORC1, is of special relevance during mitosis given that Cdk1 
hyperphosphorylation of raptor during this period allows the maintenance of mTORC1 activity during mitosis 
(Gwinn et al., 2010; Ramírez-Valle et al., 2010). Knockdown of raptor resulted in earlier death in mitosis 
whereas downregulation of several proteins involved in the induction of autophagy, such as Ulk, Vps34 or 
Beclin1, prevented MCD to a similar extent to the apoptosis inhibitor ZVAD (Figure 21a). The requirements 
for autophagy in MCD were also validated during the MG132-induced mitotic arrest after nocodazole 
synchronization in prometaphase (protocol in Figure 13a) in Atg5 wild type and null cells (Figure 21c). While 
in Atg5 wild-type MEFs SiM is 27±25, in Atg5 KO MEFs the duration of mitosis before cell death is extended 
in 10 hours in average (SiM 30±28).  
 
 
Figure 21. Autophagy modulates mitotic cell death. a) Plots representing the duration of mitosis (from mitotic entry till cell 
death) in Cdc20-null cells treated with the indicated interfering RNAs or in the presence of the caspase inhibitor ZVAD. b) 
Efficiency of siRNA Knockdown by qPCR analysis of mRNA levels (48 h after siRNA nucleofection). Data were normalized by β-
actin mRNA levels c) Plots representing the duration of mitosis (from metaphase till cell death) in Atg5 Wt and Atg5 KO MEFs 
after synchronization in prometaphase with nocodazole treatment and released in MG132. In a and c dots represent individual 
cells and a red line indicates the mean. n.s., not significant. **, p<0.01; ***, p<0.001 (Student’s t-test). 
 
 
Induction of autophagy upon inhibition of mTORC1, by using a variety of mTOR inhibitors, results in 
premature MCD in Cdc20-null cells (Figure 22a) or mitotic human cells (Figure 22b) and increased LC3bII 
levels (Figure 22 c-d) in both cell types. ATP-competitors (PP242 and BEZ235) seem to be more efficient in 
shortening SiM, compared with rapamycin and the rapalog temsirolimus.  
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Figure 22. Inhibition of mTOR decreases the time of survival in mitosis by induction of autophagy. a) Plots comparing the 
duration of mitosis (from metaphase till cell death) in Cdc20-null cells treated with in the presence of the indicated drugs. b) Plots 
comparing the duration of mitosis (from metaphase till cell death) in human cell lines arrested in mitosis treated with in the indicated 
inhibitors. c) LC3bll levels in Cdc20-null cells upon mTORC1 and mTORC2 inhibition in mitosis and interphase. d) Inmunodetection 
of LC3bll levels in human cells upon mTORC1 and mTORC2 inhibition in mitosis and interphase. In a and b dots represent 
individual cells and a red line indicates the mean. n.s., not significant. **, p<0.01; ***, p<0.001 (Student’s t-test). 
 
 
Inhibition of PI3K class III kinase (Vps34) with 3MA delayed death in mitosis (Figure 23a), yet 
concomitant inhibition of apoptosis and autophagy by the combination of ZVAD and 3MA did not further 
enhance SiM and all Cdc20-null cells eventually died in the presence of these two inhibitors (Figure 23a). 
Moreover, E64D/PA treatment inhibits poly(ADP-ribose) polymerase (PARP-1) cleavage, suggesting that 
autophagy and apoptosis are tightly coupled processes (Figure 23b) and may act in parallel in driving cell 
death in mitosis.  
 
 
Figure 23. Inhibition of autophagy protects from cell death in mitosis and prevents PARP cleavage. a) Plots 
comparing the duration of mitosis (from metaphase till cell death) in Cdc20-null cells treated with in the presence of the 
pan-caspase inhibitor ZVAD and the Vps34 inhibitor 3MA. b) Western blot for total protein levels in mitotic arrested 
Cdc20-null cells and asynchronous cultures. In a dots represent individual cells and a red line indicates the mean. n.s., 
not significant. **, p<0.01; ***, p<0.001 (Student’s t-test). 
 
Due to the lack of molecular markers for necrosis, we attempt to classify MCD morphologically. 
Electron micrografies (Figure 24) shown in wild-type MEFs the three types of cell death routines, while in 
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Bak/Bax double knockout MEFs, apoptosis is completely prevented and replaced by autophagy and necrosis, 
as previously described (Shimizu et al., 2004), 
 
 
 
Figure 24. In the absence of apoptotic machinery MCD occurs via autophagy and necrosis. Representative EM micrographies 
of Cdc20-null MEFs and Bak /Bax double knockout (dKO) MEFs arrested in mitosis shows the different types of cell death. In Bak 
/Bax WT three types of cell death with different morphological features; apoptosis, autophagy and necrosis can occur, whereas Bak 
/Bax dKO undergo autophagy, which become evident by the accumulation of double-membrane vesicles and necrotic cell death 
characterized by pronounced dilation of organelles and empty spaces are formed. For Bak/Bax dKO, apoptotic cells were not found. 
Scale bars 2µM. 
 
 
2.5 Mitochondrial mass decreases during prolonged mitotic arrest 
Mitochondria are highly dynamic organelles that respond to cellular stress through changes in overall 
mass, interconnection and subcellular localization. Changes in the overall mitochondrial mass reflect an 
altered balance between biogenesis and clearance of damaged mitochondria. Dysfunctional mitochondria are 
a potential source of reactive oxygen species (ROS) and therefore need to be removed in order to prevent 
cellular damage. Mitophagy is the autophagic process that specifically targets malfunctioning mitochondria for 
degradation and consequently could be considered as a quality control that increases cellular fitness in 
healthy conditions (Ashrafi and Schwarz, 2013). Since biosynthesis of new organelles is limited during mitosis 
due to the lack of proper transcription and translation, we next tested whether mitotic arrest was accompanied 
by mitochondrial loss. 
Mitochondrial mass started to decrease at early time of mitotic arrest (3 hours) and this reduction is 
potentiated further in time (from 18 h on) as detected by analysis of the intensity of a vital mitochondrial dye, 
by time-lapse microscopy (Figure 25a) and flow cytometry (Figure 25b). Exposure of mitotic cells to cyanide 
m-chlorophenyl hydrazine (CCCP, a mitochondrial respiratory chain uncoupler), resulted in decreased 
mitochondrial mass within the first few hours of arrest in mitosis, whereas little effect is observed during late 
mitotic arrest when the mitochondrial mass has considerably decreased. This may suggest that the loss of 
mitochondrial mass is initially due to the lack of mitochondrial biosynthesis, whereas in a more extended 
mitotic arrest an active process of elimination of dysfunctional mitochondria is taking place. Remarkably, 
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(Figure 25c) the reduction observed in mitochondrial mass after 3 hours of CCCP exposure it is equivalent to 
24 hours of mitotic arrest. Inmunodetection of the mitochondrial proteins Tom20, Tim23 and Tom 40, 
components of the mitochondrial translocases complex, corroborated the loss of mitochondrial mass and this 
effect is prevented upon blockage of the last step of autophagy by E64D/PA addition, suggesting a link 
between the reduction in mitochondrial mass and the observed induction of autophagy.  
 
Figure 25. Mitochondrial mass significantly decreases in a prolonged mitotic arrest. a) Mitochondrial signal was followed by 
time-lapse microscopy at the indicated time points after release of Cdc20-null cells from G2 arrest. White and yellow arrows 
indicate interphasic or mitotic cells respectively. Mitotracker intensity decreases rapidly in cells arrested in mitosis (red) compared 
with interphasic cells (blue). Data are represented as mean ± SD (n=18 mitotic and 12 interphasic cells). b) Quantification of 
mitotracker intensity as measured by flow cytometry at the indicated time-points after release from G2 arrest (mean ± SEM). As a 
positive control,CCCP results in a reduction of the mitochondrial mass at early but not late time points during mitotic arrest in 
comparison with one hour treated cells (n=7 independent assays).c) Inmunodetection of the mitochondrial proteins Tom20, Tim23 
and Tom40 in Cdc20-null cells at the indicated times after release from G2. As., asynchronous cultures. β-actin was used as a 
loading marker. 
 
 
We next evaluated whether the decrease in mitochondrial mass is due to an active process of 
mitochondrial degeneration and further elimination through mitophagy. This decrease in mitochondrial mass 
was accompanied by a gradual increase in colocalization of LC3-GFP foci with mitochondria as is displayed 
in (Figure 26a) in life cell microscopy assays. The concurrence of LC3-GFP vesicles and mitochondria was 
evident from 6 hours of mitotic arrest, but this event increases in frequency at later stages of mitotic arrest. 
Moreover electron microscopy images shows of mitochondrial internalized into double membrane vesicles; 
autophagosomes (Figure 26b). The loss of mitochondrial mass is efficiently rescued by the addition of the 
inhibitor of autophagy 3MA and as a consequence of Cyclosporine A exposure (CsA) after 24 hours of mitotic 
arrest. Mitochondrial membrane permeabilization is one of the triggering events for mitophagy and 
cyclosporin affects mitochondria by preventing the mitochondrial permeability transition pore from opening 
and inhibiting cytochrome c release, a potent apoptotic stimulation factor. Thus, inhibition of autophagy (by 
3MA) and inhibition of the triggering event for mitophagy (by CsA) results in a significant increase in 
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mitocondrial mass compared to basal conditions at 24 hours of arrest in mitosis. Together this result suggest 
the clearance of the mitochondrial pool by mitophagy as a major cellular process leading to the loss of 
mitochondrial mass during prolonged mitotic arrest, whereas in an early mitotic arrest, this might be due to 
the lack of mitochondrial biogenesis.  
 
 
Figure 26. Mitophagy contributes to the decrease in mitochondrial mass during prolonged mitosis. a) 
Percentage of cells showing co-localization of LC3-GFP and Mitotracker (>2 foci per cell, see yellow arrows in the 
representative images) at the indicated time points after mitotic arrest. Data represent mean ± SEM; n=30 cells per 
condition. b) Representative electron microscopy micrographs showing the accumulation of autophagosomes and 
autophagolysosomes in Cdc20-null cells at the indicated time points of mitotic arrest, either in the presence or absence 
of cathepsin and calpain inhibitors (E64d/PA). Note the inclusion of mitochondria in double-membrane structures with 
autophagosomal features. Scale bars, 2 µM for low magnificated images and 500 nm for high magnification. c) 
Mitochondrial content as measured by flow cytometry in the presence of Mitotracker in Cdc20-null cells after 24 hours 
in mitosis in the presence of vehicle (C), 3MA or CsA (related to vehicle treated cells). The plots in the right represent 
the profile of Cdc20(∆/∆) after 24 hours in mitosis in the absence or present of 3MA (red) or CsA (blue). 
 
 
Mitochondrial morphology changes can shift between small fragmented units and larger networks of 
elongated mitochondria. Remodeling of the mitochondrial network is regulated and takes place in response to 
many stimuli such as hypoxia, cell cycle regulation and also by changing energy demands and other cellular 
stress. Upon mitotic onset, mitochondria are fragmented to facilitate the segregation to daughter cells 
(Álvarez-Fernández and Malumbres, 2014). Cdk1 mediates mitochondrial fission in mitosis by 
phosphorylation and activation of the dynamin-related protein 1 (Drp1) at Ser-616. Many studies indicate that 
mitochondrial fragmentation and mitochondrial membrane depolarization precedes mitophagy and that 
mitochondrial fission is the major source of depolarized mitochondria (Chen et al., 2009). Since fragmented 
mitochondria are known to be more sensitive to mitophagy (Rambold et al., 2011), we next tested whether 
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Drp1 inactivation confers some protection to mitotic mitochondria. As depicted in Figure 27a, knockdown of 
Drp1 prevents mitochondrial fragmentation, showing tubular organelles in interphase as well as in mitotic 
Cdc20-null cells. Knockdown of Drp1 also resulted in reduced co-localization of LC3-GFP foci and 
mitochondria (Figure 27b). This data correlates with a prevented loss of mitochondrial mass and led to 
increased SiM in Cdc20-deficient cells (Figure 27c).   
 
 
Figure 27. Fragmented mitochondria are more prone to be removed by autophagy. a) Representative 
confocal microscopy live images showing the mitochondrial network (Mitotracker) of mitotic (Cdc20-null) and 
interphasic cells in the presence (Scr.) or absence of Drp1 (siDro1) after nucleofection with siRNA against this 
molecule. I: Interphase and M: Mitosis. b) Co-localization of LC3-GFP and Mitotracker at the indicated time 
points after mitotic arrest in Drp1 Knock-down (siDrp1) cells. Representative confocal microscopy live images 
show the co-localization of LC3-GFP and Mitotracker after 24 hours of mitotic arrest in siScr. and siDrp1 treated 
cells. Data represent mean ± SEM (n=30 cells per condition). c) Quantification of Mitotracker intensity by 
cytometry after 12 and 24 hours of mitotic arrest relative to 1 hours of mitotic arrest in the presence (siScr.) or 
absence (siDrp1) of Drp1. d) Plots representing the duration of mitosis (from mitotic entry till cell death) in 
Cdc20-null in the presence or absence of Drp1In d dots represent individual cells and a red line indicates the 
mean. n.s., not significant. **, p<0.01; ***, p<0.001 (Student’s t-test).  
 
 
2.6 Mitochondrial respiration extenuates during prolonged mitotic arrest 
To further investigate the functional relevance of mitochondrial loss during mitosis, we next compared 
the rates of mitochondrial respiration (oxygen consumption, OCR) and glycolysis (extracellular acidification 
rate; ECAR) from mitotic and control cells by using an Extracellular Flux Analyzer (Seahorse Bioscience). 
Cdc20(∆/∆) cells were arrested in G2 using RO-3306 for 16 h and released to arrest in mitosis (red) in a 
synchronized manner. G2-synchronized of asynchronous Cdc20(lox/lox) cells were used as controls (Figure 
28a). Our results indicated that spare respiratory capacity quickly increased upon mitotic entry in agreement 
with recent data indicating the activation of the oxidative respiration during the G2/M transition in a Cdk1-
dependent manner (Wang et al., 2014b). However, the respiratory capacity started to became extenuated 
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after ~12 h in mitosis (Figure 28b), coincident with mitochondrial mass depletion shown previously in Figure 
33 and with cell death (Figure 28b). In parallel to decreased oxidative respiration, glycolytic capacity gradually 
increased during early mitotic arrest but is further boosted during late mitotic arrest in mouse (Figure 28a) as 
well as in human (Figure 36b) cells. This metabolic profile indicates that a progressive switch from oxidative 
phosphorylation to glycolysis is taking place in prolonged mitotic arrest. While cell viability in proliferating cells 
(blue) remains constant, cells that underwent mitotic arrest (red) show decreased cell viability with time 
(Figure 28b, d), therefore OCR and ECAR rates are probably being underestimated in cells arrested in 
mitosis. 
 
 
Figure 28. Mitochondrial respiration extenuates in parallel to increased glycolysis upon prolonged mitotic arrest. a) 
Spare respiratory capacity considered as the difference between maximal uncontrolled oxygen consumption rate (OCR), 
after FCCP addition, and basal OCR levels, as a measure of cells to respond to stress under conditions of increased 
energy demands, which is influenced by the capacity of the mitochondria. And maximum glycolytic capacity which is the 
difference between the maximum extracellular acidification rate (ECAR), after inhibition of ATP synthase by oligomycin, and 
the initial ECAR levels and measures in Cdc20-null (red) and Cdc20(lox/lox) MEFs (blue), at different time points after RO-
3306 release. It is also included as G2 Cdc20(lox/lox) cells in the presence of RO-3306 (black) and asynchronous MEFs 
(green). b) Cell viability measured by flow cytometry in Cdc20-null (red bars) and Cdc20(lox/lox) after RO-3306 wash out at 
different time points, in the presence of RO-3306 as a G2 condition (black) and in asynchronic sells (green). Cell viability is 
represented as the percentage of alive cells, which are cells that do no retain To-Pro3. c) Spare respiratory capacity and 
glycolytic in MDA-MB-231 (red bars) and mitotic MDA-MB-231, which is in the presence of taxol and pro-TAME, after RO-
3306 wash out at different time points, in the presence of RO-3306 as a G2 condition (black) and in asynchronic sells 
(green). d) Cell viability measured by flow cytometry in MDA-MB-231 (red bars) and mitotic MDA-MB-231, which is in the 
presence of taxol and pro-TAME, after RO-3306 wash out at different time points, in the presence of RO-3306 as a G2 
condition (black) and in asynchronic sells (green). Cell viability is represented as the percentage of alive cells, which are 
cells that do no retain To-Pro3. 
 
 
In line with these observations, mitochondrial dysfunction was accompanied by increase in intracellular 
reactive oxygen species (ROS; Figure 29a) which is attenuated by the addition of the cell antioxidant N-
acetyl-L-cysteine (NAC). Prevention of ROS by NAC administration resulted in prolonged survival during 
mitotic arrest both in mouse and human cells (Figure 29b). It has been recently described that taxol leads to 
ROS accumulation (Alexandre et al., 2007), whether this is a consequence of the mitotic state is not known. 
The p38MAPK pathway is strongly activated in response to several cellular stress, among them is activated in 
response to ROS (Cuadrado and Nebreda, 2010; Sato et al., 2014). Inhibition of p38MAPK activity leads to 
an increase in SiM, however in combination with caspase and autophagy inhibitors did not lengthen the SiM, 
suggesting that are independent pathways. 
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Figure 29. ROS are accumulated over time in prolonged mitotic arrest. a) ROS measure in Cdc20-null cells as determined 
by the Oxiselect TM intracellular ROS assay kit. Effect of NAC treatment in the accumulation of ROS at the times indicated. b) 
Plots representing the duration of mitosis (from metaphase till cell death) in Cdc20-null MEFs and human cell lines arrested in 
mitosis treated with a ROS scavenger. c) Plots representing the duration of mitosis (from metaphase till cell death) in Cdc20-
null MEFs and human cell lines arrested in mitosis treated with p38MAPK inhibitor in combination with caspase and autophagy 
inhibitors. The differences between treatments were not statistically significant. In b and c dots represent individual cells and a 
red line indicates the mean. n.s., not significant. **, p<0.01; ***, p<0.001 (Student’s t-test). 
 
 
ROS are constantly generated as byproducts of normal mitochondrial active metabolism under 
physiological conditions. Mitochondrial respiration is indeed the major source of intracellular ROS, 
approximately 1-5% of the total oxygen consumed during normal respiration is converted to superoxide 
radicals. Low levels of ROS can activate various signaling pathways to stimulate cell proliferation and 
survival, whereas excess of ROS irreversible damage cellular macromolecular components (protein, lipids, 
nucleic acids) and cause cell death, including apoptosis (Cairns et al., 2011). Besides, membrane 
depolarization and excessive ROS production are triggering events for mitophagy (Bolland et al., 2013).  
 
2.7 AMPK-dependent induction of glycolysis during mitotic arrest 
We next investigated the molecular changes that accompany prolonged mitotic arrest by analyzing the 
phosphorylation of several regulators of key pathways upon a synchronized release from G2 arrest in the 
absence of Cdc20. Mitotic arrest was accompanied by the accumulation of phospho-histone H3 and the 
reduced mobility of Cdc27 as a consequence of its mitotic phosphorylation (Figure 30b). In addition, Mcl-1 
proteins decreased likely as a consequence of its ubiquitin-dependent degradation mediated by the SCF 
complex (Inuzuka et al., 2011; Wertz et al., 2011). In contrast, the level of expression of survivin did not 
change. Interestingly, mitotic arrest was accompanied by a progressive activation of AMPK as detected by 
increased AMPK phosphorylation of a threonine (Thr-172) within the activation loop of the kinase domain both 
in Cdc20-null and mitotic human cells (Figure 30b,d). Phosphorylation of AMPK is followed by the inhibitory 
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phosphorylation of ACC (Acetyl-CoA-carboxilase) at Ser-39 (Figure 30d) inhibiting carboxylation of acetyl-
CoA to produce malonyl-CoA, the initial step for synthesis of fatty acid. AMP-activated protein kinase (AMPK) 
plays a major role in regulating cellular energy balance by sensing and responding to increases in AMP/ADP 
concentration relative to ATP. Binding of AMP causes allosteric activation of the enzyme and binding of either 
AMP or ADP promotes and maintains the phosphorylation of Thr-172 within the activation loop of the kinase.  
 
 
Figure 30. AMPK is reactivated in a prolonged mitotic arrest. a) Protocol performed for achieve the synchronization in Cdc20 
MEFs. 4-OHT was added 12 hours before RO-3306 administration. After 18 hours of treatment, RO-3306 removal allows cell to 
enter mitosis. b) Inmunodetection of the indicated proteins in Cdc20-null cells and asynchronous cell (As) are included. c) Protocol 
performed for achieve the synchronization in human cell lines. Cells were synchronized in G2 upon RO-3306 addition. After 18 
hours, cells were released from Cdk1 inhibitor in taxol and proTAME, an APC/C inhibitor used at a concentration that inhibits 
APC/C-Cdc20. d) Inmunodetection of the indicated proteins in HeLa and MDA-MB-231 cell lines arrested in mitosis and 
asynchronous cells (As). 
 
Changes in AMPK activity in response to metabolic stress were also monitored at the single cell level 
using a FRET biosensor (Tsou et al., 2011). Time-lapse microscopy assays showed that AMPK is gradually 
activated after ~8 h in mitotic arrest in Cdc20(∆/∆) (Figure 31a) reaching a 2-fold increase in the biosensor 
signal after 8 hours of mitotic arrest, in agreement with the biochemical data presented earlier. Whereas no 
major changes were found during a normal mitosis/G1 transition in control Cdc20(lox/lox) cell (Figure 31b). 
As a control, AMPK activity was monitored in Cdc20(lox/lox) MEFs in the presence of 20mM of 2-DG. 
Addition of 2-DG leads to an increased in the biosensor of about 2-fold, similar to 8 hours of mitotic arrest 
(Figure 31c). Since AMPK is activated in the presence of reduced ATP and increased AMP, we next quantify 
the ratio between these two nucleotides at different moments of mitotic arrest. Cells arrested in G2 displayed 
increased phosphorylation of AMPK (Figure 31d) in agreement with increased AMP/ATP levels (black in 
Figure 38d), suggesting defective ATP production in the presence of the Cdk1 inhibitor RO-3306, this defect 
is likely a consequence of Cdk1 inactivation by RO-3306 given the crucial role of Cdk1 in activating 
mitochondrial function during G2/M transition (Wang et al, 2014). The AMP/ATP ratio was normalized after 
release from this compound in control Cdc20(lox/lox) cells (blue) that underwent a normal transition through 
the different phases of the cell cycle. In Cdc20(∆/∆) cells, the AMP/ATP ratio displayed a gradual increase ~8 
h after mitotic arrest (red in Figure 32d) in agreement with the timing of AMPK activation (Figure 31a and 
31b).  
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Figure 31. AMPK is reactivated in prolonged mitotic arrest a) Changes in AMPK activity were monitored using a 
FRET biosensor in Cdc20(∆/∆) (red) and Cdc20(lox/lox) (blue) Time 0 indicated mitotic entry and the length of the black 
bar represents the duration of mitosis. AMPK is activated giving an increase of about 2-fold in the biosensor signal at 8 
hours after and reaches 4-fold at 12 hours after mitotic entry in Cdc20(∆/∆), whereas no major changes in AMPK activity 
are observed in Cdc20(lox/lox) cells. Data are represented as mean ± SD (n= 12 cells). Cdc20(lox/lox), after mitotic exit 
AMPK levels remain constant. Representative micrographies shows the level of activity of AMPK FRET biosensor 
indicated by the color scale, where yellow represents the, higher activity of AMPK, increased FRET, followed by red and 
blue, which represent the lowest activity. Pictures were taken every 15 minutes.   b) AMPK activity FRET biosensor in 
Cdc20(lox/lox) after addition of 2-DG, AMPK is activated leading to an increase of about 2-fold in the biosensor signal, 
indicated in red in the images after 2-DG addition. c) AMP: ATP ratio measured by HPLC in Cdc20-null (red) and 
Cdc20(lox/lox) (blue) MEFs after release from RO-3306. There are also included measures from asynchronous cultures 
(green) and as a G2 stage, nucleotides levels were measured in the presence of RO-3306.  
 
 
It has been recently reported that the inhibitory phosphorylation of ACC decreases prior to cytokinesis 
initiation increasing fatty acid synthesis upon division, in addition, inhibition of fatty acid synthase (FAS) 
arrests cells at G2/M despite the presence of abundant fatty acid in the media (Scaglia et al, 2014). However, 
in Cdc20-null cells inhibition of FAS upon C75 treatment shows no effect in cell viability in mitosis (Figure 32).  
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Figure 32. FAS inhibition does no affect cell viability 
in prolonged mitotic arrest. Plots representing the 
duration of mitosis (from metaphase till cell death) in 
Cdc20-null MEFs. Treatment with C75 did not affect cell 
viability in mitosis. Dots represent individual cells and a 
red line indicates the mean. n.s., not significant. 
(Student’s t-test). 
 
 
To further understand these metabolic changes, murine and human cells were growth in the presence 
of 13C-labeled- glucose and the abundance of different metabolites were analyzed (Figure 33 and 34) after 
synchronization (Figure 33a). This analysis indicated that mitotic arrest resulted in a significantly higher 
consumption of glucose and a proportional generation of 13C-lactate, originated from glucose breakdown, in 
Cdc20-null cells (Figure 33c, red) as compared to G2-released Cdc20(lox/lox), non-arrested cells (blue) or 
asynchronous cultures (green). Mitotic arrest in Cdc20-null cells was also accompanied by a significant 
consumption of multiple amino acids and pyruvate, whereas Ala, Glu and Gly, along several ketonic bodies, 
were released to the extracellular medium (Figure 33d). Synthesis of ketonic bodies can occur in response to 
unavailability or low glucose levels after exhaustion of cellular carbohydrate stores as a consequence of fatty 
acid break down. As it was previously discussed for the respirometry assays, viability in Cdc20-null cells 
decreases in a 50% upon 12 hours of arrest in mitosis, and therefore metabolites concentration of Cdc20-null 
cells were underestimated. 
 
 
 
Figure 33. Metabolic profile of Cdc20 null cells. a) Schematic representation of the protocol followed for synchronized mitotic 
entry in Cdc20(lox/lox) cells (without 4-OHT) or Cdc20-null, treated with 4-OHT, to eliminate Cdc20 expression, 12 hours prior the 
addition of the Cdk1 inhibitor RO-3306 to trigger G2 arrest. This compound was washed-out 18 hours later, allowing cells to 
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progress through the cell cycle Cdc20(lox/lox) (blue), or arrest in mitosis (red). Green line represents asynchronous cultures. This 
color code is maintained throughout the manuscript to clarify the identification of the three ways of synchronization. b) 
Concentration of extracellular glucose-13C and lactate-13C present in the supernatant of cells in culture, which represents the 
glucose uptake and the concomitant production of lactate of cultured cells, monitored by NMR. Asynchronous in green, normally 
released from G2 (blue) or mitotic arrested (red) MEFs. d) Differential extracellular concentration of the indicated metabolites 24 
hours after RO-3306 release compared to time zero (fresh media) as monitored by NMR. 35 metabolites were analyzed and only 
those exhibiting significant differences are represented (20 out of 31). No differences were found in carnosine, adenine, 
glyoxylate, glycerol, cholesterol, EtOH, niacinamide, acetate, inositol, asparagine and aspartic acid. 
 
 
This increase in glucose uptake and generation of lactate was also observed in human cells subjected 
to a mitotic arrest triggered by microtubule poisons in the presence of APC/C inhibitors (proTAME) to prevent 
mitotic exit (Figure 41).  
 
 
 
 
Figure 34. Metabolic profile in MDA-MD-231 cells arrested in mitosis. a) Schematic representation of the protocol followed for 
synchronization MDA-MB-231, cells were treated with RO-3306 to trigger G2 arrest. This compound was washed-out 18 hours 
later, in the presence of taxol and pro-TAME (red) in order to induce a metaphase arrest mimicking the arrest imposed in the 
absence of Cdc20. When cells are release from G2 arrest in the absence of mitotic inhibitors, this allows cells to progress through 
the cell cycle (blue). Green line represents asynchronous cultures. This color code is maintained throughout the thesis to clarify 
the identification of the three ways of synchronization. b) Concentration of extracellular glucose-13C and lactate-13C present in the 
supernatant of cells in culture, which represents the glucose uptake and the concomitant production of lactate of cultured cells, 
monitored by NMR. Asynchronous in green, normally released from G2 (blue) or mitotic arrested (red) MDA-MB-231 cells. c) 
Differential extracellular concentration of the indicated metabolites 24 hours after RO-3306 release compared to time zero (fresh 
media) as monitored by NMR. 35 metabolites were analyzed and only those exhibiting significant differences are represented (20 
out of 31). No differences were found in carnosine, adenine, glyoxylate, glycerol, cholesterol, EtOH, niacinamide, acetate, inositol, 
asparagine and aspartic acid.  
 
 
These changes in extracellular glucose and lactate were reduced after knock down of AMPKα1 and 
AMPKα2 in mitotically arrested Cdc20-null cells (Figure 35), suggesting the involvement of AMPK in the 
glycolytic induction observed in mitotic cells.  
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Figure 35. AMPK is involved in the 
glycolytic induction observed in 
mitosis. a) Concentration of 
extracellular glucose and lactate 
present in the supernatant of cells in 
culture, which represents the glucose 
uptake and the concomitant production 
of lactate of cultured cells, monitored 
by NMR. Extracellular levels of 
glucose and lactate in Cdc20-null cells 
after knockdown of AMPKα1/α2 using 
specific siRNAs. Efficiency of the 
indicated siRNA by inmunoblotting. 
 
2.8 Glycolysis is a major determinant of survival in mitosis 
The activation of AMPK and the subsequent glycolytic switch observed in mitotic cells raised the 
possibility of a dependence on energy pathways to survive in mitosis. In fact, treatment of mitotic cells with 
the AMPK inhibitor Compound C or with the AMPK activators AICAR (an analog of adenosine) and metformin 
(a compound that inhibits mitochondrial function leading to ATP depletion) resulted in reduced SiM in mitotic 
Cdc20-null cells (Figure 43a) or human cell lines (Figure 36b). Similar results were obtained after specific 
knockdown of AMPKα1 and AMPKα2 (Figure 36c). SiM after metformin treatment was rescued by the 
additive addition of ZVAD and 3MA, this raises the possibility that in a prolonged mitotic arrest AMPK triggers 
cell death by induction of both apoptosis and autophagy. Besides, Cdc20 null cells in the absence of 
AMPKα1/α2 shows reduced levels of LC3bII (Figure 36d). 
 
 
Figure 36. Either activation or inhibition of AMPK affects survival in mitosis. a) Plots representing the duration of 
mitosis (from metaphase till cell death) in Cdc20-null MEFs treated with AMPK activators and inhibitor. b) Plots 
representing the duration of mitosis (from metaphase till cell death) in human cell lines arrested in mitosis treated with the 
indicated drugs c) Plots representing the duration of mitosis (from mitotic onset till cell death) in Cdc20-null MEFs treated 
with AMPK siRNAs. Efficiency of the indicated siRNAs by qPCR analysis of mRNA levels (48 hours after siRNA 
nucleofection). Data were normalized with β-actin mRNA levels. d) Plots representing the duration of mitosis (from 
metaphase till cell death) Cdc20-null cells treated with the AMPK activator metformin alone or in combination with inhibitors 
of programmed cell death. e) Levels of the indicated proteins detected by inmunoblotting in MEFs. In b and c dots represent 
individual cells and a red line indicates the mean. n.s., not significant. **, p<0.01; ***, p<0.001 (Student’s t-test). 
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Moreover, addition of 2-desoxi-D-glucose (2-DG; a glucose analog that cannot be metabolized 
inhibitor of hexokinase, the enzyme that catalyzes the first step of glycolysis) or oxamate (an isosteric and 
isoelectronic inhibitory analogue of pyruvate, which in turns inhibits the lactate dehydrogenase) also resulted 
in premature MCD, whereas supplementation of media with glucose led to a significant extension in SiM 
proportional to the amount of glucose added (Figure 37). When 20mM of glucose is added sequentially, SiM 
is expanded but only until 24h of mitotic arrest, after that survival in mitosis cannot be increased.  
 
 
 
Figure 37. Glucose addition fuels cell survival in mitosis. a) Plots representing the duration of mitosis (from 
metaphase till cell death) Cdc20-null cells treated with the indicated glycolytic and OXPHOS inhibitors. b) 
Schematic representation of the protocol followed, video recording was initiated 24 hours of 4-OHT addition and 
20mM was supplemented to the media at the indicated times after the video started. Plots representing the 
duration of mitosis (from mitotic entry till cell death) Cdc20-null cells in which 20mM of glucose was added 
sequentially in time. Dots represent individual cells and a red line indicates the mean. n.s., not significant. **, 
p<0.01; ***, p<0.001 (Student’s t-test). 
 
 
The relevance of the glycolytic pathway was directly addressed by testing the importance of 6-
phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3 (PFKFB3), a key regulator of the glycolytic enzyme 
phosphofructokinase-1 (PFK-1), directly linked to Warburg effect (Almeida et al., 2010; Brooke et al., 2014; 
Cordero-Espinoza et al., 2013; Seo et al., 2011) a common feature of cancer cells. AMPK directly 
phosphorylates and activates PFKPB3 at residue Ser-461 (Bando et al., 2005; Marsin et al., 2000; Marsin et 
al., 2002) and highly phosphorylated PFKFB3 protein is often found in human tumor cells (Bando et al., 
2005). Downregulation or inhibition of PFKFB3 using siRNAs or the competitive inhibitor 3-(3-pyridinyl)-1-(4-
pyridinyl)-2-propen-1-one (3PO) resulted in a significant reduction in SiM in mouse (Figure 38c) or human 
(Figure 38d) cells, in agreement with reduced glucose consumption and lactate production during mitosis in 
the absence of this regulator (Figure 38e).  
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Figure 38. AMPK boost glycolysis through PFKFB3 activation. a) Confocal microscopy images of 
Cdc20(ox/lox) and Cdc20(∆/∆) transiently expressing PFKFB3-Wt in green, shows PFKFB3 localization at the 
nuclei in interphase and pan-cytoplasmic localization in mitosis. DNA is marker with DAPI (blue) and nuclear 
lamina (red), a nuclear envelope marker. b) Imunodetection of the indicated proteins, PFKFB3 levels are 
constant in prolonged mitotic arrest and interphase and phospho-Histone (Ser10) mark for mitosis. c) Plots 
representing the duration of mitosis (from mitotic entry till cell death)  and a red line indicated the mean in 
Cdc20-null cells treated with the PFKFB3 siRNA and the efficiency of the silencing in protein levels. Efficiency 
of the siRNA for PFKFB3 knockdown by inmunoblotting at 48 hours post-transfection. d) Plots representing the 
duration of mitosis (from metaphase till cell death) Cdc20-null cells treated with the 3PO and the red line 
represented the mean. f) Extracellular levels of glucose and lactate in Cdc20-null cells in the presence or the 
absence of PFKFB3 are represented were measured by NMR. In c and d, n.s., not significant. **, p<0.01; ***, 
p<0.001 (Student’s t-test). 
 
 
Glycolytic flux was next evaluated by using a cytoplasmic FRET biosensor of glucose which activity is 
proportional to the concentration of intracellular glucose (Takanaga et al., 2007). Cells arrested in mitosis 
shown a more rapid fall in FRET signal compared to interphase cells in the presence of glucose-
supplemented media. This decrease in FRET signal is further enhanced upon removal of glucose from the 
culture media, reaching its zero 10 minutes after completely removal of glucose in mitotic cells. The absence 
of PFKFB3 attenuates the slope in the FRET signal, which supports the role of PFKFB3 in boosting glycolytic 
flux in mitosis (Figure 39).  
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Figure 39. PFKFB3 boost glycolytic flux. a) Changes in intracellular glucose concentration were monitored using a 
FRET biosensor for glucose in Cdc20(∆/∆) and Ccd20(lox/lox). Upon removal glucose-containing media and addition 
of glucose-free media, FRET signal, and therefore intracellular glucose concentration, drops.  Whereas in interphasic 
cells (green) upon glucose removal, the biosensor signal does not significantly change, in Cdc20-null cells rapidly 
decreases. When compared mitotic cells (cdc20-null) in the presence (siScramble) or the absence (siPFKFB3) of 
PFBFB3Intracellular glucose levels decreases more rapidly in Cdc20-null cells treated with PFKFB3 siRNA than 
scramble treated Cdc20-null or interphasic cells. This suggests that PFKFB3 is boost glycolysis in mitosis. b) 
Representative micrografies showing the activity of the FRET biosensor for glucose in color scale, yellow higher 
activity than blue. Data represents mean ± SD (n=12 cells). 
 
 
2.9 Inhibition of glycolysis cooperates with microtubule poisons in mitotic cell death 
Our results indicate that multiple pathways including apoptosis, autophagy and energy production 
mediate survival in mitosis. We therefore tested whether interference with these pathways could cooperate 
with the effect of microtubule poisons in MCD. As a first in vitro approach MBA-MD-231 were treated with 
multiple agents against the referred pathways either in the presence or absence of taxol. As indicated in 
Figure 40, several combinations were more efficient than the single agents in killing these breast cancer cells. 
 
 
 
Figure 40. Taxol cooperates with different inhibitors of survival pathways to promote mitotic cell death. a) Cell death in 
MDA-MB-231 as determined byTo-Pro3 levels, measured using high-throughput microscopy, after the indicated treatments in 
the presence or absence of taxol, the intensity of the staining perfectly correlates with cell death. Pink columns indicate 
significative synergistic combinations when compared to single inhibitors (black dotted comparisons) or taxol (red dotted 
comparisons). ***, p<0.001; Student´s t-test.  
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The effect of ABT263, PP242, 2DG and 3PO was additionally tested in three breast cancer cell lines 
such as MDA-MD-468, EVSA-T or MCF7 (Figure 41). 
 
 
 
  
 
Figure 41. Cooperation between taxol and different 
inhibitors of mitotic survival pathways to induce 
mitotic cell death. Cell death in MDA-MB-231 as 
determined byTo-Pro3 levels, measured using high-
throughput microscopy, after the indicated treatments in 
the presence or absence of taxol, the intensity of the 
staining perfectly correlates with cell death. Pink columns 
indicate significative synergistic combinations when 
compared to single inhibitors (black dotted comparisons) or 
taxol (red dotted comparisons). ***, p<0.001; Student´s t-
test. a) MDA-MB-467, b) EVSA-T and c) MCF7. The red 
line at 1000 of To-Pro3 intensity represents the threshold 
considered for cell viability.  
 
 
 
To further understand whether these combinations were effective in mitosis, we monitored cell fate of 
MBA-MD-231 cells treated with ABT-263, PP242, 2DG, 3PO or metformin in the absence or presence of 
taxol. As shown in Figure 42a, treatment of breast cancer cells with these individual drugs results in a variable 
efficiency in cell death ranging from 10% to 40% without affecting mitotic cells (Figure 42b,d). Single 
treatment with taxol also resulted in a significant percentage of death cells (21%) from which only 12% of cells 
died in mitosis, in agreement with previous data in transformed fibroblasts (Manchado et al., 2010). 
Interestingly, combination of taxol with ABT-263, PP242, 3PO and metformin resulted in efficient MCD (Figure 
42c,d) more than a 30% of the cells die in mitosis. We did not observe any cooperation between taxol and 
2DG, probably as a consequence of reduced entry into mitosis in cells treated with 2DG (Figure 42a-d), 
suggesting the need of energy availability for the entry into M-phase. The combination of taxol and ABT-263 
was extremely efficient and all cells died during the observation period (60 h; Figure 42c,d). About 65% of 
these deaths occurred in mitosis (Figure 42d) and the SiM was of 5.6  ± 4.7 h compared to 29.8  ±  18.0  in 
the presence of taxol alone (Figure 42e). 
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Figure 42. 3PO shows synergistic effect in vitro in MDA-MB-231 cells. a) Cell fate diagrams in which are represented the 
duration of interphase, represented in gray, and mitosis, green, in the presence of the indicated treatments. Each line 
represents an individual cell fate. Cell death in interphase is represented in violet, while cell death in mitosis is represented in 
orange.  b) Cell fate diagrams in which are represented the duration of interphase, represented in gray, and mitosis, green, in 
the presence of the indicated treatments in combination with taxol. Each line represents an individual cell fate. Cell death in 
interphase is represented in violet, while cell death in mitosis is represented in orange c) Quantification of the percentage of 
cells that die in mitosis (orange) and in interphase (violet) after the indicated treatments. d) Duration of mitosis (DOM) from 
mitotic entry to cell death induced by taxol and combination treatments. n. s., not significant. **, p<0.01; ***, p<0.001 
(Student´s t-test). 
 
 
To investigate the cooperation between taxol and the inhibition of glycolysis in tumor development in 
vivo, we generated subcutaneous xenografts of MBA-MD-231 cells in nude mice. Taxol (5 mg/Kg) and 3PO 
(5, 25 or 50 mg/Kg) were injected i.p. when tumors reached 200 mm3 and tumor growth was monitored during 
the following 12 days. Taxol was very inefficient at that doses whereas treatment with 3PO alone resulted in a 
significant reduction in tumor volume and weight (Figure 43a,c and d). The combination of taxol with 3PO 
further improved significantly the therapeutic effect when compared to single treatments (Figure 43a,c and d) 
and results in a significant raise in apoptotic cells in the tumors (Figure 43b). Taken together, these data 
suggest the potential benefit of using glycolytic inhibitors in combination with current mitotic-targeted 
therapies to inhibit tumor growth.  
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Figure 43. Anti-tumoral cooperation between microtubule poisons and PFKFB3 inhibitors in vivo. a) Effect of the 
combination of taxol (5mg/kg) and 3PO (5, 25 or 50 mg/kg) on the growth of tumor xenografts generated by subcutaneous 
injection of MDA-MB-231 cells in nude mice. b) Active caspase-3 inmunostainning in MDA-MB-231 derived-tumor xenografts. 
The numbers indicate the percentage of active caspase-3 positive cells relative to the total number of nuclei in each section ± 
SD. Six sections were counted for each of four dissected tumors per condition. Scale bars, 100µM. c) Data correspond to the 
weight of each of the tumors at the final time point of the experiment (n=10 tumors per condition). Red lines indicate mean ± 
SD. *, p<0.05; **, p<0.01; *** p<0.001 (ANOVA-test). d) Data correspond to the volume of each of the tumors at the final time 
point of the experiment. Red lines indicate mean ± SD (n=10 for each condition). *, p<0.05; **, p<0.01; *** p<0.001 (ANOVA-
test). 
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1. A search for M-phase specific compounds 
Taking advantage of Cdc20 conditional knockout mouse embryonic fibroblasts (MEFs) we tested a 
library of 300 compounds from a variety of molecular entities, provided by the Experimental Therapeutics 
Programme at CNIO, for its ability to selectively target mitotic cells. We used H-Ras transformed Cdc20 
conditional knockout cells expressing an inducible form of Cre recombinase and a histone H2B-GFP 
reporter. Addition of tamoxifen (4-OHT) results in the inactivation of Cre, the excision of Cdc20 exons and 
a metaphase arrest (Manchado et al., 2010). Ultimately, Cdc20-null cells are not able to progress to 
anaphase due to the presence of active Cdk1-cyclinB1 complexes and defective activation of separase. 
 
1.1 Screen for compounds that specifically kill cells in mitosis in Cdc20 –deficient MEFs 
Mitotic entry was efficiently synchronized in Cdc20(∆/∆) cells by the addition of RO-3306, a Cdk1 
inhibitor, which prevents mitotic entry arresting cells in G2 (for protocol see Material and Methods Figure 
10). Upon removal of the inhibitor, Cdc20-null cells progress to mitosis and remain arrested at metaphase. 
One hour after G2-release, both asynchronic Cdc20(lox/lox) and Cdc20(∆/∆), were treated in parallel with 
the compounds in the presence of To-Pro3, a DNA binding dye that do not affect cell viability. To-Pro3 
diffused into the cells immediately after permeabilization of the membranes that accompany cell death and 
was used to monitor cell viability at 6 and 24 hours after the addition of the compounds in both 
experimental conditions. Cell death was quantified at 6 and 24 hours after treatment, by scoring To-Pro3 
levels in mitotic and interphasic cells after setting a threshold for cell viability. Cell death was normalized to 
To-Pro3 levels of untreated cells, and then the increment in cell death in mitosis was calculated by 
subtracting the percentage of dead cells in interphase from the percentage of dead cells in mitosis and 
was plotted in Figure 44. Scoring a positive value means that a given compound preferentially targets 
mitotic cells, whereas a value bellow zero corresponds to a compound which is more specific for 
interphasic cells. Moreover, compounds that are cytotoxic regardless of the phase of the cell cycle will 
score values close to zero. Finally were only considered for further analysis those compounds that show 
an increment in cell viability over 40 or bellow -40. 
 
 
 
Figure 44. Screening for selective killers in mitosis. a) Schematic representation of the protocol followed for synchronization 
in Cdc20(∆/∆). Cdc20(lox/lox) cells were treated with 4-OHT to eliminate Cdc20 12 hours prior the addition of RO-3306, a Cdk1 
inhibitor, to arrest cells in G2. This compound was washed-out 18 hours after allowing mitotic entry, but in the absence of Cdc20 
cells remain arrested in mitosis. Cdc20(lox/lox) cells (violet) were not synchronized. 1 hour after G2 release, both interphasic 
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Cdc20(lox/lox) and mitotic synchronized cells, Cdc20(∆/∆) were treated with a library of 300 compounds at 10 µM in the 
presence of To-Pro3. b) Representation of the percentage of dead cells in mitosis minus percentage of dead cells in interphase 
scored at 6 hours after treatment. Values bellow -40 represents specific interphasic killers (in violet), whereas over 40 include 
compound that preferentially target mitotic cells and scoring a value in between -20 and 12 are considered non-selective killers. 
c) Representation of the percentage of dead cells in mitosis minus percentage of dead cells in interphase at 24 hours after 
treatment following the same criteria that at 6 hours. 
 
A total of 15 compounds preferentially kill cells in interphase (among them 2-DG, hexokinase 
inhibitor which is the enzyme that catalyzes the first step of glycolysis; Table 5). Whereas 10 compounds 
selectively kill cells in mitosis, being 5 out of those 10, identified with an asterisk, inhibitors of the mitotic 
kinase haspin. 
 
MITOSIS SPECIFIC INTERPHASE SPECIFIC 
6 h  24 h  6 h  24 h  
5-IU* 5-IU AA1 ETP-323 
ETP-460 AA2 ETP-567 
ETP-084* ETP-729 ETP-832 
ETP-081* ETP-832 ETP-823 
ETP-263* ETP-477 ETP-437 
PP242  2-DG ETP-477 
RB5  2-DG RB4 
ETP-254 ETP-082 ABT-737 
ETP-947 LY-294002  
ETP-340*     
 
Table 5.  Hits from the screening. 10 compounds preferentially kill cells in mitosis, whereas 15 are kill more specifically 
interphasic cells. The asterisk identifies haspin inhibitors.  
 
 
Haspin is an atypical ser/thr protein kinase, whose activity is limited to mitosis through 
autoinhibition by a basic segment (Funabiki et al., 2013; Zhou et al., 2013), and is in charge of the 
phosphorylation of Histone 3 at Thr-3 (H3T3). This phosphosite is a docking site for chromosomal 
passenger complex (CPC) composed by: survivin, INCENP, borealin and Aurora B; the catalytic subunit of 
the CPC, which coordinates mitotic processes through phosphorylation of key regulatory proteins. In an 
attempt of validation of those haspin inhibitors, we followed individual cell fate by videomicroscopy of 
Cdc20-null cells, in the presence of To-Pro3, and quantify survival in mitosis (SiM), which is the time that a 
cell spends in mitosis before cell death in mitosis (To-Pro3 positive staining). Haspin inhibition in mitosis 
(in Cdc20-null cells) by means of 5-IU, ETP-084 and ETP-081 leads to a reduced survival in mitosis 
compared to control cells, confirming that inhibition of haspin in mitosis results in reduced survival (Figure 
45). 
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Figure 45. Validation of haspin inhibitors as mitotic cell death enhancers in Cdc20-null cells. a) Time-lapse microscopy of 
Cdc20-null MEFs every 15 minutes. Upon Cdc20 ablation cells will enter mitosis and remain trapped at this state for several 
hours, as it can be easily recognized by cell rounding and chromatin condensation, marked by Histone-2B-GFP, mitotic cells 
eventually die in mitosis, To-pro3 positive cells (red). b) Schematic representation of the protocol followed for videomicroscopy. 
4-OHT was added 24 hours before the video and one hour after the beginning of the video, the indicated drugs were injected. 
For quantification were only taken into consideration cells that were in mitosis before the injection of the drug, in order to avoid 
any effect of the drug in mitotic entry. c) Plots representing the time of individual cells from metaphase till cell death in mitosis 
treated with the indicated haspin inhibitors. In c dots represent individual cells and a red line indicates the mean. n.s., not 
significant. **, p<0.01; ***, p<0.001 (Student’s t-test). 
 
Survivin is the only component of the CPC that shows pro-survival activity by direct binding and 
inhibition of caspases. The molecular mechanism still not well understood, but it seems to be linked to p53 
(Chan et al., 2012). Survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and 
may also play a contributing role in regulating mitosis. As well as haspin, depletion of survivin leads to a 
mitotic delay of 2-3 hours (Carvalho et al., 2003; Lens et al., 2003), however, the absence of survivin is 
additionally accompanied by a massive apoptosis and cells death in interphase after failing to complete 
cytokinesis (Cutts et al., 1999; Uren et al.,2000; Zuojun et al., 2008). As haspin activity is essential for 
proper localization of survivin in mitosis, we wonder whether the increased cell death observed upon 
haspin inhibition is an indirect consequence of survivin misslocalization and loss of functionality. For this 
purpose we depleted haspin and survivin protein levels by siRNA (small-interference RNA) and observed 
a more pronounced reduction of SiM after survivin knock-down compared to haspin siRNA and scramble 
(Figure 46).  
 
.   
Results 
 
 84
 
Figure 46. Haspin and survivin contribute 
to survival in prolonged mitotic arrest. a) 
Schematic representation of the protocol for 
time-lapse microscopy in Cdc20-deficient cells. 
Cells are subjected to two consecutives 
rounds of transfection, at 72 hours and 24 
hours before start recording, respectively. 4-
OHT was added 18 hours before the video. b) 
Plots representing the duration of mitosis in 
Cdc20-null cells treated with the indicated 
siRNAs. Efficiency of the indicated siRNAs by 
quantification of mRNA levels 48 hours after 
siRNA nucleofection. Data were normalized 
against the levels of β-actin transcripts. In b 
dots represent individual cells and a red line 
indicates the mean. n.s., not significant. **, 
p<0.01; ***, p<0.001 (Student’s t-test).  
 
 
To further characterize the effect of haspin inhibition, we monitor cell fate in asynchronic 
populations of Cdc20(lox/lox) and human HeLa cells. ETP-084 and I-iodotubercidine (5-IU) treatments 
results in mitotic arrest often followed by cell death in mitosis. Cells are able to successfully perform a first 
mitotic division in the presence of the inhibitors, however, in the subsequent mitosis cells either die in 
mitosis or exit mitosis in the absence of proper chromosome segregation (Figure 47a-b). Whereas ETP-
00048084 treatment leads to a 50% of cell death in mitosis in HeLa cells, 5-iodotubercidine reaches only 
30%. Cdc20(lox/lox) MEFs are more sensitive to cell death in mitosis upon haspin inhibition reaching 95% 
of cell death in mitosis for ETP-084 treatment and 60% in the case of 5-IU.  
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Figure 47. ETP-00048084 and 5-IU delays mitosis in MEFs and human cells. a) Cell fate diagrams of 
Cdc20(lox/lox) cells upon the indicated treatments. In gray is represented the duration of interphase and in green 
mitosis in the absence of segregation. Each line represents an individual cell fate in the presence of the indicated 
treatments. Cell death in interphase is represented in violet, while cell death in mitosis is represented in orange. b) 
Cell fate diagrams of HeLa cells. In gray is represented the duration of interphase and in green mitosis. Each line 
represents an individual cell fate in the presence of the indicated treatments. Cell death in interphase is represented 
in violet, while cell death in mitosis is represented in orange. c) Percentage of cell death in mitosis  (orange) and 
interphase (violet). c) Percentage of cell death in interphase (violet) and mitosis (orange) in Cdc20(lox/lox) and HeLa 
cells upon the indicated treatments. 
 
 
When haspin inhibitors were compared to current chemotherapy drugs (Figure 48), the inhibition of 
haspin resulted much more efficient in killing cells in mitosis. Upon taxol addition only a 30% of cell death 
Results 
 
 86
occurs in mitosis, whereas after ETP-340 and ETP-081 treatment more than a 60% of cells died in mitosis, 
suggesting that haspin inhibition is more efficient in killing cells in mitosis.  
 
Figure 48. Inhibition of haspin is more efficient in killing cells in mitosis than current anti-mitotic drugs. 
a) Cell fate diagrams of Cdc20(lox/lox) cells upon the indicated treatments. In gray is represented the duration 
of interphase and in green mitosis in the absence of a proper cytokinesis. Each line represents an individual 
cell fate in the presence of the indicated treatments. Cell death in interphase is represented in violet, while cell 
death in mitosis is represented in orange in Cdc20(lox/lox) cells. b) Percentage of cell death in mitosis  
(orange) and interphase (violet) Cdc20(lox/lox) cells upon the indicated treatments. 
 
 
Knock-down of haspin by siRNA means in asynchronous murine and human cells, resulted in 
mitotic delay followed by cell death in mitosis in more that 50% in MEFs and less than 40% in HeLa cells. 
Duration of mitosis in MEFs upon haspin knockdown is more prolonged than the mitotic delay induced by 
any of the haspin inhibitors (Figure 49). This result is not observed in HeLa cells and might be a 
consequence of the low efficiency achieved for haspin knockdown in those cells.  
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Figure 49. Inhibition of Haspin produces mitotic delay that results in either cell death in mitosis or mitotic exit in 
the absence of segregation. a) Cell fate diagrams of Cdc20(lox/lox) cells. In gray is represented the duration of 
interphase and in green mitosis in the absence of segregation. Each line represents an individual cell fate in the presence 
of the indicated treatments. Cell death in interphase is represented in violet, while cell death in mitosis is represented in 
orange. b) Cell fate diagrams of HeLa cells. In gray is represented the duration of interphase and in green mitosis in the 
absence of segregation. Each line represents an individual cell fate in the presence of the indicated treatments. Cell 
death in interphase is represented in violet, while cell death in mitosis is represented in orange. c) Efficiency of the 
indicated siRNAs by quantification of mRNA levels 48 hours after siRNA nucleofection. Data were normalized against the 
levels of β-actin transcripts d) Percentage of cell death in mitosis  (orange) and interphase (violet).  
 
 
Importantly, as is shown in Table 6, ETP-084, ETP-340 and ETP-081 are dual inhibitors for haspin 
and Pim, a serine/threonine kinase which expression is regulated by the JAK/STAT pathway. Pim is 
classified as a proto-oncogene and is directly involved in resistance to apoptosis through deactivation of 
Bad pro-apoptotic protein, conferring cell survival and its expression. There are three isoforms primarily 
expressed in B-lymphoid and myeloid cell lines, but also it solid tumors. It has been reported that Pim 
inhibition shows a cytostatic effect arresting cells in G1, which eventually results in cell death 
(Numenthaler et al., 2009). 
 
ETP compound ID  PIM1 IC50  PIM2 IC50   PIM3 IC50   Haspin IC50 
ETP-340 9.27E-08 2.26E-06  1.41E-06 
ETP-084 8.30E-10 1.72E-07 2.10E-08 5.34E-08 
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ETP-081 8.30E-09 6.51E-07 6.59E-08 6.25E-08 
 
Table 6. Haspin inhibitors identified in the screening as M-phase selective killers. In this table are represented the IC50 for 
the several compound identified in the screening as haspin inhibitors. Included the IC50 against haspin and also for the dual 
inhibitors haspin and Pim the IC50 for the three Pim isoforms.  
 
16 hours after ETP-084 and ETP-340 administration almost 100% of cells are in mitosis (Figure 
50b) whereas the pan-Pim inhibitor ETP-00048069 does not results in accumulation of mitotic figures. This 
was confirmed by videomicroscopy after ETP-0048069 treatment 100% of the cells, either Cdc20(lox/lox) 
or HeLa, die in interphase before mitotic entry.  
 
 
Figure 50. Inhibition of Pim leads to cell death in interphase. a) Cell fate diagrams of Cdc20(lox/lox) (lefts) and HeLa cells 
(right). In violet is represented the duration of interphase until cell death in interphase. No cell enters mitosis in the observation 
period. Each line represents an individual cell in the presence of the indicated treatments. b) Bright-field micrographies after 
16 and 24 hours of the indicated treatments. Inhibition on Pim together with Haspin leads to the accumulation of cell in mitosis.  
 
Here we have demonstrated that inhibition of haspin by 5-IU or genetic depletion by using siRNA 
result in mitotic arrest often followed by cell death in mitosis. A similar result is achieved upon dual 
inhibition of haspin and Pim by the use of: ETP-340, ETP-081 or ETP-084. Duration of mitosis (DOM) was 
plotted upon all these different treatments (Figure 51); green dots represent DOM of the cells that undergo 
mitotic slippage in the presence of the drug and in orange the DOM of cells that die in mitosis. Haspin 
knockdown results in a more prolonged DOM compared to chemical inhibition and is even longer than the 
mitotic delay imposed by taxol treatment. However, the longest DOM is achieved upon genetic ablation of 
Cdc20. Regarding the efficiency in the induction of cell death in mitosis, ETP-084 results more efficient 
than 5-IU. Taking into account that 5-IU inhibits more efficiently haspin (IC50 of 5-IU for haspin is E-09 and 
ETP-084 IC50 is 5E-08, see table 7 and De Antoni et al., 2012) this increased cell death in mitosis might 
be due to the concomitant Pim inhibition. These results shows that the dual inhibition of Pim and haspin 
enhances the efficiency of haspin inhibitors in killing cells in mitosis, suggesting that Pim activity may 
contribute to the pro-survival signals during mitosis.  
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Figure 51. Pim and haspin dual inhibition results in extended DOM compared to single haspin inhibition. a) Plot 
representing the duration of mitosis, from mitotic entry to mitotic exit in the lack of segregation (green) and from mitotic entry till 
cell death in mitosis (orange) in Cdc20-null and Cdc20(lox/lox) MEFs. b) Plot representing the duration of mitosis, from mitotic 
entry to mitotic exit in the lack of segregation (green) and from mitotic entry till cell death in mitosis (orange) in HeLa cells.  
 
 
Moreover, DOM upon haspin depletion by siRNA is in between the DOM of Cdc20-null cells, in 
which mitotic exit is prevented, and the DOM after treatment with taxol, which leads to mitotic delay by 
activation of the SAC. This prompted us to ask whether the mitotic delay observed after haspin inhibition is 
due to any of those two mechanisms. In order to test whether haspin inhibition is triggering SAC activity, 
we measure duration of mitosis upon haspin inhibition by using ETP-084 and 5-IU inhibitors in the 
presence of reversine, an Mps1 inhibitor, which is the kinase activity of the SAC. Reversine alone results 
in a reduced duration of mitosis in Cdc20(lox/lox) MEFs in the absence of chromosome segregation, and 
interestingly in combination with 5-IU or ETP-084 significantly reduces the duration of mitosis imposed by 
haspin inhibition (Figure 52). This result may suggest that rather than preventing mitotic exit, haspin 
inhibition somehow triggers the SAC.  
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Figure 52. SAC abrogation rescues the DOM upon haspin inhibition. a) Duration of interphase (gray) or 
mitosis (green) of Cdc20(lox/lox) cells treated with the indicated inhibitors. Each line represents one cell. Cell 
death observed in interphase is represented in violet, while cell death detected during mitosis is shown in 
orange. Cell fate diagrams in Cdc20 wild-type MEFs upon the indicated treatments. b) Duration of mitosis in 
Cdc20(lox/lox) upon the indicated treatments. Reversine treatment reduces mitotic length. 
 
 
All together this results suggest haspin inhibition as a potential anti-mitotic target, although its 
therapeutic potential for cancer therapy needs to be further analyzed in vitro as well as in vivo. 
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1. Disclosing the molecular mechanism of MCD 
1.1 Mitotic cell death pathways 
The arrest imposed by anti-mitotic drugs is frequently transient and cells exit from mitosis (i.e. DNA 
decondensates and the nucleus reforms in the absence of chromosome segregation) in a process known as 
mitotic slippage (Brito and Rieder, 2006; Topham and Taylor, 2013). Mitotic slippage is though to be one of 
the major mechanisms of resistance against antimitotic drugs. Such a process does not occur in the 
absence of Cdc20, which instead results in a permanent mitotic arrest until cells die, providing a clean 
genetic model to analyze molecular pathways that determine cell fate in mitosis (Manchado et al., 2010). 
Inhibiting the APC/C has been therefore proposed as a therapeutic option to prevent mitotic slippage 
(Doménech and Malumbres, 2013; Huang et al., 2009; Machado et al., 2011; Rieder and Medema, 2009).  
Cells are sensitive to multiple insults during mitosis and the cellular alterations resulting from 
aberrant mitotic progression are collectively known as mitotic catastrophe (Vitale et al., 2011). Despite the 
broad use of this concept, the molecular mechanisms that determine cell death in response to these 
alterations are not well understood. In addition, it is frequently unclear whether cell death pathways function 
in mitosis or arise as an indirect consequence of mitotic aberrations during the following cycle. For instance, 
prolonged mitotic arrest partially activates specific caspases, causing limited DNA damage and the induction 
of p53 and related apoptotic pathways in the following interphase (Orth et al., 2012). Among cell death 
pathways, multiple evidences have established the involvement of intrinsic apoptosis in response to mitotic 
aberrations  (Huang et al., 2009; Topham and Taylor, 2013), whereas the extrinsic apoptotic pathway is not 
functional at this stage of the cell cycle (Matthess et al., 2010). Using Cdc20-null cells, as well as human 
cancer cells arrested in mitosis, we show here that elimination of pro-survival factors of the Bcl-2 family 
results in a dramatic reduction in the survival, in agreement with previous reports suggesting the relevance 
of this family in mitosis (Huang et al., 2009; Inuzuka et al., 2011; Topham and Taylor, 2013; Wertz et al., 
2011). It has also been recently described that Cdc20 can suppress apoptosis targeting the pro-apoptotic 
factor Bim (Wan et al., 2014), suggesting that mitotically arrested cells in which Cdc20 is inhibited as a 
consequence of SAC activity are sensitive to this form of death. Despite that MCD mainly depends on Bak 
and Bax and caspases activation, mitotic arrested cells also die in the absence of caspase activity or in Bax 
/Bak double knockout cells (Figure 21) mainly by necrosis and autophagy, suggesting that other forms of 
cell death collaborate in MCD. The occurrence of caspase-independent cell death during mitosis has 
already been demonstrated (Niikura et al., 2007). Moreover it has been proposed that the switch between 
these two types of cell death is dictated by Bcl-xL. Whereas in the absence of Bcl-xL it turns to be caspase 
and Bak /Bax dependent (Bah et al., 2014), if Bcl-xL is present caspases are not needed for MCD.  
In a prolonged mitotic arrest Cdk1 activity is sustained and therefore it might have a role in cell death 
in mitosis, whether pro-survival or pro-death not is not clear. Cdk1 controls the degradation of Bcl-2 family 
members and restricts the activation of caspases-2, caspase-3 and caspase-8 during mitosis through 
phosphorylation (Allan et al., 2007; Andersen et al., 2009; Castedo et al., 2002). In addition, during mitosis 
Cdk1 acts as a repressor of autophagy, through phosphorylation of Vps34 (PI3K class III) at Thr-159, which 
impedes its interaction with Beclin1 during mitosis (Furuya et al., 2010) and is also implicated in multisite 
phosphorylation of Raptor (Gwinn et al., 2010; Ramírez-Valle et al., 2010) allowing mTORC1 activity during 
mitosis. 
Although we observed morphological features of necrosis in mitosis, no evidences for necroptosis 
were found: This can be explained by the fact that activation of RIPK1 and RIPK3 requires TNF receptor 
activation (Vanden Berghe et al., 2014), while as previously mentioned, during mitosis the extrinsic apoptotic 
pathway is not functional. Strikingly, we identified autophagy as a relevant pathway for the control of cell 
death during mitosis. Although it was originally argued that autophagy is shut down during the later phases 
of the cell cycle (Eskelinen et al., 2002; Furuya et al., 2012; Tasdemir et al., 2007; Tasdemir et al., 2008), 
here we demonstrated that autophagy could persist during mitosis, in agreement with recent studies (Liu et 
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al., 2009). In most known cases, autophagy constitutes a cytoprotective response in the attempt to cope 
with stress (Rosenfeldt and Ryan, 2011), however, the final outcome of autophagy depends on the cellular 
context and in particular the strength and the length of the stress-inducing signals, being cytoprotective in 
some scenarios, while considered a type II programmed cell death in some others (Levine and Kroemer, 
2008; Mathew et al., 2007). Here we demonstrate that inhibition of autophagy, in mitotically arrested cells, 
results in prolonged survival whereas induction of this process results in premature death in mitosis (Figures 
29 and 30). We may hypothesize that, in an early mitotic arrest, autophagy might be initially a survival 
mechanism in order to fuel the highly energy consuming mitotic state, but at a late stage is massive 
induction contributes to cell death. Inhibition of autophagy prevents PARP cleavage, however dual inhibition 
of caspase and autophagy does not shows an additive effect in delaying SiM, suggesting a combined 
induction of autophagy and apoptosis, acting autophagy as a facilitator or cooperator of apoptosis.  
 
1.2 Mitochondria where cell death and metabolism converge 
Mitochondria may therefore set the threshold over which cell death occurs playing a central role in 
both energy metabolism and cell death. It has been assumed that mitochondria are particularly active during 
the energy intensive process driving spindle formation and chromosome segregation. In fact, recent data 
showed that Cdk1 activity is necessary to phosphorylate and activate several components of the 
mitochondrial complex I, thus enhancing mitochondrial respiration during the G2/M transition (Wang et al., 
2014). Inhibition of Cdk1 results in decreased mitochondrial activity (Wang et al., 2014), impaired respiratory 
capacity (Figure 35), and reduced ATP levels (Figure 38c). Thus, Cdk1 activity provides cells with the 
bioenergy required for a normal mitotic progression by enhancing mitochondrial respiration. However, upon 
mitotic arrest, the mitochondrial mass initially declines (after about 3 hours) presumably as a result of 
deficient renovation of organelles. This process occurs in the presence of mitophagy (Figure 33), a critical 
autophagic process responsible for the clearance of damaged mitochondria (Okamoto, 2014; Youle and 
Narendra, 2011) promoting further decrease in mitochondrial mass. Whereas the balance between 
biogenesis and mitophagy determines the maintenance of a healthy mitochondrial pool in normal cells, the 
reduced biogenesis resulting from impaired transcription and reduced translation in mitotic cells likely 
perpetuates mitochondrial dysfunction (Figure 35) and reduced ATP levels (Figure 38) during mitotic arrest. 
Indeed mitochondrial elongation in the absence of the dynein Drp1 (Figure 33) serves a protective function 
from mitophagy, in agreement with some studies that shows that in starving conditions mitochondrial 
elongation protects from autophagy (Rambold et al., 2010). Mitochondrial fusion has been linked to 
increased ATP production during stress and starvation (Mitra et al., 2012; Tondera et al., 2010), therefore it 
is likely that elongated mitochondria in the absence of Drp1 might lead to a more efficient mitochondrial ATP 
production important for meeting the metabolic during mitosis. 
 
1.3 Cell survival control by the metabolic checkpoint AMPK  
The rise in the AMP/ATP ratio during mitotic arrest leads to activation of AMPK, a major homeostatic 
regulator of cellular ATP levels (Hardie et al., 2012a). AMPK stimulates catabolic pathways that generate 
ATP, and inhibits ATP-consuming processes such as biosynthesis and cell growth and proliferation (Hardie 
et al., 2012a). AMPK activation can acutely increase glucose uptake and glycolysis, although in the long 
term it promotes the more energy-efficient oxidative metabolism by upregulating mitochondrial biogenesis, 
however, the later process is thought to be transcription-dependent (Hardie et al., 2012b) and therefore 
inefficient in mitotic arrested cells. AMPK might be considered as a metabolic checkpoint coordinating cell 
growth with energy status.  
Among other activities, it appears that AMPK possesses at least three different ways to release the 
mTORC1-mediated repression on autophagy in case of energetic stress. Activated AMPK was thought to 
inhibit mTORC1 activity primarily in the opposite way as growth factors stimulate it, mainly by 
phosphorylation and activation of the negative regulator TSC2 (Inoki et al., 2003). Secondly AMPK 
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phosphorylates Raptor generating a docking site for inhibitory 14-3-3 proteins and is required inhibition of 
mTORC1 and cell-cycle arrest induced by energy stress. And AMPK may also controls mTORC1 indirectly 
by forming stable complexes with Ulk1 and Ulk2 and directly phosphorylates Ulk1, thus triggering autophagy 
(Egan et al., 2011; Kim et al., 2011). 
Additionally, it has been recently published that AMPK is active during mitosis and it is required for 
the completion of mitosis by phosphorylating components of the APC/C (APC1 and CDC27) and PP1 
regulatory subunits (Banko et al., 2011). In these studies, it was not obvious why a kinase activated by 
energy stress should be required for passage through mitosis (Hardie et al., 2012b). However, it is important 
to note that nocodazole-arrested cells were used in these studies as a paradigm of mitotic cells (Banko et 
al., 2011) raising the possibility that some of these conclusions may not apply to a normal lasting (<1h in 
average) mitosis. In drosophila, genetic inactivation of AMPK leads to dramatic defects in cellular 
architecture and genomic instability. AMPK-null embryos displayed mitotic defects, including chromosome 
misalignment in metaphase, chromosome lagging as well as failure in cytokinesis and polyploidy (Bland et 
al., 2012).  This phenotype is likely linked to myosin II regulatory light chain (MRLC) function (Lee et al., 
2007), since it has been recently proposed that AMP-activated protein kinase (AMPK) might indirectly 
promote the phosphorylation of MRLC at Ser-19, by phosphorylating PPP1R12C and PAK2, to regulate the 
transition from metaphase to anaphase and the completion of cytokinesis. In fact Vázquez-Martín and 
colleagues shows that the active form of the α catalytic AMPK subunit associates dynamically with essential 
mitotic regulators during mitosis in human cells. Among them Plk1 conducts the AMPK-mediated activation 
of myosin regulatory light chain at the cytokinesis cleavage furrow independently of energy balance. The 
functional link between AMPK and mitosis may be more complex than initially thought, and fine‐tuned 
biphasic activation of AMPK is required for proper cell division and faithful chromosome segregation during 
mitosis, whereas any alteration of AMPK expression or function (obtained by pharmacological sustained 
activation or AMPK depletion) alters its spatial and temporal regulation, resulting in microtubule 
misalignment, spindle missorientation, abnormal chromosome segregation followed by mitotic catastrophe 
and polyploidy  (Banko et al,. 2011; Thaiparambil., et al 2012; Vázquez-Martin et al., 2009).  
In addition AMPK activity is also pro-apoptotic, and necessary and sufficient for the activation of pro-
apoptotic proteins such as Bim or Bmf and cell death during bioenergetics stress (Concannon et al., 2010; 
Davila et al., 2012; Kilbride et al., 2010). Thus, AMPK may modulate the balance between Bcl2-family pro-
apoptotic and pro-apoptotic members, in favor of the later during prolonged mitotic arrest. Thus AMPK has a 
dual role during mitotic arrest. On one hand, it senses loss of ATP and enhances glycolysis protecting from 
death. On the other hand, it may enhance autophagy and apoptosis through the modulation of Ulk1/mTOR 
and Bim /Bmf activities, thus explaining why both the inhibition (using siRNAs or small-molecule inhibitors) 
and the activation of AMPK (with AICAR) results in reduced survival during mitosis (Figure 43).  
 
1.4 AMPK drives a metabolic switch from OXPHOS to glycolysis and cell survival 
The cease of respiration results in a bioenergetics crisis in which the concentration of AMP is 
increased, leading to AMPK phosphorylation and an increased in glucose uptake. The glycolytic activity of 
AMPK is mostly determined by the phosphorylation and activation of PFKFB3 which is related to Warburg 
effect (Marsin et al., 2002; Bando H et al. 2005). Phosphorylated PFKFB3 at ser-461 shows an increase in 
Vmax of the kinase activity and a decreased Km for Fru-6-P (Marsin et al., 2002; Novellasdemunt et al., 
2012) leading to an increased production of F2,6BP that in turn enhances PFK-1 activity and therefore 
glycolysis. Interestingly PFKFB3 is expressed in transformed cells and tumors (Almeida et al., 2010; Bando 
et al., 2005; Calvo et al., 2006; Chesney et al., 1999; Duran et al., 2008; Kesseler et al., 2008; 
Novellasdemunt et al., 2006; Riera et al., 2020; Yalcin et al., 2009). And PFK-1 is often hyperactivated in 
cancer (Bando et al., 2010) (Figure 53). 
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Figure 53. Mechanism of 
regulation of glycolysis by 
AMPK. The mitotic state facilitates 
the interaction between PFKFB3, 
which shows nuclear localization in 
interphase PFKFB3, and AMPK, 
mostly cytoplasmic, in absence of 
NE. The active form of AMPK 
phosphorylates PFKFB3 at serine 
461, producing an increase in its 
kinase activity and a decreased 
phosphatase activity. The product 
of PFKFB3 kinase activity, fructose-
2,6-BP, is a positive allosteric 
regulator of  PFK-1 the first step of 
glycolysis, resulting in an increased 
glycolytic flux. In addition to AMPK, 
PFKFB3 is phosphorylated in the 
same residue by a battery of 
protein kinases such as: RSK, 
MK2, PKB/Akt and PKC. 
 
Apart from AMPK, PFKFB3 is subject of multiregulation by several kinases. The C-terminal domain 
can be phosphorylated at Ser-461 by different protein kinases, such as RSK (ribosomal S6 kinase) 
(Novellasdemunt et al., 2012) and MK2 (Novellasdemunt et al., 2013). Is also phosphorylated at the same 
residue by PKA (protein kinase A), PKB/Akt (protein kinase B) (Deprez et al., 1007; Mouton et al., 2000) and 
PKC making it responsive to multiple external signals (Okamura and Sakakibara, 1998;). Furthermore, the 
PFKFB3 enzyme was found to be regulated through the PI3K (phosphoinositide 3-kinase)/Akt /mTOR 
pathway, turning it into a target of growth factors signaling (Duran et al., 2009; Garcia-Cao et al., 2012). 
PFKFB3 is also regulated in a cell cycle-dependent manner through ubiquitin-dependent targeting and 
degradation by APC/C-Cdh1 complexes (Herrero-Mendez et al., 2009). Since APC/C-Cdh1 is activated 
downstream of APC/C-Cdc20 after mitotic exit, the levels of PFKFB3 are high during mitosis (Fernandez-
Fernandez et al., 2012; Moncada et al., 2012; Huang et al., 2012). PFKFB3 is mostly nuclear during 
interphase, whereas the activation of AMPK elicited from addition of 2-DG or AICAR has been shown to be 
predominantly cytoplasmic (Tsou et al., 2011). During mitosis the nuclear envelope breakdown results in the 
combination of nuclear and cytoplasmic compartments during mitosis, likely facilitating the AMPK-mediated 
activation of the kinase activity. PFKFB3 in turn enhances PFK-1 activity, which results in enhanced 
glycolysis and increased cell survival in mitosis. 
 
1.5 Glycolysis is a major determinant of survival in mitosis 
Thus, whereas recent data suggest that Cdk1-dependent activation of mitochondrial respiration is 
required for the G2/M transition, our data suggest that a switch from OXPHOS to glycolysis is required 
during prolonged mitotic arrest modulated by AMPK and PFKFB3. This increases glycolysis can be viewed 
as an adaptation to loss of OXPHOS and it also may helps to evade excess ROS and alleviate oxidative 
stress. Warburg effect can be defined as a shift from ATP generation through oxidative phosphorylation to 
ATP generation through glycolysis, however this switch do not relies in an impaired mitochondrial activity; in 
fact the evidences of dysfunctional mitochondria in cancer are limited (Boland et al., 2013). Warburg 
observed that the absolute rate of mitochondrial respiration in cancer cells remains comparable to that of 
normal cells and persist in the vast majority of tumors and remain a major source of ATP generation. 
The full oxidation of one molecule of glucose produces up to 38 ATP molecules (including 2 ATP 
generated in glycolysis) vs only 2 ATP molecules generated in glycolysis, although is more rapid and 
increased glycolytic rate provide some other advantages for cell proliferation and tumor growth. Bolaños et 
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al., 2010, recently demonstrated that an enhanced glycolysis driven by PFKFB3, in astrocytes, protects from 
cell death by using the ATP generated in glycolysis to increase their mitochondrial membrane potential, cells 
become more resistant to pro-apoptotic stimuli. Moreover cancer cells boost glycolysis primarily to 
constantly supply of glycolytic intermediates, which as precursors can be diverted into anabolic pathways 
including the pentose phosphate pathways (PPP), serine and triacylglycerol synthesis pathways for de novo 
synthesis of nucleotides, aminoacids and lipids to satisfy the anabolic need of dividing cells. PPP is also a 
source of cellular NADPH as well as some reactions of glycolysis, and therefore boosting glycolysis 
replenish intracellular redox potential which can buffer increased ROS (Cairns, 2010). As it also happens in 
neurons, glucose metabolism may be directed to the PPP, leading to regeneration of reduced glutathione 
(Bolaños et al., 2010). Glycolysis diminished cellular oxidative stress also by limiting the pyruvate flux into 
mitochondrial oxidative metabolism. In summary glycolysis confers protection to cell death by affecting 
metabolic pathways, but it can directly control apoptosis, as it has been recently established by Meynet et 
al., 2012, inhibition of the glycolytic metabolism of transformed cells could decrease Mcl-1 levels, but no 
other Bcl-2 anti-apoptotic members, through a control of its translation, and therefore inhibition of glycolysis 
may restore sensitivity to ABT-737- induced death. 
 
1.6 Therapeutic implications of combination treatments 
Our results indicate that multiple pathways including apoptosis, autophagy and energy production 
mediate survival in mitosis (Figure 54).  
 
 
 
Figure 54. Mitotic cell death is dictated by cell death pathways and energy availability. Cdk1-dependent 
activation of OXPHOS is required for the G2/M transition, but in a prolonged mitotic arrest a metabolic switch from 
OXPHOS to glycolysis occurs due to, at first, of a lack o organelles biosyntesis and secondly as a consequence of an 
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active process of mitochondria degeneration, in part enhanced by ROS accumulation, and subsequent removal of 
damaged mitochondria by mitophagy. The low ATP levels, due to reduced OXPHOS and to high ATP consumption, 
leads to AMPK activation, which contributes to the increased glycolysis by phosphorylation and activation of PFKFB3 
kinase activity. PFKFB3 in turns boost glycolysis by catalyzing the formation of the principal allosteric regulator of 
PFK-1, the limiting enzyme of glycolysis. Mitochondrial degeneration, low energy levels and ROS accumulation are 
triggers of cell death which might be further enhanced by sustained AMPK activity, which may directly modulate 
apoptosis and autophagy, the two major cell death pathways involved in mitotic cell death.  Necrosis, apoptosis and 
autophagy are tightly interlinked and can be triggered and prevented among them. Whereas necrosis constituted the 
cell death by default that is unmasked when essential effectors of apoptosis are unmasked or in the absence of 
levels of ATP necessary to execute cell death programs, in prolonged mitotic arrest it seems that apoptosis and 
autophagy act in parallel and autophagy id pro-apoptotic. 
 
 
These observations may have important implications in cancer therapy since mitotic slippage is 
considered as a major mechanism of resistance in mitotic-targeted therapies (Doménech and Malumbres 
2013 Gascoigne and Taylor, 2008; Manchado and Malumbres, 2011) and inhibition of mitotic exit has been 
lately proposed as a very efficient strategy for killing tumor cells (Manchado et al., 2010; Huang et al., 2009; 
Luo J et al., 2009; Zeng et al., 2009). Thus, interfering with pathways that sustain survival in mitosis or 
induction of cell death pathways in mitosis in combination with anti-mitotic drugs (i.e. taxol) may promote cell 
death before mitotic slippage and the accumulation of aneuploidy cells, ultimately improving therapeutic 
efficiency. Here we demonstrate that treatment with several small-molecule compounds directed against 
these pathways result in enhanced cell death in mitosis in cooperation with taxol and preventing cell 
proliferation of breast cancer cells both in vitro (Figure 49) and in vivo (Figure 50). The combination between 
microtubule poisons and apoptotic inducers has been extensively studied (Inuzuka et al., 2011; Oltersdorf et 
al., 2005; Topham and Taylor, 2013; Wertz et al., 2011) and are of particular interest in some particular 
settings, for instance in Bcl-2 expressing tumors (Oakes et al., 2011). As well as combinations with mTOR 
and metabolic inhibitors have been thoroughly tested in xenograft mouse mode (Campone et al., 2009; 
Lieber et al., 2011; Meier et al., 2009), however here we show for the first time the molecular basis for this 
synergistic effect. Single treatment with glycolytic inhibitors i.e. 3PO shows a modest effect so far, however 
cooperates with taxol in preventing cell proliferation of breast cancer calls both in vitro and in vivo. 
Collectively, these data provide the cellular basis for new combinatory therapies targeting cell cycle cell 
death pathways and metabolism in cancer.  
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2. Targeting mitosis: the need for new therapeutic options 
Selective cancer chemotherapy is based on the assumption that tumor cells proliferate rapidly and 
cytotoxic drugs gain specificity from their ability to preferentially kill rapidly proliferating cells (Chabner et al., 
2006). However, proliferation rate is low in many chemosensitive human cancers, and it is not clear how a 
drug that only kills dividing cells could promote tumor regression. After treatment with anti-mitotic drugs only 
cells that enter mitosis are killed or rendered senescence (Baguley et al., 1995; Blagosklonny et al., 2006; 
Gascoigne and Taylor, 2008; Orth et al., 2008; Shi et al., 2008), whereas quiescent cells or cells that do not 
reach mitosis during the exposure time remain unaffected. According to the “fractional kill” theory, only cells 
that pass through the phase of the cell cycle, towards a given drug was targeted to, when drug is present 
above its cytotoxic threshold are killed.  Therefore a cell cycle phase–specific cytotoxic drug only kills a fixed 
fraction of cancer cells, necessitating multiple doses to eradicate the tumor (Berenbaum, 1972). This 
predicts a strong correlation between proliferation rate and drug sensitivity in both cancer and normal 
tissues. This prediction fits well for paclitaxel in tissue culture (Baguley et al., 1995), whereas data from 
treatment of human solid tumors are less homogeneous. A positive correlation between proliferation rate 
and clinical response was seen in breast cancer for mostly DNA-targeted chemotherapy (Amadori et al., 
1997) but not for docetaxel (Noguchi, 2006). However some studies consider mitotic index as a prognosis 
value. Hasebe et al., in 2011 suggested that mitotic index can efficiently categorize breast carcinomas, 
transitional cell bladder carcinomas and ovarian carcinomas into groups of distinctly different prognoses, 
being the survival of patients with slowly proliferating tumors significantly better than the survival of patients 
with a higher mitotic frequency.  
Anti-microtubule drugs such as taxanes and vinca alkaloids, has shown great clinical success 
encouraging the development of drugs that specifically target mitosis. Nevertheless, some of the anti-tumour 
effects of the tubulin drugs might be attributed to interphase interactions with the tubulin cytoskeleton. The 
newer targets might not afford the opportunity to alter both the mitotic spindle and the cytoskeleton, that 
many of these proteins appear to function solely in mitosis makes them ideal targets for the development of 
mitosis-specific cancer drugs. The selectivity for mitosis and the distinct ways in which these new agents 
interfere with mitosis provides the potential to not only overcome certain limitations of current tubulin-
targeted anti-mitotic drugs, but to expand the scope of clinical efficacy that those drugs have established. 
Drugs that selectively inhibit mitotic kinesins involved in spindle and kinetochore functions, as well as 
kinases that regulate these activities, are currently in various stages of clinical trials. Although promising it 
have not achieved the desired efficiency in patients. Evidence for clinical efficacy was reduced with very 
limited objective responses and these compounds were mostly inefficient in patients. In general, the current 
generation of targeted mitotic inhibitors displays less anticancer activity than paclitaxel, although 
neurotoxicity has been abolished. It has been argued that mitotic rates in human tumors are much lower 
than in preclinical models and this may limit the effect of these drugs (Doménech and Malumbres, 2013). 
Considering these limitations it is critical to evaluate how antimitotic therapies can be improved in the clinic. 
One emergent strategy is the combination of antimitotic drugs with additional compounds. Examples of the 
combinations preclinical models and clinical trials are displayed in Table 8. Moreover drug discovery 
programs has mainly focused in Plk1 and Aurora A and B as cancer targets, and now several member of the 
kinesin superfamily are emerging as putative anticancer targets, however the are several others mitotic 
kinases which potential as anticancer targets remain unexplored, that is the case for Nek, Mps1, Mastl or 
Haspin.  
Target Combination Model Description 
Plk1 BI2536, BI6727, 
ON01910 and DNA 
damage agents 
(doxorubicin, 
cyclophosphamide, 
irinotecan, etc.) 
Breast cancer cell 
lines, Phase I/II 
Solid and 
hematopoietic 
tumors 
Impaired tumor growth in xenografts. Combinations lead to a 
faster complete response and prevent relapse. Clinical trials 
ongoing 
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Target Combination Model Description 
 BI2536 and 
bortezomib 
(proteasome inhibitor) 
Tumor cell lines Enhanced anti-proliferative and apoptotic effects 
 BI6727, BIBF1120 
(VEGFR inhibitor) and 
BIBW2992 (EGFR 
inhibitor) 
Phase I Advanced 
solid tumors 
Ongoing/no results published 
Aurora 
kinases  
AZD1152, PHA-
680632, MLN8237 
and DNA damage 
agents (platinum, 
gemcitabine, 
radiation, etc.) 
Solid tumor cell 
lines. Phase I in 
AML 
Synergistic effects in proliferation and apoptosis. Enhance the 
effectiveness of the single therapy. Radisensitizer specially in 
p53-deficient cells 
 VX-680, VE-465, 
AT9283, CYC3, 
MLN8237 and 
microtubule agents 
Tumor cell lines. 
Phase I in 
adenocarcinoma 
Synergistic or additive effect in different cell lines 
 MLN8237 and 
bortezomid 
Phase I 
Lymphoma and 
multiple myeloma 
Ongoing/no results published 
 MLN8237 and 
vorinostat (HDAC 
inhibitor) 
Tumor celll lines. 
Phase I in 
lymphoma 
Tumor growth inhibition in xenografts but additive cytotoxicity in 
leukemias. 
 MLN8237 and 
rapamycin (mTOR 
inhibitor) 
Uterine 
leiomyosarcoma 
cell lines 
Synergistic antiproliferative effect (only when preadministered) 
 MLN8237 and 
erlotinib (EGFR 
inhibitor) 
Phase I NSCLC Ongoing/no results published 
 Kinesins SB-715992 and 
carboplatin or 
capecitabine 
Phase I Solid 
tumors 
Ongoing/no results published 
 SB-715992 and 
docetaxel 
Phase I Solid 
tumors 
Ongoing/no results published 
 ARRY-520, 
carfilzomib,  
bortezomid and 
dexamethalone 
Phase I Relapsed 
or refractory 
multiple myeloma 
Ongoing/no results published 
 
Table 8. Therapeutic treatments using mitotic inhibitors in combination with additional compounds 
Abbreviations: AML, acute mieloide leucemia; CLL, chronic lymphocytic leukemia; pH3, phospho-histine H3. Clinical trials are indicated 
using the ClinicalTrials.gov identifier. 
 
By screening a library of 300 compounds for its ability to specifically kill cells in mitosis, we identified 
the kinase haspin as potential anti-mitotic target. Haspin inhibition in asynchronic cultures leads to mitotic 
delay in agreement with previous data  (Dai J et al., 2005; Niedzialdhowska et al., 2012; Wang et al., 2011). 
This mitotic arrest is longer than the mitotic delay observed after taxol treatment and is often followed by cell 
death in mitosis, resulting more efficient than taxol in inducing mitotic cell death. Since reversine is able to 
rescue the duration of mitosis when haspin is inhibited, this may suggest that the mitotic delay observed 
upon haspin inhibition is dependent on SAC activation. However, recent work has suggested that chemical 
inhibition of haspin may impair the activation of the SAC (De Antoni et al., Wang et al., 2010), although, 
haspin downregulation via siRNA does not seem to produce the same SAC defect (Wang et al., 2012). 
Moreover, yeast cells lacking haspin paralogs, ALK1 and ALK2 (Panigada et al., 2013) propertly activate the 
SAC, and are especially sensitive to microtube deploymerizing drugs (i.e. nocodazole). Indeed, after 
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transient nocodazole treatment, cells lacking haspin shows a misspositioned spindle, leading to unequal 
segregation, but haspin does not interfere with microtubule dynamics. In summary, yeast haspin has a role 
in allowing cells to tolerate the mitotic delay induced by SAC activation and reestablish proper spindle 
positioning. Furthermore, inhibition of haspin results in some cases in problems in DNA condensation. This 
event might be a direct consequence of the lack of histone H3 phosphorylation at Thr-3, although the 
function of this modification is debated, it may facilitate chromatin condensation or the release of cohesin 
and ISWI chromatin-remodeling ATPases (Andrews et al., 2003; Pringent et al., 2003; Swedlow and Hirano 
2003; van Hooser et al., 1998). As defects in cohesion leads to SAC activation (Hoque and Ishikawa, 2002), 
these defects in condensation may also trigger the SAC delaying mitotic progression. 
Haspin mitotic phosphorilarylation of histone 3 at threonine-3, acts as a docking site for the CPC 
(survivin, Aurora B, borealin and INCENP) (Cuny et al., 2012) and therefore haspin inhibition may lead to 
misslocalization of the CPC and lack of activation of Aurora B. However, the phenotype observed in Aurora 
B knockout MEFs and upon Aurora B chemical inhibition is the opposite: a rapid mitotic exit as a 
consequence of SAC abrogation, showing a shorter mitotic length compared to wild-type MEFs (Fernández-
Miranda et al., 2010). On the other hand, as before mentioned, it has been described that survivin depletion 
leads to a mitotic delay of 2-3 hours and massive interphase apoptosis after failing to complete cytokinesis 
(Carvalho et al., 2003; Cutts et al., 1999; Lens et al., 2003; Uren et al., 2000; Zuojun et al., 2008). 
Noteworthy, survivin is the only component of the mitotic machinery that function in preventing apoptosis by 
directly inhibiting caspases (Chan et al., 2012), however the role of survivin in the CPC, wheter is mere 
structural or something else, is under debate. The expression of survivin reaches a maximum during G2/M 
and is highly expressed in many tumors being a mechanism of resistance (Rödel F et al., 2011). Disruption 
of survivin leads to increased apoptosis and decrease tumor growth, what makes survivin interesting from a 
therapeutic point of view. To what extent survivin is responsible for the increased cell death in mitosis 
observed upon haspin inhibition is not known and need to be further studied. However, if that is the case, by 
indirectly targeting survivin through haspin inhibition will be beneficial in survivin overexpressing tumors. 
 
Haspin inhibitors generated by the Experimental Therapeutics Progremme at CNIO are more efficient 
in induction of mitotic arrest and mitotic cell death than the commercial haspin inhibitor 5-IU.  The possibility 
that this enhanced efficacy might be due to the additional anti-Pim activity needs to be further analyzed. 
Interestingly, it has been reported a dynamic redistribution of Pim-1 during the cell cycle. The protein moves 
from the nucleus and cytoplasm in interphase to the spindle poles during mitosis (Bhatteaharya et al., 2002) 
where it interacts with NuMA, playing a role in promoting association between NuMA, HP1beta, dynein and 
dynactin, a complex that is necessary for mitosis. Whereas Pim-1 overexpression shows defects in the SAC, 
abnormal mitotic spindles, centrosome amplification, and chromosome missegregation, resulting in 
polyploidy and aneuploidy due to a delay in completing cytokinesis (Roh et al., 2003), the absence of Pim-1 
promotes apoptosis. Pim inhibitors decreased levels of the Bcl-2 family member Mcl-1, an essential pro-
survival signal in mitosis, both by blocking 50-cap dependent translation and decreasing protein half life. In 
addition, Pim inhibition transcriptionally increased levels of the pro-apoptotic BH3 protein Noxa (Song and 
Kraft, 2011). In addition, inhibition of Pim kinases in prostate cancer resensitizes chemoresistant cells to 
taxanes (Numenthaler et al., 2009). All together these evidences support the idea of a specific pro-survival 
role of Pim during mitosis and provides a possible molecular explanation for the fact that dual inhibition 
potenciates the effect of haspin inhibitors, however, this need to be further characterized. 
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Conclussions/Conclusiones 
 
 102
 
 
 
 
Haspin inhibition leads to a SAC-dependent mitotic delay often followed by cell death in mitosis. We therefore 
propose that Haspin is a critical player in cell survival during prolonged mitotic arrest. In addition, chemical 
inhibition as well as genetic depletion of haspin is much more efficient than taxol in killing cells in mitosis. All 
together, these data suggest that haspin is a potential target for anti-mitotic chemotherapy whose utility in 
cancer therapy deserves further validation. 
  
In conditions in which mitotic arrest is perpetuated cells eventually die. Mitotic cell death is mainly driven by 
the intrinsic or mitochondrial apoptotic pathway. In addition, necrosis, but not necroptosis, may also 
participate in mitotic cell death and it may be the major mechanism when apoptosis is inhibited. 
  
Autophagy is induced upon prolonged mitotic arrest. In these conditions, a decrease in mitochondrial mass is 
observed. Since this occurs in the presence of mitophagy, and can be partially rescued by inhibiting 
autophagy, we conclude that autophagy also contributes to mitotic cell death, at least partially due to the 
destruction of mitochondria. 
  
As an adaptation to loss of mitochondrial respiration, a glycolytic switch mediated by AMPK and 
PFKFB3 takes places during mitotic arrest contributing to cell survival in these conditions. Thus, mitotically 
arrested cells display a strong dependency on glycolysis, an observation that has important therapeutic 
implications. In fact, interfering with pathways that sustain survival in mitosis, such as glycolysis, promotes 
cell death prior to mitotic slippage. PFKFB3 inhibition cooperates in vitro and in vivo with taxol in promoting 
cell death and preventing tumor cell proliferation. We therefore conclude that glycolysis is a major survival 
mechanism in mitotically arrested cancer cells. 
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ABSTRACT 
 
Blocking mitotic progression has been proposed as an attractive therapeutic strategy to impair proliferation of 
tumor cells. However, how cells survive during prolonged mitotic arrest is not well understood. By using a genetic 
model of defective mitotic exit in mammalian cells, we show that survival during prolonged mitotic arrest is 
modulated by the special energetic requirements of cells during mitotic arrest. Prolonged mitotic arrest results in 
mitophagy-dependent loss of mitochondria, accompanied by reduced ATP levels and the activation of AMPK. As a 
consequence, oxidative respiration is replaced by glycolysis in a PFKFB3-dependent manner. Induction of 
autophagy or inhibition of AMPK or PFKFB3 results in enhanced cell death in mitosis and increases the anti-
tumoral efficiency of microtubule poisons in breast cancer cells. Thus, survival of mitotic-arrested cells is limited by 
their metabolic requirements, a feature with critical implications in cancer therapies aimed to impair mitosis or 
metabolism in tumor cells. 
 
 
 
INTRODUCTION 
 
Progression through the cell division cycle is 
modulated by multiple cellular machineries that 
control the biochemical and structural changes 
required for DNA replication in S-phase and 
chromosome segregation during mitosis. Entry into 
mitosis requires a dramatic structural re-
organization including centrosome duplication and 
generation of the microtubule spindle, disassembly 
of the Golgi apparatus, breakdown of the nuclear 
envelope and chromosome condensation. At this 
stage, transcription is strongly suppressed, 
translation is limited to a subset of mRNAs, and the 
absence of the nuclear envelope temporally 
maintains on hold multiple regulatory mechanisms 
based on the separation of the nuclear and 
cytoplasmic compartments 1.Progression through 
mitosis is monitored by the Spindle Assembly 
Checkpoint (SAC), a regulatory pathway that delays 
mitotic exit until all chromosomes are bipolarly 
attached to the spindle 2. The target of the SAC is 
the Anaphase-promoting complex/Cyclosome 
(APC/C), an E3 ubiquitin ligase that, when activated 
by Cdc20, targets for degradation the separase 
inhibitor securin, and the Cdk1 activatory subunit 
cyclin B. Complete bipolar attachment of 
chromosomes results in APC/C-Cdc20 activation, 
Cdk1 inhibition and activation of separase, leading 
to chromosome segregation and the reformation of 
two new nuclei 3. These nuclei and the rest of 
cytoplasmic structures are physically separated 
after cytokinesis to form two new daughter cells. 
Disruption of the mechanisms that regulate the 
proper attachment of chromosomes to the bipolar 
spindle results in mitotic arrest in a SAC-dependent 
manner. Thus, inhibition of mitotic kinases or 
treatment of cells with microtubule poisons that 
disrupt the proper dynamics of the spindle, results in 
mitotic arrest, a feature that may be used to prevent 
tumor cell proliferation 5. Yet, the success of 
mitotic-4 targeted therapies is limited by two major 
problems: a) the low mitotic index of human tumors, 
and b) mitotic slippage; i.e. the ability of cells to exit 
from mitosis in the presence of mitotic blockers 5-8. 
Since mitotic slippage is APC/C-Cdc20-dependent 
9, targeting the mitotic exit machinery has been 
proposed as an efficient method to prevent 
resistance to antimitotic drugs 9-12. In the absence 
of Cdc20, cells cannot exit mitosis and irremediably 
die in mitosis after a prolonged arrest 9,11.Cell fate 
upon mitotic arrest is thought to be determined by 
the balance between mitotic slippage pathways and 
apoptotic cell death10, 13. We therefore reasoned 
that interfering with the pathways that determine 
survival in mitosis could improve the efficiency of 
mitotic-targeted therapies. Although death in mitosis 
is thought to be at least partly mediated by 
apoptosis, the molecular pathways that control 
survival or death in mitosis are not well 
understood14. Here we show that death in mitosis 
is modulated by the energetic balance that 
counteracts the loss of mitochondrial mass during 
mitotic arrest. Using Cdc20 knockout cells or human 
cells treated with microtubule poisons, we describe 
here that the presence of autophagy during mitotic 
arrest is accompanied by a gradual decline in the 
mitochondrial mass and oxidative respiration. This 
results in the activation of AMPK and the induction 
of glycolysis in a PFKFB3-dependent 
manner.Inhibition of these energetic pathways in 
breast cancer cells prevents mitotic slippage and 
results in accelerated death of mitotic cells, thus 
potentiating the therapeutic effect of microtubule 
poisons currently used in the clinic. 
 
 
RESULTS 
 
Mitotic death is modulated by the intrinsic 
apoptotic pathway 
To analyze the molecular pathways modulating cell 
viability in mitosis we made use of  
Cdc20 conditional knockout fibroblasts in which 
Cdc20 is excised upon treatment with 5 4-hydroxy-
tamoxifen (4OHT)9. These cells display normal 
mitotic entry but mitotic exit is completely prevented 
due to the lack of APC/C-Cdc20-dependent cyclin 
B1 degradation. Mitotic cell death (MCD) can be 
observed in these cells by time-lapse microscopy 
using TO-PRO3, a dye that is internalized into the 
cells upon the permeabilization of membranes that 
precedes cell death (Fig. 1a,b). Cdc20(D/D) cells 
display a variable survival in mitosis (SiM, time 
since mitotic entry till cell death) of 22 ±14 h until 
they finally died in mitosis (Fig. 1b,c). No 
Cdc20(D/D) cell was able to exit from the mitotic 
arrest suggesting that this APC/C cofactor is 
essential for mitotic slippage.To test the relevance 
of apoptosis in MCD, we transfected these cells with 
small interfering (si)RNAs (Supplementary Fig. 1) 
against several apoptotic regulators following the 
protocol depicted in Figure 1a. Knockdown of Mcl1, 
an anti-apoptotic regulator of the Bcl2 family 
involved in the response to taxol15, 16, or BclX 
resulted in earlier MCD whereas knockdown of both 
caspase 2 and caspase 3 significantly delayed MCD 
(Fig. 1b,c). Double knockdown of the pro-apoptotic 
regulators Bax and Bak also resulted in a significant 
increase in SiM and delay in MCD (Fig. 1c). The 
involvement of the apoptotic machinery was also 
validated using the pan-caspase inhibitor ZVAD or 
two different inhibitors of the Bcl2 family (Fig. 1d). 
SiM was improved with ZVAD and significantly 
decreased with the two Bcl2 family inhibitors (Fig. 
1d) being more dramatic in the case of ABT-263, 
perhaps as a consequence of the more potent effect 
of this compound against Mcl1 17.Downregulation 
or inactivation of caspases or Bax/Bak proteins 
delayed but did not prevent MCD as all cells died in 
these assays in the absence of Cdc20 (Fig. 1c,d).  
To test whether this was a consequence of partial 
inactivation of apoptosis, we next used Bax/Bak 
double knockout cells in which the intrinsic apoptotic 
pathway is totally 6 inhibited18. To mimic the 
metaphase arrest caused by Cdc20 ablation, cells 
were released from a nocodazole-induced 
prometaphase arrest in the presence of the 
proteasome inhibitor MG132, thus preventing cyclin 
B degradation and mitotic exit (Fig. 1e). This 
protocol resulted in a SiM value of 13.0 ± 9.5 h in 
wild-type cells, which was significantly expanded to 
39.0 ± 28.9 h in the absence of Bak and Bax. Yet, 
all cells died in mitosis in these conditions in the 
presence of necrotic figures (SupplementaryFig. 1). 
Similar data were obtained in human cancer cells 
(HeLa or MDA-MB-231)sSubjected to the same 
protocol (Fig. 1f), suggesting that apoptosis is 
involved but not essential for MCD. 
 
Figure 1. Mitotic cell death is modulated by the intrinsic 
apoptotic pathway. a)Protocol used for time-lapse microscopy 
in Cdc20-deficient cells. Ras/E1A-transformed Cdc20(lox/lox); 
CreERT2 cells were nucleofected with siRNAs, seeded at low 
density and treated with 4-hydroxytamoxifen (4OHT) 18h before 
starting the video in the presence of TO-PRO3 or other 
chemicals. b) Representative micrographs of Cdc20-deficient 
[Cdc20(D/D)] cells after the indicated periods of mitotic arrest (h 
after chromosome condensation and cell rounding) in the 
presence of siRNAs against Mcl1 or caspase 2 and 3. c) Plots 
representing the duration of mitosis (from mitotic entry until cell 
death) in Cdc20-null cells treated with the indicated siRNAs (Scr., 
scrambled sequences) or in the presence of the caspase inhibitor 
ZVAD. d) Duration of mitosis (from metaphase until cell death) in 
Cdc20-null cells treated with caspase or Bcl-2 family inhibitors. e) 
Schematic representation of the protocol followed for 
videomicroscopy in Bax/Bak-deficient MEFs and human cell lines 
cells (left panel). Cells were synchronized in prometaphase for 
12 hours with nocodazole, and released in the presence of the 
proteasome inhibitor MG132. The duration of mitosis (from 
metaphase until cell death) in Bax/Bak-null and control MEFs is 
represented in the right panel. f) Duration of mitosis in human cell 
lines cells treated with caspase inhibitors or the indicated Bcl-2 
family inhibitors. In (c-f) dots represent individual cells and the 
mean is indicated by a red line. Green or red columns indicate a 
significant delay or premature cell death in mitosis. n.s., not 
significant. **, p<0.01; ***, p<0.001 (Student’s t-test). 
 
 
Autophagy modulates survival during mitotic 
arrest 
We next investigated other pathways known to 
regulate apoptotic-independent cell death. 
Downregulation of both Ripk1 and Ripk3 using 
siRNAs, or their inhibition using necrostatin1, did 
not modify MCD in Cdc20-null cells (Supplementary 
Fig. 1), suggesting that necroptosis or programmed 
necrosis is not a major pathway for death in mitosis.  
Although autophagy has been previously found to 
be inhibited during mitosis 19, we tested the 
changes in this process during prolonged mitotic 
arrest. Cdc20-null cells were first synchronized in 
G2 using the Cdk1 inhibitor RO-3306 and mitotic 
entry and progression were monitored after release 
from this compound (Fig. 2a andSupplementary Fig. 
2). The autophagic flux was scored using a 
fluorescent-tagged LC3 sensor in which the pH 
sensitivity differences exhibited by GFP (green 
fluorescent protein) and mRFP (red fluorescent 
protein) can monitor progression from the 
autophagosome to autolysosome 20. Whereas 
autophagosomes emit both mRFP and GFP signals 
(yellow in overlaid images), autolysosomes emit 
only an acid-stable mRFP signal because the pH-
sensitive GFP signal is quenched in acidic 
lysosomes. Autophagy was increased after 
prolonged mitotic arrest in comparison with normal 
mitosis in asynchronous cultures in the absence of 
4-OHT or with the initial arrest in Cdc20-null cells 
(Fig. 2b).! Both the accumulation of 
autophagosomes and autophagolysosomeswere 
significantly prevented in the presence of the Class 
III PI3K inhibitor 3-methyladenine (3MA), and 
increased upon treatment with the mTOR inhibitor 
PP242, confirming the dynamic autophagic flux in 
mitotic cells. The lapidated and autophagosome 
membrane-associated form of LC3 (LC3-II) 
increased after 24 or 36 h in mitosis in parallel to 
the cleavage of caspase 3, both in human and 
mouse cells (Fig. 2d and Supplementary Fig. 2), 
indicating the concomitant presence of autophagy 
and apoptosis in these cultures. Incubation during 
mitotic arrest with the lysosomal protease inhibitors 
E64d (a calpain and cathepsin B inhibitor) and 
pepstatin A (PA, an inhibitor of aspartic proteases), 
which blocks the last steps of autophagic 
degradation, enhanced accumulation of LC3-II, 
confirming the presence of a dynamic autophagy 
flux during mitosis (Supplementary Fig. 2). 
 
We then tested whether autophagy was able to 
modulate MCD by scoring the SiM upon 
downregulation of several autophagy regulators 
(Supplementary Fig. 2).Knockdown of Raptor, a 
member and positive regulator of the mTOR 
complex 1 that inhibits autophagy, resulted in earlier 
death in mitosis whereas downregulation of several 
proteins involved in the induction of autophagy, 
such as Ulk1, Vps34 or Beclin1, prevented MCD to 
a similar extent to the apoptosis inhibitor ZVAD (Fig. 
2e). The requirements for autophagy in MCD were 
also validated during mitotic arrest inAtg5-null cells 
(Fig. 2f). Induction of autophagy by inhibitors of the 
PI3K-Akt-mTOR pathway resulted in premature 
MCD in Cdc20-null cells (Fig. 2g and 
SupplementaryFig. 2) or mitotic human cells (Fig. 
2h), whereas 3MA delayed death in mitosis (Fig. 
2h,i). Yet, concomitant inhibition of apoptosis and 
autophagy using a combination of ZVAD and 3MA 
did not further enhance SiM and all Cdc20-null cells 
eventually died in the presence of these two 
inhibitors (Fig. 2i). Finally, whereas caspase 
inhibition did not prevent LC3 lipidation, treatment of 
cells with E64d/PA inhibited poly(ADP-ribose) 
polymerase (PARP-1) cleavage (Supplementary 
Fig. 2), suggesting a pro-apoptotic activity for 
autophagy in mitotic arrested cells. 
 
 
 
Figure 2. Autophagy modulates cell death during mitotic 
arrest. a) Protocol for synchronized entry into mitosis in 
Cdc20(D/D) cells. Cdc20(lox/lox) cells are first 25 
treated with 4OHT, Cdk1 is then inhibited with RO-3306 during 
18 h for G2 arrest, and cells are released to enter into mitosis in 
a synchronized manner (see also Supplementary Fig. 2). b) Live 
confocal microscopy pictures of Cdc20-null cells transiently 
expressing the LC3 reporter system in the presence of a mTOR 
inhibitor (PP242) and the autophagy inhibitor 3MA. Quantification 
of the autophagic flux (at least 5 puncta per cell) in asynchronous 
(As.) cultures or at the indicated times after release from the G2 
arrest. Data are represented as mean ± SEM (n=30 cells per 
point).c) Electron microscopy micrographs showing the presence 
of autophagosomes in Cdc20-null cells after release from G2, 
either in the absence or presence of E64d/PA. Scale bars, 2 mm 
and 500 nm for low and high magnification images, respectively. 
d) Immunodetection of the indicated proteins in MDA-MB-231 
cells after release from the G2 arrest. b-actin is included as a 
loading control. e) Duration of mitosis (from mitotic entry until cell 
death) in Cdc20-null cells transfected with the indicated 
interfering RNAs or in the presence of the caspase inhibitor 
ZVAD. f) Duration of mitosis (from metaphase until cell death) in 
Atg5–null and control MEFs synchronized following the protocol 
depicted in Figure 1e. g) Duration of mitosis (from metaphase 
until cell death) in Cdc20-null cells treated with ZVAD, the 
indicated inducers of autophagy (mTORinhibitors PP242, 
temsirolimus, BEZ235), or transfected with siRNAs against 
Raptor (Rap.). h) Duration of mitosis (from metaphase until cell 
death) in human cell lines cells treated with the indicated 
compounds. i) Duration of mitosis in Cdc20-null cells treated with 
caspase and/or autophagy inhibitors. In (e-i) dots represent 
individual cells and the mean is indicated by a red line. Green or 
red columns indicate a significant delay or premature cell death 
in mitosis. n.s., not significant. *, p<0.05; **, p<0.01; ***, p<0.001 
(Student’s t-test).We then tested whether autophagy was able to 
modulate MCD by scoring the SiM upon downregulation of 
several autophagy regulators (Supplementary Fig. 2).Knockdown 
of Raptor, a member and positive regulator of the mTOR 
complex 1 that inhibits autophagy, resulted in earlier death in 
mitosis whereas downregulation of several proteins involved in 
the induction of autophagy, such as Ulk1, Vps34 or Beclin1, 
prevented MCD to a similar extent to the apoptosis inhibitor 
ZVAD (Fig. 2e). The requirements for autophagy in MCD were 
also validated during mitotic arrest inAtg5-null cells (Fig. 2f). 
Induction of autophagy by inhibitors of the PI3K-Akt-mTOR 
pathway resulted in premature MCD in Cdc20-null cells (Fig. 2g 
and Supplementary Fig. 2) or mitotic human cells (Fig. 2h), 
whereas 3MA delayed death in mitosis (Fig. 2h,i). Yet, 
concomitant inhibition of apoptosis and autophagy using a 
combination of ZVAD and 3MA did not further enhance SiM and 
all Cdc20-null cells eventually died in the presence of these two 
inhibitors (Fig. 2i). Finally, whereas caspase inhibition did not 
prevent LC3 lipidation, treatment of cells with E64d/PA inhibited 
poly(ADP-ribose) polymerase (PARP-1) cleavage 
(Supplementary Fig. 2), suggesting a pro-apoptotic activity for 
autophagy in mitotic arrested cells. 
 
 
Mitophagy leads to loss of mitochondria during 
mitotic arrest 
The cellular mitochondrial mass is tightly regulated 
by a balance between biosynthesis of new 
mitochondrial proteins and the removal of old 
mitochondria by a specific autophagy process 
known as mitophagy 21, 22. Since protein synthesis 
is limited during mitosis due to the lack of proper 
transcription and translation, we next tested whether 
mitotic arrest was accompanied by mitochondrial 
loss. In fact, the cellular mitochondrial content 
started to decrease a few hours (3-6 h) after mitotic 
arrest in Cdc20-null cells as detected by time-lapse 
microscopy (Fig. 3a) and cytometry (Fig.3b), using a 
mitochondrial dye resistant to loss of membrane 
potential. Exposure of  
mitotic cells to carbonyl cyanide m-chlorophenyl 
hydrazine (CCCP), a classical inducer of mitophagy, 
resulted in decreased mitochondrial signal during 
the first few hours after mitotic arrest, whereas this 
compound had little effect during late mitotic arrest, 
when the mitochondrial mass was already severely 
reduced (Fig. 3b,c). Immunodetection of the 
mitochondrial proteins Tom20, Tim23 or Tom40 
corroborated the loss of mitochondrial mass and 
this effect was prevented when the lysosomal 
function was inhibited with E64d/PA (Fig. 3d).9 The 
decrease in mitochondrial content was 
accompanied by a gradual colocalization of LC3 in 
the mitochondria suggesting the presence of 
mitophagy in mitotically arrested cells (Fig. 3e). In 
fact, the formation of autophagosomes affecting 
mitochondria was evident as early as 6 h after 
mitotic arrest and these organelles were frequently 
found within the autophagosomes at later stages 
(Fig. 3f and SupplementaryFig. 3). Prevention of 
mitophagy or lysosomal function with 3MA, or 
exposure to Cyclosporin A (CsA), a blocker of the 
opening of mitochondrial permeability transition 
pores, significantly prevented loss of mitochondrial 
content (Fig. 3g). In line with these observations, 
loss of mitochondrial function was accompanied by 
increased reactive oxygen species (ROS) and 
prevention of ROS with N-acetyl-L-cysteine (NAC) 
resulted in prevention of death during prolonged 
mitotic arrest both in mouse and human cells 
(Supplementary Fig. 3). 
 
 
Figure 3. Reduced mitochondrial mass as a consequence of 
mitophagy during mitotic arrest. a) Mitotracker signal was 
followed by time-lapse microscopy at the indicated time points 
after release of Cdc20-null cells from G2 arrest. White and yellow  
arrows indicate interphasic or mitotic cells, respectively. 
Mitotracker intensity decreases rapidly in cells arrested in mitosis 
(red) compared with interphasic cells (blue). Data are 
represented as mean ± SD (n= 18 mitotic and 12 interphasic 
cells). b) Quantification of mitotracker intensity as measured by 
flow cytometry at the indicated time points after  
release from G2 arrest (mean ± SEM). As a positive control, 
CCCP results in a reduction of the mitochondrial mass at early 
but not late time points during mitotic arrest in comparison with 1 
h- treated cells (n=7 independent assays). c) Representative 
profiles of Cdc20(D/D) after 3h in mitosis in the absence or 
presence of CCCP (left panel), or after 1h and 24h in mitosis 
(right panel). d) Immunodetection of the mitochondrial proteins 
Tom20, Tim23 and Tom40 in Cdc20-null cells at the indicated 
times after release from G2. As., asynchronous cultures. b-actin 
was used as a loading marker. e) Percentage of cells showing 
co-localization of LC3-GFP and Mitotracker (>2 foci per cell; see 
yellow arrows in the representative images) at the indicated time 
points after mitotic arrest. Data represent mean ± SEM; n=30 
cells per condition. f) Representative electron microscopy images 
showing the inclusion of mitochondria inautophagosomes during 
mitotic arrest either in the absence or presence of 
E64d/PA.Scale bars, 200 nm in Asyn. cells and 500 nm in 
mitotic-arrested cells. g) Mitochondrial content as measured by 
flow cytometry in the presence of Mitotracker in Cdc20-null cells 
after 24 h in mitosis in the presence of vehicle (C), 3MA or CsA 
(related to vehicle-treated cells). The plots in the right represent 
the profile of Cdc20(D/D) after 24h in mitosis in the absence or 
presence of 3MA (red) or Cyclosporine A (blue). h) 
Representative confocal microscopy live images showing the 
mitochondrial network.(Mitotracker) in the presence (siScr.) or 
absence (siDrp1) of Drp1 after nucleofection with siRNAs against 
this molecule. i) Co-localization of LC3-GFP and Mitotracker (>2 
foci per cell) at the indicated time points after mitotic arrest in 
Drp1 knock-down (siDrp1) cells. (n=30 cells per condition). 
Representative confocal microscopy live images show the co-
localization of LC3-GFP and Mitotracker at 24 h in siScr. and 
siDrp1-transfected cells (right panel). j) Quantification of 
Mitotracker intensity by cytometry after 12 and 24 h of mitotic 
arrest relative to 1 hour of mitotic arrest in the presence (siScr.) 
or absence (siDrp1) of Drp1. k) Duration of mitosis (from mitotic 
entry until cell death) in Cdc20-null cells treated with specific 
siRNAs against Drp1 (siDrp1). n.s., not significant. *, p<0.05; **, 
p<0.01; ***, p<0.001, Student’s t-test. 
 
During mitosis, mitochondria are fragmented to 
facilitate segregation of this organelle to daughter 
cells 1. Mitochondrial fission is mediated by Cdk1-
dependent phosphorylation and activation of the 
dynamin-like protein Drp1. Since fragmented 
mitochondria are known to be more sensitive to 
mitophagy23, we next tested whether inactivation of 
Drp1 resulted in a specific protection of mitotic 
mitochondria. As depicted in Figure 3h, knock-down 
of Drp1 by short interfering RNAs (siDrp1) in Cdc20-
null cells prevented fragmentation of mitochondria 
and siDrp1 cells displayed longer tubular organelles 
during mitosis. Knock-down of Drp1 also resulted in 
reduced co-localization of mitophagy markers in 
mitochondria (Fig. 3i), prevented loss of 
mitochondrial mass (Fig. 3j) and led to increased 
SiM in Cdc20-deficient cells (Fig. 3k),in agreement 
with the relevance of maintaining the proper level of 
mitochondrial mass to prevent cell death in mitosis. 
 
AMPK promotes glycolysis during mitotic arrest 
We next investigated the functional relevance of 
mitochondrial loss during mitosis by comparing the 
rates of mitochondrial respiration (oxygen 
consumption, OCR) and glycolysis (extracellular 
acid release; ECAR) from mitotic and control cells.  
Cdc20(D/D) cells were arrested in G2 using RO-
3306 for 18 h and released to arrest in mitosis (red) 
in a synchronized manner. G2-synchronized (blue) 
or asynchronous(green) Cdc20(lox/lox) cells were 
used as controls (Fig. 4a). Our results indicated that  
OCR quickly increased upon mitotic entry in 
agreement with recent data indicating the activation 
of the oxidative respiration during the G2/M 
transition in a Cdk1-dependent manner24. 
However, the respiratory capacity started to become 
extenuated after ~12 h in mitosis (Fig. 4b). ECAR 
levels gradually increased during mitosis but were 
further augmented during late mitotic arrest in 
parallel with the loss of oxidative respiration both in 
mouse (Fig. 4b) and human (Fig. 4c) cells.In 
agreement with increased AMP/ATP levels (black 
versus green in Fig. 4f). This defect is likely a 
consequence of Cdk1 inactivation by RO-3306 
given the crucial role of Cdk1 in activating 
mitochondrial function during the G2/M transition24. 
The AMP/ATP ratio was normalized after release 
from this compound in control Cdc20(lox/lox) cells 
(blue) that underwent a normal transition through 
the different phases of the cell cycle. In Cdc20(D/D) 
cells, the AMP/ATP ratio displayed a new gradual 
increase ~8 h after mitotic arrest (red in Fig. 4f) in 
agreement with the timing of AMPK activation (Fig. 
4d). 
 
 
Figure 4. Metabolic switch from OXPHOS to glycolysis is 
mediated by AMPK. a) Protocol used to synchronize entry into 
mitosis. Treatment of Cdc20(lox/lox) cells with 4-OHT results in 
Cdc20(D/D) cells (red) which arrest in mitosis after release from 
the G2 arrest. Control cells include Cdc20(lox/lox) cells which do 
not arrest (blue) or asynchronous cultures (green). Color codes 
are maintained throughout the figure foreasier identification of the 
three cell types. b) Respirometry profile of asynchronous (As.) 
Cdc20(lox/lox) cells, or G2-arrested or mitotic arrested 
Cdc20(D/D) cells at the indicated time points after the release 
from G2. OCR (oxygen consumption rate) measures 
mitochondrial respiration, whereas ECAR (extracellular 
acidification rate) is a measure of glycolysis. OCR or ECAR data 
represent the difference between maximum (in the presence of 
FCCP or oligomycin, respectively) and basal values. c) Similar 
respirometry profile in MDA-MB-231 human breast cancer cells. 
b and c are representative assays from three separate 
experiments. d) Immunodetection of the indicated antigens in 
asynchronous (As.) Cdc20(lox/lox) cells, or G2-arrested or 
mitotic 28 arrested Cdc20(D/D) cells at the indicated time points 
after the release from G2. a-tubulin was used as a loading 
marker. e) AMPK activity is monitored by a FRET biosensor in 
control Cdc20(lox/lox) (blue) or Cdc20-null (red) cells upon 
mitotic entry at the cell single level. Time 0 indicates mitotic entry 
and the length of the black bar represents duration of mitosis. 
Data are represented as mean ± SD (n= 12 cells per genotype). 
f) AMP/ATP ratio measured by HPLC in control Cdc20(lox/lox) 
and Cdc20-null cells. **, p<0.01; ***, p<0.001, Student’s t-test. g) 
Glucose uptake and concentration of extracellular lactate (NMR 
analysis) in the indicated cultures in the presence of 13C-labelled 
glucose. h) Similar glucose uptake and concentration of 
extracellular lactate in Cdc20-null cells after knock-down of 
AMPKa1/a2 using specific siRNAs. In g) and h) data represent 
mean ± SD and a spline function is used to connect the sampled 
points. Data in b), c) and g) are not normalized for death cells 
and the differences in mitotic-arrested cells are likely under-
estimated. 
 
 
 
 
Glycolysis is a major determinant of survival in 
mitosis 
The activation of AMPK and the subsequent 
glycolytic switch observed in mitotic cells raised the 
possibility of a dependence on energy pathways to 
survive in mitosis. Treatment of mitotic cells with 
Compound C, a molecule known to inhibit AMPK 12 
among other kinases, or with metformin, which 
inhibits mitochondrial function resulting in ATP 
depletion frequently activating AMPK, resulted in 
reduced SiM in mitotic Cdc20-null cells (Fig. 5a) or 
human cell lines (Fig. 5b). Specific knockdown of 
AMPKa1 and AMPKa2 transcripts also resulted in 
reduced viability in mitosis (Fig.5c). Furthermore, 
addition of two different glycolytic poisons, 2-desoxi-
D-glucose (2-DG; a glucose analogue that cannot 
be metabolized) or oxamate (an isosteric and 
isoelectronic inhibitory analogue of pyruvate), also 
resulted in premature MCD; whereas 
supplementation of media with glucose led to a 
significant increase in SiM (Fig. 5d). The relevance 
of the glycolytic pathway was directly addressed by 
testing therelevance of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a 
key regulator of the glycolytic enzyme 
phosphofructokinase-1 (PFK-1) that is activated by 
AMPK in a phosphorylation-dependent manner and 
frequently expressed in cancer cells 26. 
Downregulation or inhibition of PFKFB3 using 
siRNAs or the competitive inhibitor 3-(3-pyridinyl)-1-
(4-pyridinyl)-2-propen-1-one (3PO) resulted in a 
significant reduction in SiM in mouse (Fig. 5e) or 
human (Fig. 5f) cells, in agreement with reduced 
glucose consumption and lactate production during 
mitosis in the absence of this  
regulator (Fig. 5g). 
   
 
Figure 5. Glycolysis determines survival during mitotic 
arrest. a) Duration of mitosis (from metaphase until cell death) 
in Cdc20-null cells treated with the indicated AMPK modulators. 
b) Duration of mitosis in human cell lines treated with the 
indicated modulators of AMPK or the caspase inhibitor ZVAD. c) 
Duration of mitosis in Cdc20-null cells transfected with Scramble 
or AMPKa1/a2 siRNAs. d) Duration of mitosis in Cdc20-null cells 
treated with the indicated inhibitors of glycolysis and upon 
glucose addition at the indicated concentration. e) Duration of 
mitosis in Cdc20-null cells treated with PFKFB3 siRNAs. Bottom 
panel shows PFKFBP3 protein levels upon knockdown with the 
corresponding siRNAs. f) Duration of mitosis in Cdc20- null and 
in human cell lines arrested in mitosis treated with the PFKFB3 
inhibitor 3PO. g) Glucose uptake (left panel) and concentration of 
extracellular lactate (right panel) 29measured by NMR in Cdc20-
null cells transfected with Scramble or PFKFB3 siRNA.Data 
represent mean ± SD. In (a-f) dots represent individual cells and 
the mean is indicated by a red line. Green or red columns 
indicate a significant delay or premature cell death in mitosis. 
n.s., not significant. **, p<0.01; **, p<0.01; ***, p<0.001 
(Student’s t-test). 
 
 
 
Figure 6. Taxol cooperates with different inhibitors of 
survival pathways to promote mitotic cell death. a) Cell death 
in MDA-MB-231 as determined by To-Pro3 levels, measured 
using high-throughput microscopy, after the addition of the 
indicated compounds in the presence or absence of taxol. Pink 
columns indicate significant synergistic combinations when 
compared to single inhibitors (black dotted comparisons) or taxol 
(red dotted comparisons). ***, p<0.001; Student’s t-test. b) 
Duration of interphase (gray) or mitosis (green) of MDA-MB-231 
cells treated with the indicated inhibitors. Each lane represents 
one cell. Cell death observed in interphase is represented in 
violet, while cell death detected during mitosis is shown in 
orange. c) Cell fate of single MDA-MB-231 cells treated with the 
indicated inhibitors in combination with Taxol. d) Quantification of 
the percentage of cells dying in interphase (violet) or in mitosis 
(orange) after the indicated treatments (n=50 cells per condition).  
e) Duration of mitosis (from mitotic entry until cell death) in MDA-
MB-231 cells treated with the indicated drugs, alone or in 
combination with Taxol. n.s., not significant. **, p<0.01; ***, 
p<0.001 (Student’s t-test). 
 
Inhibition of glycolysis cooperates with 
microtubule poisons in mitotic cell death 
We next tested the relevance of apoptosis, 
autophagy and energy production, in the therapeutic 
effect of microtubule poisons. MBA-MD-231 breast 
cancer cells were treated with multiple agents 
against the referred pathways either in the presence 
or absence of taxol. As indicated in Fig. 6a, several 
combinations were more efficient than the single 
agents in killing these breast cancer cells. The 
effect of ABT-263, PP242, 2DG and 3PO was also 
tested in additional breast cancer cell lines such as 
MDA-MD-468, EVSA-T or MCF7 (Supplementary 
Fig. 6). To understand whether these combinations 
were effective in mitosis, we monitored the cell fate 
of MBA-MD-231 cells treated with ABT-263, PP242, 
2DG, 3PO or Metformin in the absence or presence  
of taxol. As shown in Figure 6b-e, treatment of 
breast cancer cells with these individual drugs 
results in a variable efficiency in cell death ranging 
from 10% to 40% without affecting mitotic cells (Fig. 
6b,d). Single treatment with taxol also resulted in a  
significant percentage of death cells (21%) from 
which only 12% of cells died in mitosis, in 
agreement with previous data in transformed 
fibroblasts 9. Notably, combination of taxol with 
ABT-263, PP242 and 3PO resulted in efficient MCD 
(Fig.6c,d) and the SiM was significantly reduced 
compared to the effect of taxol alone (Fig.6e).  
 
The synergism between taxanes and Bcl2- and 
mTORC1-inhibitors in tumor growth has been 
explored in the past27-29. We therefore tested the 
cooperation between taxol and the inhibition of 
glycolysis in tumor development in vivo. 
Subcutaneous xenografts were generated with 
MBA-MD-231 cells, and taxol (5 mg/Kg) and 3PO 
(5, 25 or 50 mg/Kg) were injected i.p. when tumors 
reached 200 mm3. Taxol was very inefficient at that 
dose whereas treatment with 3PO alone resulted in 
a significant reduction in tumor volume and weight 
(Fig. 7a,b and Supplementary Fig. 7). The 
combination of taxol with 3PO further improved 
significantly the therapeutic effect when compared 
to single treatments (Supplementary Fig. 7 and Fig. 
7b) and resulted in a significant raise in apoptotic 
cells in the tumors (Fig. 7c). Taken together, these 
data suggest the potential benefit of using glycolytic 
inhibitors in combination with current mitotic-
targeted therapies to inhibit tumor growth. 
 
Figure 7. Anti-tumoral cooperation between microtubule 
poisons and PFKFB3 inhibitors in vivo. a) Effect of the 
combination of Taxol (5 mg/kg) and 3PO (5, 25 or 50 mg/kg) on 
the growth of tumor xenografts generated by subcutaneous 
injection of 30MDA-MB-231 cells in nude mice. b) Data 
correspond to the volume of each of the tumors at the final time 
point of the experiment (n=10 tumors per condition). Red lines 
indicate mean ± SD. *, p<0.05; **, p<0.01; ***, p<0.001 (ANOVA-
test). c) Active caspase 3 immunostaining in MDA-MB-231-
derived tumor xenografts. The numbers indicate the percentage 
of active caspase-3- positive cells relative to the total number of 
nuclei in each section ± SD. Six sections were counted for each 
of four dissected tumors per condition. Scale bars, 100 mm. **, 
p<0.01 relative to 3PO-treated tumors; ###, p<0.001 relative to 
taxol-treated tumors (Student’s t-test). 
 
DISCUSSION 
 
The arrest imposed by anti-mitotic drugs is 
frequently transient and cells exit from mitosis in an 
APC/C-Cdc20-dependent process9known as mitotic 
slippage13, 30. Inhibiting the APC/C has been 
therefore proposed as a therapeutic option to 
prevent mitotic slippage, a possible mechanism of 
resistance to mitotic therapies in cancer cells 5, 8, 
11, 12. Cdc20-knockout cells display a permanent 
mitotic arrest until death 9, providing a clean genetic 
model to analyze molecular pathways that 
determine cell fate in mitosis.Cells are sensitive to 
multiple insults during mitosis and the cellular 
alterationsresulting from aberrant mitotic 
progression are collectively known as mitotic 
catastrophe 14Despite the broad use of this 
concept, the molecular mechanisms that determine 
cell death in response to these alterations are not 
well understood. Among cell death pathways, 
multiple evidences have established the 
involvement of intrinsic apoptosis in response to 
mitotic aberrations11, 13, whereas the extrinsic 
apoptotic pathway is thought to be inhibited at this 
stage of the cell cycle32. Our results confirm 
previous results suggesting the relevance of the 
Bcl2 family in response to mitotic defects11, 13, 15, 
16, 33. It has also been recently described that 
Cdc20 can suppress apoptosis targeting the pro-
apoptotic factor Bim34, suggesting that mitotically 
arrested cells in which Cdc20 is inhibited as a 
consequence of SAC activity are sensitive to this 
form of death. However, mitotic arrested cells also 
die in the absence of caspase activity or in Bax/Bak 
double knockout cells in the presence of necrotic 
figures (Fig. 1 and Supplementary Fig. 1). 
 
The two major cell death pathways in the cell, 
apoptosis and necrosis, proceed via a loss in 
mitochondrial membrane potential, reduced ATP 
levels and generation of ROS22. It has been 
assumed that mitochondria are particularly active 
during the energy expensive process driving spindle 
formation and chromosome segregation36. In fact,!
recent data showed that Cdk1 activity is necessary 
to phosphorylate and activate several components 
of the mitochondrial complex I thus enhancing 
mitochondrial respiration during the G2/M 
transition24. Inhibition of Cdk1 results in decreased 
mitochondrial activity 24, impaired respiratory 
capacity (Fig. 4b,c), and reduced ATP levels (Fig. 
4f).  
 
Thus, Cdk1 activity provides cells with the 
bioenergy required for a normal mitosis by 
enhancing mitochondrial respiration. However, upon 
mitotic arrest, the mitochondrial mass declines after 
about 6 h, presumably as a result of deficient 
renovation of organelles. This process occurs in the 
presence of mitophagy (Fig. 3), a critical autophagic 
process responsible for the clearance of damaged 
mitochondria in cells37, 38 .Although it was 
originally argued that autophagy was shut down 
during the later phases of the cell cycle19, 39, 40, it 
has been more recently shown that autophagy can 
persist during mitosis 36. Thus, the reduced 
biogenesis resulting from impaired transcription and 
reduced translation in mitotic cells likely perpetuates 
mitochondrial dysfunction (Fig. 3) and reduced ATP 
levels (Fig. 4) during mitotic arrest, a situation not 
easily compensated by glycolysis as this pathway is 
much less efficient in generating ATP. The rise in 
the AMP/ATP ratio during mitotic arrest likely 
contributes to the activation of AMPK, a major 
homeostatic regulator of cellular ATP levels41 . 
Whereas the activation of AMPK has been shown to 
be predominantly cytoplasmic25, mitotic cells may 
become more sensitive to AMPK due to the 
absence of the nuclear envelope. Once activated, 
AMPK stimulates catabolic pathways that generate 
ATP, and inhibits ATP-consuming processes such 
as biosynthesis, cell growth and proliferation41. 
AMPK activation can acutely increase glucose 
uptake and glycolysis, although in the long-term it 
promotes the more energy-efficient oxidative 
metabolism by upregulating mitochondrial 
biogenesis and expression of oxidative enzymes. 
However, the later process is thought to be 
transcription-dependent 42 and therefore inefficient 
in mitotic 16 arrested cells. Among other activities, 
AMPK forms stable complexes with Ulk1 and Ulk2 
and directly phosphorylates Ulk1, triggering 
autophagy 43, 44. Thus, in the presence of 
mitochondrial dysfunction, AMPK likely determines 
a glycolytic switch, and can further promote 
autophagy during prolonged mitotic arrest (Fig. 4). It 
has been recently published that AMPK is active 
during mitosis and it is required for the completion 
of mitosis by phosphorylating components of the 
APC/C (APC1 and CDC27) and PP1 regulatory 
subunits45. In these studies, it was not obvious why 
a kinase activated by energy stress should be 
required for passage through mitosis42. However, it 
is important to note that nocodazole-arrested cells 
were used in these studies as a paradigm of mitotic 
cells45, raising the possibility that some of these 
conclusions may not apply to a normal, short (<1h) 
mitosis. Yet, AMPK deficiency in flies results in 
altered chromosome compositions, a phenotype 
likely linked to myosin regulatory light chain (MRLC) 
function46 and the links between AMPK and mitosis 
may be more complex than initially thought. AMPK 
activity is also pro-apoptotic, and necessary and 
sufficient for the activation of pro-apoptotic proteins 
such as Bim or Bmf and cell death during 
bioenergetics stress 47-49. Thus, we hypothesize 
that AMPK may have a dual role during mitotic 
arrest. On one hand, it senses loss of ATP and 
enhances glycolysis protecting from death. On the 
other hand, it may enhance autophagy and 
apoptosis through the modulation of Ulk1 and 
Bim/Bmf activities43, 44, 48, 49, thus explaining 
why both the inhibition (using siRNAs or small-
molecule inhibitors) and the activation of AMPK 
(with metformin) results in reduced survival during 
mitosis (Fig. 5). The glycolytic activity of AMPK is 
thought to be determined by the phosphorylation 
and activation of PFKFB326, 50. PFKFB3 is a 
critical activator of 6-phosphofructo-1-kinase 
(PFK1), the rate-limiting enzyme in the conversion 
of glucose! to pyruvate, the precursor of anaerobic 
ATP production. PFKFB3 is commonly 
overexpressed in human cancer26 contributing to 
the Warburg effect, a switch away from oxidative 
metabolism and towards rapid glucose uptake, 
glycolysis and lactate output that is characteristic of 
many tumor cells51 
 
Since APC/C-Cdh1 is activated downstream of 
APC/C-Cdc20 after mitotic exit, the levels of 
PFKFB3 are high during mitosis (data not shown). 
In addition, whereas this protein is mostly nuclear 
during interphase, the combination of nuclear and  
cytoplasmic compartments during mitosis likely 
facilitates its AMPK-driven activation as well as its 
promoting function on the glycolytic machinery.!As a 
summary, whereas recent data suggest that Cdk1-
dependent activation of mitochondrial respiration is 
required for the G2/M transition, our observations 
suggest a switch to glycolysis during prolonged 
mitotic arrest. This switch is modulated by AMPK 
and requires key glycolytic enzymes such as 
PFKFB3. These observations may have important 
implications in cancer therapy. Mitotic slippage may 
be considered as a major mechanism of resistance 
in mitotic-targeted therapies8, 10. Whereas the 
combination between microtubule poisons and 
apoptotic inducers has been extensively studied13, 
15, 16, 53, our data suggest that promoting 
autophagy or inhibiting glycolysis may therefore 
promote mitotic cell death before cells exit from 
mitosis. In fact,treatment with several small-
molecule compounds directed against these 
pathways results in enhanced mitotic cell death in 
mitosis and cooperates with taxol in preventing cell 
proliferation of breast cancer cells both in vitro (Fig. 
6) and in vivo (Fig. 7). Collectively, these data 
provide the cellular basis for new combinatory 
therapies targeting cell cycle and metabolic 
pathways in cancer 
 
 
METHODS 
 
Cell culture and synchronization. The Cdc20 
conditional allele and its deletion by 4-OHT-
inducible forms of Cre (RERT) were reported 
previously9. Atg5 and Bax/Bak mutant MEFs were 
described previously54-56. MEFs and human cell 
lines were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) or RPMI (Sigma) complemented 
with fetal bovine serum (FBS) and gentamycin at 
37ºC and 5% CO2. For synchronization in G2, 
Cdc20(lox/lox); RERT MEFs and MDA-MB-231 cells 
were treated with RO-3306 (Calbiochem; 5 µM) for 
18 hours and released in DMEM with or without 4-
OHT (Sigma; 1 µM), or DMEM with or without Taxol 
(Sigma; 700 nM) and proTAME (Boston Biochem., 
Inc.; 10 µM). For mitotic synchronization of Cdc20-
proficient mouse or human cultures, cells were 
treated for 12 hours with 200 nM 
nocodazole(Sigma) and released in fresh media 
containing 10µM MG132. Cells were treated 
withsmall molecule inhibitors as indicated in 
Supplementary Table 1. One µM TO-PRO®-3 
Iodide (642⁄661; Invitrogen T3605) was added to 
cultures to monitor cell death.MEFs and human 
cells lines were transfected with Lipofectamine 2000  
(Invitrogen) or Amaxa reagents (Dharmacon smart 
pool) in accordance with the manufacturer´s 
recommendations.  
 
For quantitative RT-PCR studies, total RNA was 
isolated by using the Qiagen RNeasy kit, according 
to the manufacturer’s instructions. cDNA was 
synthesized with a Superscript III reverse 
transcriptase (Invitrogen) and PCR amplification 
was performed using SYBR Green PCR Master mix 
(Applied Biosystems) with specific primers 
(Supplementary Table 2). 
 
Cytometry. Cell cycle profiles were monitored by 
adding 0.2 µg/ml DAPI (Sigma) to the samples prior 
to their analysis on the LSR Fortessa (BD, San 
Jose). All data were analyzed using FlowJo v9.6.4 
(Treestar, Oregon). For quantifying mitochondrial 
mass, adherent cells were trypsinized for 5 min at 
37 ºC and resuspended in complete medium with 
10 nM Mitotracker Deep Red (MTDR, M22426, 
Invitrogen) and 1 m/mL propidium iodide (P4864, 
Sigma) and then incubated for 15 min at 37 ºC. 
Using an FC500 flow cytometer (Beckman Coulter), 
10,000 cells were acquired in the FL3 and FL4 
channels. Mean fluorescence in the FL4 channel in 
the viable cell (PI-negative) population was plotted 
and normalized against that of untreated cells. 
 
Biochemical analysis and immunofluorescence. 
For Western blotting, cells were lysed in RIPA or a 
buffer containing 50 mM Tris HCl, pH 7.5, 1 mM 
phenylmethylsulfonyl fluoride, 50 mM NaF, 5 mM 
sodium pyrophosphate, 1 mM sodium 
orthovanadate, 0.1% Triton X-100, 1 µg/ml 
leupeptin, 1mM EDTA, 1 mMEGTA and 10 mM 
sodium-glicerophosphate54. 30 µg of total protein 
was separated by SDS-PAGE and probed with 
antibodies as indicated in Supplementary Table 3.!
For immunofluorescence (IF) cells were fixed in 4% 
buffered paraformaldehyde for 10 min at RT, 
permeabilized in 0.15% Triton-X 100 for 5-10 min at 
RT and stained with 4,6 diaminophenylindole (DAPI; 
Prolong Gold antifade, Invitrogen) to visualize 
nuclei. Images were captured using a laser 
scanning confocal microscope TCS-SP5 (AOBS) 
Leica or a Leica DMI 6000B microscope and 
quantified with ImageJ. The tandem fluorescent-
tagged LC3 reporter20 and the AMPK biosensor25 
were described previously 
 
Microscopy. For videomicroscopy human cell lines 
at 60-70% confluency were infected with 
lentiviruses containing H2B-GFP.  lens, maintained 
at 37 °C in a humidified CO2 chamber. 1 µM TO-
PRO®-3 Iodide 642⁄661; Invitrogen T3605) or 10 
nM Mitotracker (Life Technologies) were added 
prior to recording. Images were acquired every 15 
min, and processed and analyzed using ImageJ 
software.For high-throughput microscopy (HTM) 
cells were grown on µCLEAR bottom 96-well plates 
(Greiner Bio-One). After specific treatments, 1 µM 
TO-PRO®-3 Iodide (642⁄661; Invitrogen T3605) and 
5 µg/ml Hoechst 33342 (Invitrogen H3570) were 
added. After 30 min at 37 ºC, images were 
automatically acquired from each well by an Opera 
High-Content Screening System (Perkin Elmer). A 
20x magnification lens was used and pictures were 
taken at non-saturating conditions. Images were 
segmented using the Hoechst 33342 staining to 
generate masks matching cell nuclei from which the 
mean TO-PRO®-3 signal were calculated. To 
monitor ROS, cells were with specific drugs and 
incubated for 30 min at 37ºC as indicated in 
OxiSelect TM Intracellular ROS assay kit, Cell 
Biolabs and 5 µg/ml Hoechst 33342 (Invitrogen 
H3570). Images were automatically acquired from 
each well by an Opera High-Content Screening 
System (Perkin Elmer) as indicated above.For 
FRET analysis 25, cells were plated on eight-well 
flow chambers (Ibidi) and imaged with a Leica 
AF6000W equipped with a fast external filter 
wheels, Hamamatsu CCD Camera, HCX PL APO 
40X/ oil 1.25 NA objective lens and AFC hardware 
autofocus system, maintained at 37 °C in a 
humidified CO2 chamber. Images were acquired 
every 1 or 10 min. Images were processed and 
analyzed using ImageJ software. 
 
AMP/ATP levels, metabolic flux and NMR. 
Respirometry (OCR) and the extracellular 
acidification rate (ECAR) of cells were measured 
with an XF96 Extracellular Flux Analyzer (Seahorse 
Bioscience). In brief, cells were plated at 1.5-2×104 
cells/well in buffered DMEM containing 25 mM 
glucose and 2 mM glutamine. Cells were incubated 
in a CO2-free incubator at 37°C for 1 h to allow for 
temperature and pH equilibration prior to loading 
into the XF96 apparatus. Assays consisted of 
sequential mix (2 min), pause (2 min), mix (0.33 
min) and measurement (4 min) cycles, allowing for 
determination of OCR/ECAR every 8.33 min. Mitotic 
cells were obtained after shake off and plated in BD 
Cell-TaK coated plates. Concentration of ATP was  
determined spectrophotometrically as described 
previously 57.For NMR analysis of cell media 
metabolites58, 0.5 x106 MEFs were plated in 
DMEM containing 13C-labeled–glucose and 
synchronized as described above. 500 µLof 
supernatant were recovered for every time point, 
centrifuged at 10000g for 10 min and filtered in 
10Kd Spin Columns (BioVision). Before 
measurements by NMR,samples were dissolved 1:3 
in buffer (0.3 mM TMSP, PBS 3X, 70% deuterated 
water and 0.09% azide). High-resolution NMR 
spectra were registered on a Bruker Avance 
spectrometer operating at 16.4T and integration 
regions were then manually defined using the 
AMIX3.8 software. 
 
 Transmission electron microscopy. Cells were 
fixed for 4 hours at 4°C in 4% paraformaldehyde 
(w/v) and 2.5% glutaraldehyde (v/v) in 0.4 M 
HEPES buffer pH 7.4, washed and fixed again in 
aqueous 1% (w/v) osmium tetroxide, and embedded 
in Epon.  
Electron microscopy was performed with a JEOL 
1230 transmission electron microscope, at 80 kV, 
on ultra-thin sections of 60 nm. 
 
In vivo studies. Mice were injected subcutaneously 
in the right and the left flank with 3 x106 MDA-MB-
231 cells in 0.1 ml of PBS + 0.5% BSA. 20 days 
after cell injection, 22 tumors had grown to an 
average volume of 150-200 mm3. Mice were then 
divided into different experimental groups of 5 
animals each, which received the following 
treatments as intraperitoneal injections: saline 
(control); 5 mg/kg Taxol; 5 mg/kg 3PO;25 mg/kg 
3PO; 50 mg/kg 3PO; 5 mg/kg Taxol + 5 mg/kg 3PO; 
5 mg/kg Taxol + 25 mg/kg 3PO; 5 mg/kg Taxol + 50 
mg/kg 3PO. The injection was repeated every two 
days and treatment was continued for 12 days. 
Tumor volumes were monitored using calliper 
measurements and were calculated by the formula: 
(4p/3) * (w/2)2 * (l/2). 
 
Statistics. Statistical analysis was carried out using 
Prism 5 (GraphPad). All statistical tests were 
performed using two-sided, unpaired Student’s t 
tests, or the Fisher’s exact Test. Data with p<0.05 
were considered statistically significant (*, p<0.05; 
**, p<0.01; ***, p<0.001). 
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Mitosis-targeting therapies: a troubleshooting guide
Elena Dome´nech and Marcos Malumbres
Several mitotic kinases and kinesins are currently considered
as cancer targets based on their critical role during the cell
division cycle and their significant level of expression in human
tumors. Yet, their use is limited by the lack of selectivity against
tumor cells, the low percentage of mitotic cells in many human
tumors, and dose-limiting side-effects. As a consequence,
initial clinical trials have shown limited responses. Despite
these drawbacks, inhibiting mitosis is a promising strategy that
deserves further development. Future advances will benefit
from more specific inhibitors with better pharmacodynamic
properties, a clear physiological characterization and cell-type-
specific requirements of old and new mitotic targets, and
rational strategies based on synthetic lethal interactions to
improve selectivity against tumor cells.
Addresses
Cell Division and Cancer Group, Spanish National Cancer Research
Centre (CNIO), Madrid, Spain
Corresponding author: Malumbres, Marcos (malumbres@cnio.es,
mmm@cnio.es)
Current Opinion in Pharmacology 2013, 13:519–528
This review comes from a themed issue on Cancer
Edited by Massimo Santoro and Francesca Carlomagno
For a complete overview see the Issue and the Editorial
Available online 12th April 2013
1471-4892/$ – see front matter, # 2013 Elsevier Ltd. All rights
reserved.
http://dx.doi.org/10.1016/j.coph.2013.03.011
Introduction
Cell cycle deregulation is a common feature of human
cancers and multiple therapeutic strategies are aimed to
inhibit the cell division cycle in tumor cells. Current efforts
can be broadly divided into three different groups: first,
preventing the commitment to cell cycle entry imposed by
oncogenic signals [1]; second, abrogation of the DNA
damage checkpoint to increase lethality in highly prolif-
erating cells [2,3]; and third, taking advantage of the special
sensitivity of cells to abnormal chromosome segregation
during mitosis [4]. The two first approaches are clearly
based on the specific signals originated from the oncogenic
stress in tumor cells. This has been far more difficult to
achieve in targeted therapies directed against mitosis given
the conservation in the essential mechanism that regulates
chromosome segregation in normal or tumor cells.
Classical antimitotic therapies have made use of spindle
poisons that bind tubulin subunits and either stabilize, for
example, taxanes (paclitaxel, Nab-paclitaxel and doce-
taxel), or de-stabilize, for example, vinka-alkaloids (vinor-
elbine, vinblastine, vincristine) and microtubules. In all
these cases, these compounds prevent microtubule
dynamics, a process required for the generation of a
bipolar spindle and chromosome segregation during mito-
sis. Microtubules are also necessary for multiple cellular
functions during interphase and the use of these spindle
poisons is associated to side-effects such as neurotoxicity
that can lead to irreversible neuropathologies. It is
expected that dividing cells are more vulnerable to these
microtubule-disturbing agents due to the increased rate
or microtubule turnover during mitosis. In fact, micro-
tubule poisons can be considered as one of the major
additions to the clinic in the last decades. However,
whether mitotic inhibition explains the clinical success
of these drugs is now under debate [5,6].
The success of spindle poisons and the susceptibility of
cells to mitotic arrest have led in the last years to a search
for improved therapeutic strategies based on specific
mitotic targets (Figure 1). Several mitotic kinases have
been evaluated including members of the Polo-like
kinase (Plk) and Aurora families. Mitotic targets also
include kinesins, a class of motor proteins with ATPase
activity that move along microtubule filaments and are
required for proper microtubule function. Abrogation of
the mitotic checkpoint has been also considered to
specifically generate lethal aberrations in chromosomally
unstable tumor cells. Preventing mitotic exit has been
recently proposed as a complementary alternative since
cells cannot survive for long time in mitosis and they
eventually die if components of the mitotic exit pathway,
such as the E3 ubiquitin ligase APC/C (Anaphase Pro-
moting Complex/Cyclosome) are inhibited. In this review
we will discuss the recent data generated from these
studies as well as proposals that need to be evaluated
in the near future.
Mitotic kinases and kinesins
Multiple enzymatic activities are required for mitosis.
These include centrosomal and mitotic kinases required
for the maintenance of the mitotic state, generation of
the mitotic spindle, and proper attachment of chromo-
somes to microtubules for segregation [7]. The cyclin-
dependent kinase Cdk1 is a major driver of mitotic entry
and progression. Its activity is essential for mitotic entry
and lack of Cdk1 activity prevents cell proliferation in
every cell type tested [8]. Inhibition of this kinase is
thought to result in high levels of toxicity in normal cells
and it is not frequently considered as an interesting
target for cancer therapy [9]. However, some recent
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